TW201936209A - Anti-PDL1 antibody formulations - Google Patents

Abstract

The invention provides a stable aqueous pharmaceutical formulation comprising an anti-PDL1 antibody. The invention also provides methods for preparing the formulations and methods for using the formulations.

Description

Anti-PDL1 antibody formulation

The invention relates to a stable aqueous pharmaceutical formulation comprising an anti-PDL1 antibody.

Providing T cells with two different signals is a widely accepted model of lymphocyte activation of dormant T lymphocytes by antigen presenting cells (APC). Lafferty et al., Aust. J. Exp. Biol. Med. ScL 53: 27-42 (1975). This model further provides discrimination and immune tolerance to distinguish between self and non-self. Bretscher et al., Science 169: 1042-1049 (1970); Bretscher, PA, PNAS USA 96: 185-190 (1999); Jenkins et al., J. Exp. Med. 165: 302-319 (1987). After recognizing a foreign antigen peptide that is present in the context of the major histocompatibility complex (MHC), the first signal or antigen-specific signal is transduced via the T cell receptor (TCR). The second signal or the co-stimulatory signal is transmitted to the T cells through the co-stimulatory molecules expressed on the antigen-presenting cells (APC), and induces the T cells to promote pure line expansion, cytokine secretion, and effector functions. Lenschow et al., Ann. Rev. Immunol. 14: 233 (1996). In the absence of co-stimulation, T cells become unresponsive to antigen stimulation, do not produce an effective immune response, and may further lead to depletion or tolerance of foreign antigens.
In a two-signal model, T cells receive a positive second co-stimulatory signal and a negative second co-stimulatory signal. The regulation of these positive and negative signals is essential for maximizing the host's protective immune response, while maintaining immune tolerance and preventing the generation of autoimmunity. A negative second signal seems to be essential for inducing T cell tolerance, while a positive signal promotes T cell activation. Although a simple two-signal model can still effectively explain the primary lymphocytes, the host's immune response is a kinetic process and can also provide a co-stimulatory signal to T cells exposed to the antigen. The mechanism of co-stimulation has therapeutic significance because the processing of co-stimulation signals has been shown to provide a way to enhance or terminate cell-based immune responses. Recently, it has been found that T cell dysfunction or anergy and the inhibitory receptor (progressive death polypeptide 1 (PD-1)) are induced and maintained simultaneously. Therefore, therapies that target PD-1 and other molecules that signal by interacting with PD-1, such as Stylized Death Ligand 1 (PD-Ll) and Stylized Death Ligand 2 (PD-L2) For areas of close attention.
PD-L1 is overexpressed in many cancers and generally has a poor prognosis (Okazaki T et al., Intern. Immun. 2007 19 (7): 813) (Thompson RH et al., Cancer Res 2006, 66 (7): 3381). Interestingly, in contrast to T lymphocytes in normal tissues and peripheral blood T lymphocytes, most tumors that infiltrate T lymphocytes mainly show PD-1, indicating that upregulation of PD-1 on tumor-reactive T cells can cause antitumor The immune response is weakened (Blood 2009 114 (8): 1537). This can be attributed to the use of PD-L1 signaling mediated by tumor cells expressing PD-L1, which interact with T cells expressing PD-1, resulting in reduced T cell activation and evasion of immune surveillance (Sharpe et al. (Nat Rev 2002) (Keir ME et al. 2008 Annu. Rev. Immunol. 26: 677). Therefore, inhibiting the mutual use of PD-L1 / PD-1 can promote CD8 + T cell-mediated tumor killing.
Therapies that target PD-1 and other molecules that signal by interacting with PD-1, such as programmed death ligand 1 (PD-Ll) and programmed death ligand 2 (PD-L2), are intensive Areas of focus. Inhibition of PD-L1 signaling has been proposed as a method to enhance T-cell immunity to treat cancer (e.g., tumor immunity) and infections (including acute and chronic (e.g., persistent) infections). However, because the best treatments for the goals in this path have not yet been commercialized, there are clearly unmet medical needs.
All references (including patent applications, patent publications, and UniProtKB / Swiss-Prot registration numbers) cited herein are incorporated herein by reference in their entirety, as if each individual reference was specifically and individually cited The way merges into the general.

Cross-References to Related Applications <br/> This application claims priority from US Provisional Application No. 61 / 883,953, filed September 27, 2013, which is incorporated herein by reference in its entirety.
Provided herein are stable aqueous pharmaceutical formulations comprising antibodies. The formulation comprises an antibody (eg, an anti-PDL1 antibody), a buffer, sucrose, and a surfactant, wherein the pH of the formulation is from about 5.0 to about 7.0.
In one aspect, provided herein is a stable aqueous pharmaceutical formulation comprising an anti-PDL1 monoclonal antibody at a concentration of about 40 mg / ml to about 125 mg / ml in a group of about 15 mM to about 25 mM Uric acid acetate or sodium acetate, sucrose at a concentration of about 60 mM to about 240 mM, polysorbate at a concentration of about 0.005% (w / v) to about 0.06% (w / v), and a pH of about 5.0 To about 6.3.
In some embodiments, the monoclonal antibody in the formulation is from about 40 mg / ml to about 80 mg / ml. In some embodiments, the monoclonal antibody in the formulation is from about 54 mg / ml to about 66 mg / ml. In some embodiments, the monoclonal antibody in the formulation is about 60 mg / ml. In some embodiments, the monoclonal antibody in the formulation is from about 60 mg / ml to about 125 mg / ml. In some embodiments, the monoclonal antibody in the formulation is about 125 mg / ml.
In some embodiments, the concentration of the histidine acetate or sodium acetate in the formulation is from about 17 mM to about 22 mM. In some embodiments, the concentration of the histidine acetate or sodium acetate in the formulation is about 20 mM.
In some embodiments, the sucrose in the formulation is from about 60 mM to about 180 mM. In some embodiments, the sucrose in the formulation is about 120 mM. In some embodiments, the sucrose in the formulation is about 240 mM.
In some embodiments, the pH of the formulation is from about 5.5 to about 6.1. In some embodiments the pH of the formulation is about 5.5 or about 5.8.
In some embodiments, the polysorbate in the formulation is polysorbate 20. In some embodiments, the polysorbate (eg, polysorbate 20) in the formulation is from about 0.02% to about 0.04%.
In some embodiments, the monoclonal antibody in the formulation is about 60 mg / ml, the sucrose in the formulation is about 120 mM, and the pH is about 5.8. In some embodiments, the monoclonal antibody in the formulation is about 125 mg / ml, the sucrose in the formulation is about 240 mM, and the pH is about 5.5.
In some embodiments, the formulation comprises a monoclonal antibody (such as an anti-PDL1 antibody described herein) in an amount of about 60 mg / mL, histidine acetate in a concentration of about 20 mM, and sucrose in a concentration of about 120 mM And a concentration of 0.04% (w / v) is polysorbate of polysorbate 20, and the pH of the formulation is about 5.8.
In some embodiments, the formulation comprises a monoclonal antibody in an amount of about 125 mg / mL, histidine acetate at a concentration of about 20 mM, sucrose at a concentration of about 240 mM, and polysorbate at a concentration of 0.02% Polysorbate of alcohol ester 20, and the pH of the formulation is about 5.5.
In some embodiments, the monoclonal antibody in the formulation is not previously lyophilized. In some embodiments, the monoclonal antibody in the formulation is a full-length antibody. In some embodiments, the monoclonal antibody in the formulation is an IgG1 antibody. In some embodiments, the monoclonal antibody in the formulation is a humanized antibody. In some embodiments, the monoclonal antibody in the formulation is an antibody fragment comprising an antigen-binding region. In some embodiments, the antibody fragment is a Fab or F (ab ') ₂ fragment.
In some embodiments, the monoclonal antibody in the formulation comprises
(a) a light chain variable region comprising:
(1) HVR-L1, which comprises an amino acid sequence RASQDVSTAVA (SEQ ID NO: 1);
(2) HVR-L2, which comprises an amino acid sequence SASFLYS (SEQ ID NO: 2);
(3) HVR-L3, which comprises an amino acid sequence QQYLYHPAT (SEQ ID NO: 3); and
(b) a heavy chain variable region comprising:
(1) HVR-H1, which comprises an amino acid sequence GFTFSDSWIH (SEQ ID NO: 4);
(2) HVR-H2, which comprises an amino acid sequence AWISPYGGSTYYADSVKG (SEQ ID NO: 5);
(3) HVR-H3, which comprises an amino acid sequence RHWPGGFDY (SEQ ID NO: 6).
In some embodiments, the monoclonal antibody in the formulation comprises a light chain variable region comprising an amino acid sequence of SEQ ID NO: 7, and a heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 8. In some embodiments, the monoclonal antibody in the formulation comprises at least 85%, 86%, 87%, 88%, 89%, 90% and 90% of a light chain variable region having an amino acid sequence of SEQ ID NO: 7. %, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of the sequence identity of the light chain variable region, and with the amino acid sequence SEQ ID NO: 8 The heavy chain variable region has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% consistent heavy chain variable regions. In some embodiments, the monoclonal antibody in the formulation comprises a light chain variable region comprising an amino acid sequence of SEQ ID NO: 7, and a heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 32. In some embodiments, the monoclonal antibody in the formulation comprises at least 85%, 86%, 87%, 88%, 89%, 90% and 90% of a light chain variable region having an amino acid sequence of SEQ ID NO: 7. %, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity of the light chain variable region, and with the amino acid sequence SEQ ID NO: 32 The heavy chain variable region has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% consistent heavy chain variable regions. In some embodiments, the monoclonal antibody in the formulation comprises a light chain comprising an amino acid sequence of SEQ ID NO: 9 and a heavy chain comprising an amino acid sequence of SEQ ID NO: 10. In some embodiments, the monoclonal antibody in the formulation comprises at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, and 91% of the light chain having the amino acid sequence of SEQ ID NO: 9. %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of the sequence identity of the light chain, and the heavy chain with the amino acid sequence SEQ ID NO: 10 has at least 85 %, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% consistent heavy chains.
In some embodiments, the formulation comprising the antibody is stored in a glass bottle or metal alloy container. In some embodiments, the metal alloy is 316L stainless steel or hastelloy. In some embodiments, the formulation is stable at 2-8 ° C for at least 6 months, at least 12 months, at least 18 months, or at least 24 months. In some embodiments, the antibodies in the formulation retain at least about 75%, at least about 80%, at least about 85%, at least about 90% of the biological activity prior to storage after storage. In some embodiments, biological activity is measured by an antibody that binds to PD-L1.
In some embodiments, the formulations described herein are sterile. In some embodiments, the formulations described herein are suitable for administration to an individual. In some embodiments, the formulations described herein are used for intravenous (IV) administration.
In another aspect, provided herein is an article or kit comprising a container containing any stable aqueous pharmaceutical formulation described above and herein. In some embodiments, the container is a glass bottle or a metal alloy container. In some embodiments, the metal alloy is a 316L stainless steel or a Herst alloy.
In another aspect, provided herein is a method of treating a disease or condition in an individual, comprising administering to the individual an effective amount of a formulation described herein, wherein the disease or condition is selected from the group consisting of infection, cancer, and inflammation Groups of diseases.
It should be understood that one, some, or all of the features of the various embodiments described herein may be combined to form other embodiments of the invention. These and other aspects of the invention will become apparent to those skilled in the art. These and other embodiments of the present invention are further described by the following [Embodiments].

I. definition .
Before describing the invention in detail, it should be understood that the invention is not limited to a particular composition or biological system, and it can of course vary. It should also be understood that terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting. As used in this specification and the scope of the accompanying patent application, unless the content clearly indicates the contrary, the singular forms "a" and "the" include plural referents. Thus, for example, reference to "molecule" optionally includes a combination of two or more such molecules, and the like.
The term "about" as used herein refers to a common range of errors for individual values that are readily known to those skilled in the art. References to "about" a value or parameter herein include (and describe) embodiments directed to that value or parameter itself.
It should be understood that the aspects and embodiments of the present invention described herein include "including" aspects and embodiments, "consisting of aspects and embodiments" and "consisting essentially of aspects and embodiments."
The term "pharmaceutical formulation" refers to a preparation in a form that renders the biological activity of the active ingredient effective and does not contain additional components that have unacceptable toxicity to the individual to whom the formulation is to be administered. These formulations are sterile. "Pharmaceutically acceptable" excipients (vehicles, additives) are those active ingredients that can be reasonably administered to an individual mammal to provide an effective dose.
A "sterile" formulation is sterile or free or essentially free of all living microorganisms and their spores.
A "frozen" formulation is one whose temperature is below 0 ° C. Generally speaking, freeze-dried formulations have not been freeze-dried and have not been subjected to prior or subsequent freeze-drying. In some embodiments, the frozen formulations include frozen drug substances (in stainless steel tanks) or frozen medicines (final vial configuration) for easy storage.
A "stable" formulation is one that substantially retains its physical stability and / or chemical stability and / or biological activity after storage. The formulations preferably retain substantially their physical and chemical stability and their biological activity after storage. The shelf life is generally selected based on the expected shelf life of the formulation. Various analytical techniques for measuring protein stability are available in this technology and, for example, are reviewed inPeptide and Protein Drug Delivery , 247-301, edited by Vincent Lee, Marcel Dekker, Inc., New York, N.Y., Pubs. (1991) and Jones, A.Adv. Drug Delivery Rev. 10: 29-90 (1993). Stability can be measured at a selected temperature for a selected period of time. Stability can be assessed qualitatively and / or quantitatively in a number of different ways, including assessing aggregate formation (e.g., using size exclusion chromatography, by measuring turbidity, and / or by visual inspection); by using cation exchange chromatography, imaging Capillary isoelectric focusing (icIEF) or capillary zone electrophoresis assessment; Amino- or carboxy-terminal sequence analysis; Mass spectrometry; SDS-PAGE analysis comparing shortened and intact antibodies; Peptide mapping (such as trypsin or LYS-C) analysis ; Assess the biological activity or antigen-binding function of the antibody; etc. Instability may involve any one or more of the following: agglomeration, deamidation (e.g., Asn deamidation), oxidation (e.g., Met oxidation), isomerization (e.g., Asp isomerization), splicing / hydrolysis / fragmentation (Eg fragmentation of the hinge region), succinimide formation, unpaired cysteine, N-terminal extension, C-terminal processing, differences in glycosylation, and the like.
If the protein exhibits no or little evidence of aggregation, precipitation, and / or denaturation when visually inspecting color and / or transparency or by UV light scattering or by size exclusion chromatography measurements, the protein in the pharmaceutical formulation "keep Its physical stability. "
A protein in a pharmaceutical formulation "maintains its chemical stability" if it is chemically stable at a given time such that the protein is considered to retain its biological activity as defined below. Chemical stability can be assessed by detecting and quantifying chemically altered proteins. Chemical alterations can involve dimensional modification (eg, splicing), which can be assessed, for example, using size exclusion chromatography, SDS-PAGE, and / or matrix-assisted laser desorption ionization / time of flight mass spectrometry (MALDI / TOF MS). Other types of chemical changes include changes in charge (such as caused by amidin), which can be assessed by, for example, ion exchange chromatography or icIEF.
If the biological activity of the antibody at a given time is at least about 60% (within the analytical error) of the biological activity exhibited during the preparation of the pharmaceutical formulation, as determined in an analytical method (e.g., antigen binding analysis) "Retain its biological activity." Additional "biological activity" analyses of antibodies are detailed below.
As used herein, the "biological activity" of a monoclonal antibody includes the ability of the antibody to bind to an antigen and result in a measurable biological response that can be measured in vitro or in vivo.
The "deamidine" monoclonal antibodies herein are monoclonal antibodies in which one or more asparagine residues have been derived, for example, aspartic acid or isoaspartic acid.
An "oxidized" monoclonal antibody herein is a monoclonal antibody in which one or more tryptophan residues and / or one or more methionine has been oxidized.
A "glycosylated" monoclonal antibody herein is a monoclonal antibody in which one or more lysine residues have been glycosylated.
An "easy deamidation" antibody is an antibody that contains one or more residues that have been found to be deamidated.
An "easy to oxidize" antibody is an antibody that contains one or more residues that have been found to have a tendency to oxidize.
"Easily aggregated" antibodies are antibodies that have been found to aggregate with other antibody molecules, especially after freezing and / or stirring.
"Easily fragmented" antibodies are antibodies that have been found to cleave, for example, into two or more fragments in the hinge region.
It is expected that by "reducing deamidation, oxidation, aggregation or fragmentation" to prevent or reduce the amount of deamidation, oxidation, aggregation or fragmentation of individual antibodies formulated in different formulations.
The formulated antibody is preferably substantially pure and desirably substantially homogeneous (e.g., free of contaminating proteins, etc.). By "substantially pure" antibody, it is meant that the composition comprises at least about 90% by weight antibody, preferably at least about 95% by weight antibody, based on the total weight of protein in the composition. By "substantially homogeneous" antibody, it is meant that the composition comprises at least about 99% by weight of antibody based on the total weight of protein in the composition.
"Isotonic" means that the formulation of interest has substantially the same osmotic pressure as human blood. Isotonic formulations typically have an osmotic pressure of about 250 to 350 mOsm. Isotonicity can be measured using, for example, a vapor pressure or frozen osmometer.
As used herein, "buffer" refers to a buffer solution that prevents the pH from changing by the action of an acid-base conjugate component. The buffer of the present invention preferably has about 4.5 to about 7.0, and preferably about 5.6 to about 7.0, such as 5.6 to 6.9, 5.7 to 6.8, 5.8 to 6.7, 5.9 to 6.6, 5.9 to 6.5, 6.0, 6.0 to 6.4, or 6.1 PH in the range of 6.3. In one embodiment, the buffer has a pH of 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, or 7.0. For example, sodium phosphate is an example of a buffer that will control the pH in this range.
As used herein, "surfactant" refers to a surfactant, preferably a non-ionic surfactant. Examples of surfactants herein include polysorbates (such as polysorbate 20 and polysorbate 80); poloxamer (such as poloxamer 188); triton; Sodium lauryl sulfate (SDS); sodium lauryl sulfate; sodium octyl glucoside; lauryl-, myristyl-, linoleyl- or stearyl-sulfobetaine; lauryl-, meat Myristyl-, linoleyl- or stearyl-carnosine; linoleyl-, myristyl- or cetyl-betaine; laurylaminopropyl-, cocoamine Propyl-, linoleylaminopropyl-, myristylaminopropyl-, palmitoylaminopropyl- or isostearylaminopropyl-betaine (e.g. laurylaminopropyl) ; Myristylamidopropyl-, palmitoylaminopropyl- or isostearylamidopropyl-dimethylamine; methyl cocoamidinyl sodium taurate or disodium methyloleyl taurate ; And MONAQUAT^TM Series (Mona Industries, Inc., Paterson, N.J.); polyethylene glycol, polypropylene glycol, and copolymers of ethylene glycol and propylene glycol (such as Pluronics, PF68, etc.); etc. In one embodiment, the surfactant herein is polysorbate 20.
From a pharmacological point of view, in the context of the present invention, a "therapeutically effective amount" of an antibody refers to an amount effective to prevent or treat a condition in which the antibody is effective in the treatment of the condition. A "disorder" is any condition that benefits from treatment with antibodies. This includes chronic and acute conditions or diseases, including their pathological conditions that predispose mammals to the conditions in question.
"Preservatives" are compounds that are optionally included in the formulation to substantially reduce the bacterial effects therein, thereby facilitating, for example, the manufacture of multipurpose formulations. Examples of potential preservatives include stearyl dimethyl benzyl ammonium chloride, hexahydroxy quaternary ammonium chloride, benzalkonium chloride (alkyl benzyl dimethyl chloride with alkyl being a long chain compound Of ammonium) and benzethonium chloride. Other types of preservatives include aromatic alcohols such as phenol, butanol, and benzyl alcohol; alkyl parabens such as methyl paraben or propyl paraben; catechol, resorcinol , Cyclohexanol, 3-pentanol and m-cresol. In one embodiment, the preservative herein is benzyl alcohol.
As used herein, the term "treatment" refers to a clinical intervention designed to alter the natural course of an individual or cell being treated during the course of clinical pathology. Desired therapeutic effects include reducing the rate of disease development, improving or reducing disease conditions, and alleviating or improving prognosis. For example, if one or more cancer-related symptoms are reduced or eliminated, including (but not limited to) reducing (or destroying) the proliferation of cancer cells, reducing the symptoms caused by the disease, improving the quality of life of the affected person, reducing treatment Doses of other agents required for the disease, delaying the progression of the disease, and / or prolonging the survival time of the individual, successfully "treat" the individual.
As used herein, "delaying disease progression" means delaying, hindering, slowing, retarding, stabilizing, and / or delaying the development of a disease, such as cancer. The length of this delay can vary depending on the history of the disease and / or the individual being treated. As will be apparent to those skilled in the art, adequate or significant delays can actually cover prevention, where the individual does not develop the disease. For example, advanced cancers, such as the development of metastases, can be delayed.
An "effective amount" is the minimum amount necessary to achieve at least a measurable improvement or prevention of a particular condition. Effective amounts herein may vary depending on factors such as the patient's disease condition, age, sex, and weight, and the ability of the antibody to elicit a desired response in the individual. An effective amount is also one in which a therapeutically beneficial effect exceeds any toxic or detrimental effect of the treatment. For preventive use, beneficial or desired results include results such as eliminating or reducing risk, reducing severity, or delaying the onset of a disease, which includes the biochemical, tissue, and / or behavioral symptoms of the disease, which are manifested during the development of the disease Complications and intermediate pathology phenotype. For therapeutic use, beneficial or desired results include, for example, reducing one or more symptoms caused by the disease, improving the quality of life of the affected person, reducing the dose of other drugs required to treat the disease, enhancing the effect of another agent (such as via a target To), clinical outcomes that delay disease progression and / or prolong survival. In the case of cancer or tumor, an effective amount of the drug can have the following effects: reduce the number of cancer cells; reduce the size of the tumor; inhibit (ie, slow down or ideally stop to a certain extent) the infiltration of cancer cells into peripheral organs; inhibit (I.e., slowing or ideally stopping to some extent) tumor metastasis; inhibiting tumor growth to a certain extent; and / or alleviating one or more symptoms associated with the disorder to a certain extent. The effective amount can be administered in one or more administrations. For the purposes of the present invention, an effective amount of a medicament, compound or pharmaceutical composition is an amount sufficient to directly or indirectly achieve a prophylactic or therapeutic treatment. As understood in the clinical context, an effective amount of a drug, compound or pharmaceutical composition can be achieved with or without another drug, compound or pharmaceutical composition. Therefore, an "effective dose" can be considered in the case of administration of one or more therapeutic agents, and if the desired result can be achieved or achieved in combination with one or more other agents, a single agent can be regarded as being given in an effective amount.
As used herein, "combination" means that in addition to one treatment mode, another treatment mode is administered. Thus, "combination" means performing a treatment mode before, during, or after performing another treatment mode on the individual.
A "disorder" is any condition that would benefit from treatment, including (but not limited to) chronic and acute conditions or diseases, including those pathological conditions that predispose a mammal to the condition of interest.
The terms "cell proliferative disorder" and "proliferative disorder" refer to disorders associated with a certain degree of abnormal cell proliferation. In one embodiment, the cell proliferative disorder is cancer. In one embodiment, the cell proliferative disorder is a tumor.
As used herein, "tumor" refers to all neoplastic cell growth and proliferation, whether malignant or benign, and all precancerous and cancerous cells and tissues. As mentioned herein, the terms "cancer", "cancerous", "cell proliferative disorder", "proliferative disorder" and "tumor" are not mutually exclusive.
The terms "cancer" and "cancerous" refer to or describe mammalian physiological conditions that are typically characterized by unregulated cell growth. Examples of cancer include, but are not limited to, cancerous tumors, lymphomas, blastomas, sarcomas, and leukemia or lymphatic malignancies. More specific examples of such cancers include, but are not limited to, squamous cell carcinoma (e.g., epithelial squamous cell carcinoma), lung cancer (including small cell lung cancer, non-small cell lung cancer, lung adenocarcinoma, and lung squamous carcinoma), peritoneal cancer , Hepatocellular carcinoma, gastric cancer (including gastrointestinal cancer and gastrointestinal stromal cancer), pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, urinary tract cancer, liver cancer, breast cancer, colon cancer, rectum Cancer, colorectal cancer, endometrial or uterine cancer, salivary adenocarcinoma, kidney cancer, prostate cancer, vulvar cancer, thyroid cancer, liver cancer, anal cancer, penile cancer, melanoma, superficially disseminated melanoma, malignant Nevus melanoma, acral freckles melanoma, nodular melanoma, multiple myeloma, and B-cell lymphoma (including mild / follicular non-Hodgkin's lymphoma, NHL), small lymphocytic (SL) NHL, moderate / follicular NHL, moderate diffuse NHL, severe immunoblast NHL, severe lymphoblast NHL, severe small non-split cell NHL, megaloblastic NHL, Mantle cell lymphoma, AIDS-related lymphoma, and Waldenstrom Waldenstrom's Macroglobulinemia), chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), hairy cell leukemia, chronic myelogenous leukemia and post-transplant lymphoproliferative disorder (PTLD), and Abnormal angiogenesis, edema (such as edema associated with brain tumors), Meigs' syndrome, brain cancer, and head and neck cancer and related metastases associated with macular cytopathy. In certain embodiments, cancers suitable for treatment with the antibodies of the invention include breast cancer, colorectal cancer, rectal cancer, non-small cell lung cancer, glioblastoma, non-Hodgkin's lymphoma (NHL), kidney cells Cancer, prostate cancer, liver cancer, pancreatic cancer, soft tissue sarcoma, kaposi's sarcoma, carcinoid, head and neck cancer, ovarian cancer, mesothelioma, and multiple myeloma. In some embodiments, the cancer line is selected from the group consisting of: small cell lung cancer, glioblastoma, neuroblastoma, melanoma, breast cancer, gastric cancer, colorectal cancer (CRC), and hepatocellular carcinoma. In some embodiments, the cancer is selected from the group consisting of non-small cell lung cancer, colorectal cancer, glioblastoma, and breast cancer, including metastatic forms of these cancers.
A "chemotherapeutic agent" is a compound suitable for treating cancer. Examples of chemotherapeutic agents include alkylating agents such as thiotepa and CYTOXAN^® ); Alkyl sulfonates, such as busulfan, improsulfan, and piosulfan; aziridines, such as benzodopa, carboquone ), Metedopa and uredopa; ethyleneimine and methyl melamine, including altretamine, triethylamine melamine, triethylethylphosphonium, triethylene Thiophosphoramidamine and trimethylolmelamine; polyethylene glycol (especially bulatacin and bulatacinone); δ-9-tetrahydrocannabinol (dronabinol ( dronabinol), MARINOL^® ); Β-lapachone; lapachol; colchicine; betulinic acid; camptothecin (including synthetic analog topotecan (HYCAMTIN^® ), CPT-11 (irinotecan, CAMPTOSAR^® ), Ethinocamptothecin, scopolamine, and 9-aminocamptothecin); bryostatin; callystatin; CC-1065 (including its adozelesin, Carzelesin and bizelesin synthetic analogs); Podophyllotoxin; Podophyllotoxic acid; Teniposide; Candida cyclic peptides (especially Candida cyclic peptide 1 and Candida) Cyclic peptide 8); dolastatin; doocarmycin (including synthetic analogs KW-2189 and CB1-TM1); eleutherobin; pancratistatin; Sarcodictyin; spongistatin; nitrogen mustards such as chlorambucil, chlornaphazine, chlorophosphamide, estramustine, Ifosfamide, mechlorethamine, methanothine hydrochloride, melphalan, novembichin, phenesterine, prednisolone Mustard (prednimustine), trofosfamide, uracil mustard; nitrosourea, such as carmustine , Chlorozotocin, fotemustine, lomustine, nimustine, and ranimnustine; antibiotics such as enediyne antibiotics (e.g. Calicheamicin, especially calicheamicin γ1I and calicheamicin ωIl (see, for example, Nicolaou et al.,Angew. Chem Intl. Ed. Engl. , 33: 183-186 (1994)); CDP323, an oral alpha-4 integrin inhibitor; dynemicin, including dynemicin A; esperamicin; and new Cancer suppressor chromophore and related chromatin dichromin antibiotic chromophore); aclacinomysin; actinomycin; autramycin; azaserine; Bleomycin; Cactinomycin; Carabicin; Caminomycin; Carzinophilin; Chromomycin; Actinomycin d ( dactinomycin); daunorubicin; (detorubicin); 6-diazo-5-sideoxy-L-n-leucine; cranberry (doxorubicin) (including ADRIAMYCIN®, (N-morpholine) ) -Cranberry, Cyano- (N-morpholinyl) -Cranberry, 2-Pyrrolyl-Cranberry, Cranberry HCl Liposomal Injection (DOXIL®), Lipid Cranberry TLC D-99 (MYOCET®), PEGylated lipid cranberries (CAELYX®) and deoxy cranberries); epirubicin; esorubicin; idarubicin; Moxithromycin rcellomycin); mitomycin, such as mitomycin C; mycophenolic acid; nogalamycin; olivomycin; peplomycin; Porfiromycin; puromycin; quelamycin; rodorubicin; streptonigrin; streptozocin; tuberculosis Tubercidin; ubenimex; zinostatin; zorubicin; antimetabolites, such as methotrexate, gemcitabine (GEMZAR® ), Tegafur (UFTORAL®), capecitabine (XELODA®), epothilone, and 5-fluorouracil (5-FU); combbutastatin (combretastatin); folic acid Analogs such as denopterin, methotrexate, pteropterin, trimetrexate; Purine analogs such as fludarabine, 6-mercaptopurine, sulfur Thiamiprine, thioguanine; pyrimidine analogs, such as ancitabine, Azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine Floxuridine; androgen, such as calusterone, drostmostanolone propionate, epitiostanol, mepitiostane, and testosterone (androgen) testolactone); anti-adrenal drugs, such as aminoglutethimide, mitotane, trilostane; folic acid supplements, such as frolinic acid; acetonyl glucuronide ( aceglatone); aldophosphamide glycoside; aminolevulinic acid; eniluracil; amsacrine; bestrabucil; beabucil bisantrene); edatraxate; defofamine; demecolcine; diaziquone; elformithine; elliptinium acetate; Epothilone; etoglucid; nitrate Gallium nitrate; hydroxyurea; lentinan; lonidainine; maytansinoids, such as maytansine and ansamitocin; mitoguanine Mitoguazone; mitoxantrone; mopidanmol; nitraerine; pentostatin; phenamet; pirarubicin ); Losoxantrone; 2-ethylhydrazine; procarbazine; PSK® polysaccharide complex (JHS Natural Products, Eugene, Oreg.); Razoxane; rhizoxin); sizofuran; spirogermanium; tenuazonic acid; triaziquone; 2,2 ', 2'-trichlorotriethylamine; Telomeres (especially T-2 toxin, verracurin A, roridin A, and anguidine); urethan; vincristine ( vindesine) (ELDISINE®, FILDESIN®); dacarbazine; mannomustine; miobronitol; mitolactol ); Pipobroman; gacytosine; arabinoside ("Ara-C"); thiotepa; taxoid, such as paclitaxel (TAXOL)^® , Bristol-Myers Squibb Oncology, Princeton, N.J.), Paclitaxel's albumin engineered nanoparticle formulation (ABRAXANE^TM ) And TAXOTERE^® , Rhome-Poulene Rorer, Antony, France); chlorambucil; 6-thioguanine; thiopurine; methotrexate; platinum reagents such as cisplatin, oxaliplatin (oxaliplatin) ( For example, ELOXATIN® and carboplatin; vincas, which prevents tubulin from polymerizing to form microtubules, including vinblastine (VELBAN®), vincristine (ONCOVIN®), Vindesine (ELDISINE®, FILDESIN®) and vinorelbine (NAVELBINE®); etoposide (VP-16); ifosfamide; mitoxantrone ; Leucovorin; novantrone; edatrexate; daunomycin; aminopterin; ibandronate Topoisomerase inhibitor RFS 2000; difluoromethyl ornithine (DMFO); retinoids, such as retinoic acid, including bexarotene (TARGRETIN®); bisphosphine Acid salts such as clodronate (e.g. BONEFOS® or OSTAC®), etidronate (DIDROCAL®), NE-58095, Zoledronic acid / zoledronate (ZOMETA®), alendronate (FOSAMAX®), pamidronate (AREDIA®), tiludron Tiludronate (SKELID®) or risedronate (ACTONEL®); troxacitabine (1,3-dioxolane nucleoside cytosine analog); antisense oligo Nucleotides, especially those expressing genes in signaling pathways involved in abnormal cell proliferation, such as PKC-α, Raf, H-Ras, and epidermal growth factor receptor (EGF-R) (such as erlotinib ) (Tarceva^TM )); And VEGF-A that reduces cell proliferation; vaccines such as THERATOPE® vaccine and gene therapy vaccines, such as ALLOVECTIN® vaccine, LEUVECTIN® vaccine, and VAXID® vaccine; topoisomerase inhibitors of type 1 (such as LURTOTECAN®); rmRH (such as ABARELIX®); BAY439006 (sorafenib; Bayer); SU-11248 (sunitinib; SUTENT®, Pfizer); perifosine; COX-2 inhibition Agents (such as celecoxib or etoricoxib); proteasome inhibitors (such as PS341); bortezomib (VELCADE®); CCI-779; tipifarnib ) (R11577); sorafenib (ABT510); Bcl-2 inhibitors such as oblimersen sodium (GENASENSE®); pixantrone; EGFR inhibitors; tyrosine Kinase inhibitors; serine-threonine kinase inhibitors, such as rapamycin (sirolimus, RAPAMUNE®); farnesyl transferase inhibitors, such as lonafani ( lonafarnib) (SCH 6636, SARASAR^TM ); And a pharmaceutically acceptable salt, acid, or derivative of any of the above; and a combination of two or more of the above, such as CHOP, cyclophosphamide, cranberry, vincristine, and prednisolone Short for combination therapy; and FOLFOX, using oxaliplatin (ELOXATIN^TM ) An abbreviation for a treatment regimen combined with 5-FU and formamidinetetrahydrofolate, and a pharmaceutically acceptable salt, acid, or derivative of any of the foregoing; and a combination of two or more of the foregoing.
As defined herein, chemotherapeutic agents include "antihormones" or "endocrine therapeutic agents" that are used to modulate, reduce, block or inhibit the effects of hormones that promote cancer growth. It can be the hormone itself, including (but not limited to): anti-estrogens and selective estrogen receptor modulators (SERM), including, for example, tamoxifen (including NOLVADEX® tamoxifen), ranoxib Raloxifene, droloxifene, 4-hydroxytamoxifen, trioxifene, keoxifene, LY117018, onapristone, and FARESTON.cndot Toremifene; an aromatase inhibitor that inhibits the enzyme aromatase, which regulates the production of estrogen in the adrenal glands, such as 4 (5) -imidazole, aminoglutethimide, MEGASE® formazone Progesterone, AROMASIN® exemestane, formestanie, fadrozole, RIVISOR® vorozole, FEMARA® letrozole and ARIMIDEX® anastrozole ( anastrozole); and antiandrogens such as flutamide, nilutamide, bicalutamide, leuprolide, and goserelin; and trifloxacin Troxacitabine (1,3-dioxolane cytosine analog); antisense oligonucleotide, It inhibits gene expression in signaling pathways involved in abnormal cell proliferation, such as PKC-α, Raf, and H-Ras; ribonucleases such as VEGF expression inhibitors (such as ANGIOZYME® ribonuclease) and HER2 expression inhibitors ; Vaccines, such as gene therapy vaccines, such as ALLOVECTIN® vaccine, LEUVECTIN® vaccine, and VAXID® vaccine; PROLEUKIN® rIL-2; LURTOTECAN® type 1 topoisomerase inhibitors; ABARELIX® rmRH; Vinorelbine and Angstrom Esperamicin (see US Patent No. 4,675,187), and a pharmaceutically acceptable salt, acid, or derivative of any of the foregoing; and a combination of two or more of the foregoing.
"Growth inhibitor" as used herein refers to a compound or composition that inhibits cell growth in vitro or in vivo. In one embodiment, the growth inhibitory agent is a growth inhibiting antibody that prevents or reduces the proliferation of cells that express the antigen to which the antibody binds. In another embodiment, the growth inhibitor may be a growth inhibitor that significantly reduces the percentage of cells in the S phase. Examples of growth inhibitors include agents that block cell cycle progression (other than S-phase), such as agents that induce G1 arrest and M-phase arrest. Classic M-phase blockers include vinblastine (vincristine and vinblastine), taxanes, and type II topoisomerase inhibitors (such as cranberry, epirubicin, daunorubicin, Etoposide and Bleomycin). Their G1 stasis agents also go deep into S phase stasis, such as DNA alkylating agents such as tamoxifen, prednisone, azolidamine, methamphetamine, cisplatin, methotrexate, 5-Fluorouracil and ara-C. Additional information can be found in Mendelsohn and Israel, The Molecular Basis of Cancer, Chapter 1, entitled "Cell cycle regulation, oncogenes, and antineoplastic drugs", Murakami et al. (W.B. Saunders, Philadelphia, 1995), for example, page 13. Taxanes (paclitaxel and docetaxel) are anticancer drugs derived from the yew tree. TAXOTERE^® , Rhone-Poulenc Rorer) is TAXOL^® , Bristol-Myers Squibb). Paclitaxel and docetaxel promote the assembly of microtubules from tubulin dimers and stabilize the microtubules by preventing depolymerization, which will inhibit mitosis in the cells.
"Radiation therapy" means the use of directed gamma or beta rays to induce sufficient damage to the cells in order to limit the ability of the cells to function properly or to completely destroy the cells. It should be understood that there are many ways to determine the therapeutic dose and duration in the art. Typical treatments are given in a single administration and typical doses range from 10 to 200 units (Gray) per day.
For the purposes of treatment, "individual" means any animal classified as a mammal, including humans, domestic and agricultural animals, and zoo animals, sport animals, or pet animals, such as dogs, horses, cats, cattle, etc. Mammals are preferably humans.
The term "antibody" is used herein in the broadest sense and specifically covers monoclonal antibodies (including full-length monoclonal antibodies), polyclonal antibodies, multispecific antibodies (such as bispecific antibodies) and antibody fragments, as long as they exhibit the desired biological activity .
An "isolated" antibody is one that has been identified and separated from and / or recovered from a component of its natural environment. The pollutant component of its natural environment is a substance that interferes with antibody research, diagnostic or therapeutic use, and may include enzymes, hormones, and other proteinaceous or non-proteinaceous solutes. In some embodiments, the antibody is purified (1) to greater than 95% by weight of the antibody as determined by, for example, the Lowry method, and in some embodiments to greater than 99% by weight; (2) to sufficient Degree of at least 15 N-terminal residues or internal amino acid sequences determined by using, for example, a spinning cup sequenator; or (3) to by using, for example, Coomassie blue) or silver staining. The extent of homogeneity was determined by SDS-PAGE under reducing or non-reducing conditions. Since at least one component of the antibody's natural environment will not be present, isolated antibodies include antibodies in situ within recombinant cells. However, isolated antibodies will usually be prepared by at least one purification step.
A "natural antibody" is usually a heterotetrameric glycoprotein of about 150,000 daltons, consisting of two identical light chains (L) and two identical heavy chains (H). Each light chain is connected to the heavy chain via a covalent disulfide bond, and the number of disulfide bonds in the heavy chain of different immunoglobulin isotypes is different. Each heavy and light chain also has regularly spaced intrachain disulfide bridges. Each heavy chain has a variable domain (V_H ), Followed by a large number of constant domains. Each light chain has a variable domain (V_L ) And has a constant domain at the other end; the constant domain of the light chain is aligned with the first constant domain of the heavy chain, and the variable domain of the light chain is aligned with the variable domain of the heavy chain. It is believed that specific amino acid residues form the interface between the light and heavy chain variable domains.
The term "constant domain" refers to a portion of an immunoglobulin molecule having an amino acid sequence that is more conserved relative to other parts of the immunoglobulin (a variable domain containing an antigen binding site). C of heavy chain_H 1, C_H 2 and C_H 3 domain (collectively referred to as CH) and the CHL (or CL) domain of the light chain.
The "variable region" or "variable domain" of an antibody refers to the amino-terminal domain of the heavy or light chain of an antibody. The variable domain of the heavy chain can be called "V_H ". The variable domain of the light chain can be called "V_L ". These domains are usually the most variable part of an antibody and contain an antigen binding site.
The term "variable" refers to the fact that the sequence of certain portions of the variable domain varies widely between antibodies and is used for the binding and specificity of each particular antibody for its particular antigen. However, variability is not evenly distributed throughout the variable domains of antibodies. It is concentrated in three segments called hypervariable regions (HVR) in the light chain variable domain and the heavy chain variable domain. The more highly conserved portion of the variable domain is called the framework region (FR). The variable domains of the native heavy chain and light chain each contain four FR regions mainly adopting a β-sheet configuration. These FR regions are connected by three HVRs. These HVRs form a loop connecting the β-sheet structure, and in some cases Forms part of a β-sheet structure. The HVRs in each chain are tightly bound together by the FR regions and with the HVRs in other chains to form the antigen-binding site of the antibody (see Kabat et al.,Sequences of Proteins of Immunological Interest , 5th ed., National Institute of Health, Bethesda, Md. (1991)). The constant domain does not directly participate in the binding of the antibody to the antigen, but exhibits various effector functions, such as involving the antibody in antibody-dependent cytotoxicity.
The "light chain" of an antibody (immunoglobulin) from any mammalian species can be assigned to one of two distinctly different types called kappa and lambda based on the amino acid sequence of its constant domain.
The term IgG "isotype" or "subclass" as used herein means any subclass of immunoglobulins defined by the chemical and antigenic characteristics of the constant region.
Antibodies (immunoglobulins) can be classified into different classes depending on the amino acid sequence of the constant domain of their heavy chains. There are five main classes of immunoglobulins: IgA, IgD, IgE, IgG, and IgM, and several of these classes can be further divided into subclasses (isotypes), such as IgG₁ IgG₂ IgG₃ IgG₄ , IgA₁ And IgA₂ . The heavy chain constant domains corresponding to different classes of immunoglobulins are called α, δ, ε, γ, and μ, respectively. The subunit structures and three-dimensional configurations of different classes of immunoglobulins are well known and are generally described in, for example, Abbas et al.,Cellular and Mol. Immunology , 4th ed. (W.B. Saunders, Co., 2000). An antibody may be part of a larger fusion molecule formed by covalent or non-covalent association of the antibody with one or more other proteins or peptides.
The terms "full-length antibody", "intact antibody" and "whole antibody" are used interchangeably herein to indicate a substantially complete form of the antibody rather than an antibody fragment as defined below. These terms refer in particular to antibodies having a heavy chain containing an Fc region.
For the purposes of the present invention, a "naked antibody" is an antibody that does not bind to a cytotoxic moiety or a radioactive label.
An "antibody fragment" comprises a portion of an intact antibody, preferably its antigen binding region. In some embodiments, the antibody fragments described herein are antigen-binding fragments. Examples of antibody fragments include Fab, Fab ', F (ab')₂ And Fv fragments; bifunctional antibodies; linear antibodies; single chain antibody molecules and multispecific antibodies formed from antibody fragments.
The papain digestion of the antibody produces two identical antigen-binding fragments called "Fab" fragments, each with a single antigen-binding site; and an "Fc" fragment, whose name reflects its ability to crystallize easily. Pepsin treatment produces F (ab ') with two antigen-combination sites and still capable of cross-linking with the antigen₂ Fragment.
"Fv" is the smallest antibody fragment that contains a complete antigen-binding site. In one embodiment, the double-chain Fv substance consists of a dimer of a heavy chain variable domain and a light chain variable domain that are closely non-covalently associated. In single-chain Fv (scFv) substances, a heavy chain variable domain and a light chain variable domain can be covalently linked by a flexible peptide linker, so that the light and heavy chains can be similar to double-chain Fv substances "Dimerization" structure association. In this configuration, three HVRs of each variable domain interact to define an antigen-binding site on the surface of the VH-VL dimer. Overall, six HVRs confer antibodies with antigen-binding specificity. However, even a single variable domain (or only one half of the Fv containing three HVRs specific for the antigen) has the ability to recognize and bind the antigen, but the affinity is lower than the entire binding site.
The Fab fragment contains the heavy chain variable domain and the light chain variable domain and also contains the constant domain of the light chain and the first constant domain (CH1) of the heavy chain. Fab 'fragments differ from Fab fragments by adding a small number of residues (including one or more cysteine from the hinge region of the antibody) to the carboxy terminus of the heavy chain CH1 domain. Fab'-SH refers herein to a Fab 'having a cysteine residue in the constant domain with a free thiol group. F (ab ')₂ Antibody fragments were originally made as Fab 'fragment pairs with a hinge region cysteine in the middle. Other chemical couplings of antibody fragments are also known.
A "single-chain Fv" or "scFv" antibody fragment comprises the VH and VL domains of an antibody, where these domains are present in a single polypeptide chain. Generally speaking, scFv polypeptides additionally comprise a polypeptide linker between the VH and VL domains that enables scFv to form the structure required for antigen binding. scFv for comments see e.g. Pluckthün,The Pharmacology of Monoclonal Antibodies Vol. 113, edited by Rosenburg and Moore, (Springer-Verlag, New York, 1994), pp. 269-p. 315.
The term "bifunctional antibody" refers to an antibody fragment having two antigen binding sites, the fragments comprising a heavy chain variable domain (VL) linked to a light chain variable domain (VL) in the same polypeptide chain (VH-VL) VH). By using linkers that are too short to allow pairing between two domains on the same chain, these domains are forced to pair with complementary domains of the other chain and create two antigen-binding sites. Bifunctional antibodies can be bivalent or bispecific. Bifunctional antibodies are more fully described, for example, in EP 404,097; WO 1993/01161; Hudson et al.,Nat. Med. 9: 129-134 (2003); and Hollinger et al.,Proc. Natl. Acad. Sci. USA 90: 6444-6448 (1993). Trifunctional antibodies and tetrafunctional antibodies are also described in Hudson et al.,Nat. Med. 9: 129-134 (2003).
The term "single antibody" as used herein refers to an antibody obtained from a group of substantially homologous antibodies, for example, the individual antibodies constituting the group are identical except for possible mutations that can be present in trace amounts (such as naturally occurring mutations). Therefore, the modifier "single strain" indicates the characteristics of the antibody when it is not a mixture of discrete antibodies. In certain embodiments, such monoclonal antibodies generally include antibodies comprising a polypeptide sequence that binds to a target, wherein the target binding polypeptide sequence is obtained by a method that includes selecting a single target binding polypeptide sequence from a plurality of polypeptide sequences. For example, the selection method may be selecting a unique pure line from a plurality of pure lines (such as a library of fusion tumor pure lines, phage pure lines, or recombinant DNA pure lines). It should be understood that the selected target binding sequence may further alter, for example, to improve affinity for the target, humanize the target binding sequence, improve its production in cell culture, reduce its in vivo immunogenicity, and produce multispecific antibodies Etc., and the antibody comprising the altered target binding sequence is also a monoclonal antibody of the present invention. In contrast to multiple strain antibody preparations, which typically include different antibodies directed against different determinants (antigenic determinants), each monoclonal antibody system of a monoclonal antibody preparation is directed against a single determinant on the antigen. In addition to its specificity, monoclonal antibody preparations are advantageous because they are generally not contaminated with other immunoglobulins.
The modifier "single strain" indicates the characteristics obtained by the anti-system from a substantially homogeneous population of antibodies, and should not be construed as requiring the production of antibodies by any particular method. For example, the monoclonal antibodies to be used according to the present invention can be prepared by a variety of techniques including, for example, fusion tumor methods (e.g., Kohler and Milstein,Nature 256: 495-97 (1975); Hongo et al.,Hybridoma , 14 (3): 253-260 (1995); Harlow et al.,Antibodies: A Laboratory Manual , (Cold Spring Harbor Laboratory Press, 2nd edition. 1988); Hammerling et al.,Monoclonal Antibodies and T-Cell Hybridomas 563-681 (Elsevier, N.Y., 1981)); recombinant DNA methods (see, e.g., U.S. Patent No. 4,816,567); phage presentation techniques (see, e.g., Clackson et al.,Nature , 352: 624-628 (1991); Marks et al.,J. Mol. Biol. 222: 581-597 (1992); Sidhu et al.,J. Mol. Biol. 338 (2): 299-310 (2004); Lee et al.,J. Mol. Biol. 340 (5): 1073-1093 (2004); Fellouse,Proc. Natl. Acad. Sci. USA 101 (34): 12467-12472 (2004); and Lee et al.,J. Immunol. Methods 284 (1-2): 119-132 (2004); and techniques for producing human or human-like antibodies with part or all of human immunoglobulin loci or genes encoding human immunoglobulin sequences in animals (see, for example, WO 1998/24893; WO 1996/34096; WO 1996/33735; WO 1991/10741; Jakobovits et al.,Proc. Natl. Acad. Sci. USA 90: 2551 (1993); Jakobovits et al.,Nature 362: 255-258 (1993); Bruggemann et al.,Year in Immunol. 7:33 (1993); U.S. Patent Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425 and 5,661,016; Marks et al.,Bio / Technology 10: 779-783 (1992); Lonberg et al.,Nature 368: 856-859 (1994); Morrison,Nature 368: 812-813 (1994); Fishwild et al.,Nature Biotechnol. 14: 845-851 (1996); Neuberger,Nature Biotechnol. 14: 826 (1996); and Lonberg and Huszar,Intern. Rev. Immunol. 13: 65-93 (1995).
Monoclonal antibodies herein include, in particular, "chimeric" antibodies in which a portion of the heavy and / or light chain is identical or homologous to a corresponding sequence in an antibody obtained from a particular species or belonging to a particular antibody class or subclass, and The remainder of the chain is identical to or homologous to the corresponding sequence in an antibody obtained from another species or belonging to another antibody class or subclass and fragments of those antibodies, as long as it displays the desired biological activity (see, for example, the United States Patent No. 4,816,567; and Morrison et al.,Proc. Natl. Acad. Sci. USA 81: 6851-6855 (1984)). Chimeric antibodies include PRIMATIZED^® Antibodies, wherein the antigen-binding region of an antibody is obtained from an antibody produced, for example, by immunizing a cynomolgus monkey with the antigen of interest.
A "humanized" form of a non-human (e.g., murine) antibody is a chimeric antibody that contains minimal non-human immunoglobulin-derived sequences. In one embodiment, the humanized antibody is a residue of the HVR from the recipient replaced with an HVR from a non-human species (donor antibody) such as a mouse, rat, rabbit or non-human primate and has Human immunoglobulins (recipient antibodies) of the desired specificity, affinity and / or ability residues. In some cases, the FR residues of a human immunoglobulin are replaced with corresponding non-human residues. In addition, the humanized antibody may comprise residues not found in the recipient antibody or the donor antibody. These modifications can be made to further improve antibody efficacy. In general, a humanized antibody will contain substantially all of at least one and usually two variable domains, where all or substantially all of the hypervariable loops correspond to non-human immunoglobulin's hypervariable loops, and all or substantially all FR is the FR of the human immunoglobulin sequence. Humanized antibodies will also optionally contain at least a portion of the immunoglobulin constant region (Fc), usually the constant region of human immunoglobulin. For further details see for example Jones et al.Nature 321: 522-525 (1986); Riechmann et al.,Nature 332: 323-329 (1988); and Presta,Curr. Op. Struct. Biol. 2: 593-596 (1992). See also e.g. Vaswani and Hamilton,Ann. Allergy, Asthma & Immunol. 1: 105-115 (1998); Harris,Biochem. Soc. Transactions 23: 1035-1038 (1995); Hurle and Gross,Curr. Op. Biotech. 5: 428-433 (1994); and U.S. Patent Nos. 6,982,321 and 7,087,409.
A "human antibody" is an antibody having an amino acid sequence corresponding to the amino acid sequence of an antibody produced by a human and / or an antibody that has been prepared using any of the techniques for producing human antibodies as disclosed herein. This definition of human antibody specifically excludes humanized antibodies that include non-human antigen-binding residues. Various techniques known in the art, including phage presentation libraries, can be used to generate human antibodies. Hoogenboom and Winter,J. Mol. Biol ., 227: 381 (1991); Marks et al.,J. Mol. Biol ., 222: 581 (1991). Cole et al.,Monoclonal Antibodies and Cancer Therapy , Alan R. Liss, p. 77 (1985); Boerner et al.,J. Immunol. , 147 (1): 86-95 (1991) can also be used to prepare human monoclonal antibodies. See also van Dijk and van de Winkel,Curr. Opin. Pharmacol. 5: 368-74 (2001). Human antibodies can be prepared by administering an antigen to a transgenic animal (such as an immunized xenomice) that has been modified to produce such antibodies in response to antigen challenge, but whose endogenous loci are no longer available (e.g., xenomice). About XENOMOUSE^TM (See, for example, U.S. Patent Nos. 6,075,181 and 6,150,584). For human antibodies produced by human B-cell fusion tumor technology, see also, for example, Li et al.,Proc. Natl. Acad. Sci. USA J. 103: 3557-3562 (2006).
A "species-dependent antibody" is an antibody that has a stronger binding affinity for an antigen from a first mammalian species than that of a homologue of that antigen from a second mammalian species. In general, species-dependent antibodies "specifically bind" human antigens (e.g., binding affinity (Kd) values do not exceed about 1 x 10^-7 M, preferably not more than about 1 × 10^-8 M and preferably not more than about 1 × 10^-9 M), but the binding affinity for a homologue of an antigen from a second non-human mammalian species is at least about 50 times, or at least about 500 times, or at least about 1000 times weaker than its binding affinity for a human antigen. The species-dependent antibody may be any of the various types of antibodies as defined above, but is preferably a humanized or human antibody.
As used herein, the term "hypervariable region", "HVR" or "HV" refers to a region in which the sequence of a variable domain of an antibody is highly variable and / or forms a structurally defined loop. In general, antibodies include six HVRs; three in VH (H1, H2, H3), and three in VL (L1, L2, L3). Among the native antibodies, H3 and L3 show the most diversity among the six HVRs, and in particular, H3 plays a unique role in imparting fine specificity to antibodies. See, for example, Xu et al.Immunity 13: 37-45 (2000); Johnson and Wu,Methods in Molecular Biology 248: 1-25 (ed. Lo, Human Press, Totowa, NJ, 2003). In fact, naturally occurring camel antibodies composed of only the heavy chain are functional and stable in the absence of light chains. See, for example, Hamers-Casterman et al.Nature 363: 446-448 (1993); Sheriff et al.,Nature Struct. Biol. 3: 733-736 (1996).
Many HVR narratives are used and covered in this article. Kabat complementarity determining regions (CDRs) are based on sequence variability and are most commonly used (Kabat et al.,Sequences of Proteins of Immunological Interest , 5th edition, Public Health Service, National Institutes of Health, Bethesda, Md. (1991)). Chothia also points out the position of the structural ring (Chothia and LeskJ. Mol. Biol. 196: 901-917 (1987)). AbM HVR represents a compromise between Kabat HVR and Chothia structural loops and is used by Oxford Molecular's AbM antibody modeling software. "Contact" HVR is based on an analysis of the complex crystal structures available. The residue annotations for each of these HVRs are as follows.
Ring Kabat AbM Chothia contact
L1 L24-L34 L24-L34 L26-L32 L30-L36
L2 L50-L56 L50-L56 L50-L52 L46-L55
L3 L89-L97 L89-L97 L91-L96 L89-L96
H1 H31-H35B H26-H35B H26-H32 H30-H35B (Kabat number)
H1 H31-H35 H26-H35 H26-H32 H30-H35 (Chothia number)
H2 H50-H65 H50-H58 H53-H55 H47-H58
H3 H95-H102 H95-H102 H96-H101 H93-H101
HVRs can include "extended HVRs": 24-36 or 24-34 (L1), 46-56 or 50-56 (L2) and 89-97 or 89-96 (L3) in VL, and 26 in VH -35 (H1), 50-65 or 49-65 (H2) and 93-102, 94-102 or 95-102 (H3). Variable domain residues are numbered as described by Kabat et al. (Ibid.) Above for each of these definitions.
"Framework" or "FR" residues are their variable domain residues other than HVR residues as defined herein.
The terms "variable domain residue numbering as in Kabat" or "amino acid position numbering as in Kabat" and variations thereof refer to the heavy chain variable domain of Kabat et al. (Ibid.) Used to compile antibodies or Numbering system for light chain variable domains. Using this numbering system, the actual linear amino acid sequence can contain fewer or additional amino acids, which is equivalent to simplifying or inserting a variable domain FR or HVR. For example, the heavy chain variable domain may include a single amino acid insertion after residue 52 of H2 (residue 52a according to Kabat) and an insertion residue after residue 82 of the heavy chain FR (eg, according to Kabat's Residues 82a, 82b, 82c, etc.). The Kabat numbering of residues in a given antibody can be determined by comparing the antibody sequence to the homology regions of the "standard" Kabat numbering sequence.
The Kabat numbering system is generally used when referring to residues in the variable domain (approximately residues 1-107 of the light chain and residues 1-113 of the heavy chain) (e.g., Kabat et al.,Sequences of Immunological Interest 5th Edition. Public Health Service, National Institutes of Health, Bethesda, Md. (1991)). When referring to residues in the constant region of the immunoglobulin heavy chain, the "EU numbering system" or "EU index" is generally used (e.g., the EU index reported in Kabat et al., Supra). "EU index as in Kabat" refers to the residue numbering of the human IgG1 EU antibody.
The expression `` linear antibody '' refers to Zapata et al. (1995Protein Eng , 8 (10): 1057-1062). Briefly, these antibodies include a pair of tandem Fd segments (VH-CH1-VH-CH1), which together with a complementary light chain polypeptide form a pair of antigen-binding regions. Linear antibodies can be bispecific or monospecific.
As used herein, the term "specific binding" or "specificity" refers to a measurable and reproducible interaction such as the binding between a target and an antibody in the presence of a heterogeneous population of molecules including biomolecules Determine the existence of goals. For example, an antibody that specifically binds a target (which may be an epitope) is an antibody that binds this target with greater affinity (avidity), easier and / or longer duration than other targets. In one embodiment, as measured, for example, by radioimmunoassay (RIA), the extent to which an antibody binds to an unrelated target is less than about 10% of the binding of the antibody to the target. In certain embodiments, the dissociation constant (Kd) of the antibody that specifically binds the target is ≦ 1 μM, ≦ 100 nM, ≦ 10 nM, ≦ 1 nM, or ≦ 0.1 nM. In certain embodiments, the antibody specifically binds to an epitope on a protein that is conserved among proteins from different species. In another embodiment, specific binding may include, but is not required to be, exclusive binding.
II. Antibody formulations and preparations
The invention herein relates to a stable aqueous formulation comprising an antibody, such as an anti-PDL1 antibody. In some embodiments, the formulation comprises an antibody (eg, a monoclonal antibody), sucrose, a buffer, and a surfactant, wherein the pH of the formulation is from about 5.0 to about 7.0. In some embodiments, the antibody (e.g., an anti-PDL1 antibody described herein) in the formulation is in an amount from about 40 mg / ml to about 125 mg / ml. In some embodiments, the buffer is histidine (eg, histamine acetate) or sodium acetate. In some embodiments, the buffer in the formulation is at a concentration of about 15 mM to about 25 mM. In some embodiments, the sucrose in the formulation is from about 60 mM to about 240 mM. In some embodiments, the surfactant in the formulation is a polysorbate (eg, polysorbate 20). In some embodiments, the polysorbate in the formulation is at a concentration of about 0.005% (w / v) to about 0.06% (w / v). In some embodiments, the pH of the formulation is from about 5.0 to about 6.3. In some embodiments, provided herein is a stable aqueous pharmaceutical formulation comprising an anti-PDL1 monoclonal antibody at a concentration of about 40 mg / ml to about 125 mg / ml, and histamine at a concentration of about 15 mM to about 25 mM Acid acetate or sodium acetate, sucrose at a concentration of about 60 mM to about 240 mM, polysorbate at a concentration of about 0.005% (w / v) to about 0.06% (w / v), and a pH of about 5.0 to About 6.3. In some embodiments, the formulation comprises an anti-PDL1 monoclonal antibody in an amount of about 125 mg / ml, sucrose in a concentration of about 240 mM, and a pH of about 5.5. In some embodiments, the formulation comprises an anti-PDL1 monoclonal antibody in an amount of about 60 mg / ml, sucrose in a concentration of about 120 mM and a pH of about 5.8.
In some embodiments, the antibody in the formulation is stable at -20 ° C for at least about 6 months, at least about 12 months, at least about 18 months, at least two years, at least three years, or at least four years. In some embodiments, the antibody in the formulation is stable at 2-8 ° C for at least about 6 months, at least about 12 months, at least about 18 months, at least two years, or at least three years. In some embodiments, the antibody retains at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, or at least about 95% after storage. % Its biological activity (eg, binding to the target or therapeutic efficacy) before storage (ie, when the pharmaceutical formulation is prepared).
In certain embodiments, the formulation is stable at about 40 ° C for at least about 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 14 days, 21 days, 28 days, or more than 28 days . In certain embodiments, the formulation is stable at about 40 ° C for at least about 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, or more than 8 weeks. In certain embodiments, the formulation is stable for at least 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months at about 25 ° C. Month, 10 months, 11 months, 12 months, 13 months, 14 months, 15 months, 16 months, 17 months, 18 months, 19 months, 20 months, 21 months, 22 months, 23 months, 24 months or more. In certain embodiments, the formulation is stable for at least 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months at about 5 ° C. Month, 10 months, 11 months, 12 months, 13 months, 14 months, 15 months, 16 months, 17 months, 18 months, 19 months, 20 months, 21 months, 22 months, 23 months, 24 months or more. In certain embodiments, the formulation is stable at about -20 ° C for at least 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 Months, 10 months, 11 months, 12 months, 13 months, 14 months, 15 months, 16 months, 17 months, 18 months, 19 months, 20 months, 21 months , 22 months, 23 months, 24 months, 25 months, 26 months, 27 months, 28 months, 29 months, 30 months, 31 months, 32 months, 33 months, 34 Months, 35 months, 36 months, 37 months, 38 months, 39 months, 40 months, 41 months, 42 months, 43 months, 44 months, 45 months, 46 months , 47 months, 48 months, or more. In certain embodiments, the formulation is stable at 5 ° C or -20 ° C for at least 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months , 9 months, 10 months, 11 months, 12 months, 13 months, 14 months, 15 months, 16 months, 17 months, 18 months, 19 months, 20 months, 21 Months, 22 months, 23 months, 24 months, 25 months, 26 months, 27 months, 28 months, 29 months, 30 months, 31 months, 32 months, 33 months , 34 months, 35 months, 36 months, 37 months, 38 months, 39 months, 40 months, 41 months, 42 months, 43 months, 44 months, 45 months, 46 Months, 47 months, 48 months or more. In addition, the formulation is preferably stable after freezing (to, for example, -20 ° C, -40 ° C, or -70 ° C) and thawing the formulation, such as after 1, 2, 3, 4, or 5 freezing and thawing cycles.
A. antibody ( Such as anti PDL1 antibody )
In some embodiments, the antibody in the formulation comprises at least one tryptophan (eg, at least two, at least three, or at least four) in the heavy and / or light chain sequences. In some embodiments, the amino acid tryptophan is in the CDR region, framework region, and / or constant region of the antibody. In some embodiments, the antibody comprises two or three tryptophan residues in the CDR region. In some embodiments, the antibody in the formulation is an anti-PDL1 antibody. PD-L1 (progressive cell death 1 ligand 1), also known as PDL1, B7-H1, B7-4, CD274, and B7-H, is a transmembrane protein and its interaction with PD-1 inhibits T Cell activation and cytokine production. In some embodiments, the anti-PDL1 antibodies described herein bind to human PD-L1. Examples of anti-PDL1 antibodies that can be formulated using the formulations described herein are described in PCT patent applications WO 2010/077634 A1 and US 8,217,149, which are incorporated herein by reference.
In some embodiments, the anti-PDL1 antibody is capable of inhibiting the binding between PD-L1 and PD-1 and / or between PD-L1 and B7-1. In some embodiments, the anti-PDL1 antibody is a monoclonal antibody. In some embodiments, the anti-PDL1 antibody is an antibody fragment selected from the group consisting of: Fab, Fab'-SH, Fv, scFv, and (Fab ')<sub>2</sub> Fragment. In some embodiments, the anti-PDL1 antibody is a humanized antibody. In some embodiments, the anti-PDL1 antibody is a human antibody.
The anti-PDL1 antibodies described in WO 2010/077634 A1 and US 8,217,149 can be formulated in the formulations described herein. In some embodiments, the anti-PDL1 antibody comprises a heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 30, and a light chain variable region comprising an amino acid sequence of SEQ ID NO: 31.
In one embodiment, the anti-PD-L1 antibody contains a heavy chain variable region polypeptide comprising HVR-H1, HVR-H2, and HVR-H3 sequences, wherein:
(a) HVR-H1 sequence is GFTFSX<sub>1</sub> SWIH (SEQ ID NO: 11);
(b) HVR-H2 sequence is AWIX<sub>2</sub> PYGGSX<sub>3</sub> YYADSVKG (SEQ ID NO: 12);
(c) the HVR-H3 sequence is RHWPGGFDY (SEQ ID NO: 13);
In addition: X<sub>1</sub> D or G; X<sub>2</sub> Is S or L; X<sub>3</sub> Is T or S.
In a particular aspect, X<sub>1</sub> Is D; X<sub>2</sub> Is S and X<sub>3</sub> Is T. In another aspect, the polypeptide is further comprised according to the formula: (HC-FR1)-(HVR-H1)-(HC-FR2)-(HVR-H2)-(HC-FR3)-(HVR-H3)- (HC-FR4) sequence of variable region heavy chain framework juxtaposed between HVRs. In another aspect, the framework sequence is derived from a human common framework sequence. In another aspect, the framework sequence is a VH subgroup III common framework. In another aspect, at least one framework sequence is as follows:
HC-FR1 is EVQLVESGGGLVQPGGSLRLSCAAS (SEQ ID NO: 14)
HC-FR2 is WVRQAPGKGLEWV (SEQ ID NO: 15)
HC-FR3 is RFTISADTSKNTAYLQMNSLRAEDTAVYYCAR (SEQ ID NO: 16)
HC-FR4 is WGQGTLVTVSA (SEQ ID NO: 17).
In another aspect, the heavy chain polypeptide is further combined with a variable region light chain comprising HVR-L1, HVR-L2, and HVR-L3, wherein:
(a) HVR-L1 sequence is RASQX<sub>4</sub> X<sub>5</sub> X<sub>6</sub> TX<sub>7</sub> X<sub>8</sub> A (SEQ ID NO: 18);
(b) HVR-L2 sequence is SASX<sub>9</sub> LX<sub>10</sub> S (SEQ ID NO: 19);
(c) HVR-L3 sequence is QQX<sub>11</sub> X<sub>12</sub> X<sub>13</sub> X<sub>14</sub> PX<sub>15</sub> T (SEQ ID NO: 20);
In addition: X<sub>4</sub> D or V; X<sub>5</sub> V or I; X<sub>6</sub> Is S or N; X<sub>7</sub> A or F; X<sub>8</sub> V or L; X<sub>9</sub> F or T; X<sub>10</sub> Y or A; X<sub>11</sub> Is Y, G, F or S; X<sub>12</sub> Is L, Y, F or W; X<sub>13</sub> Is Y, N, A, T, G, F or I; X<sub>14</sub> H, V, P, T or I; X<sub>15</sub> It is A, W, R, P or T.
In another aspect, X<sub>4</sub> Is D; X<sub>5</sub> V; X<sub>6</sub> Is S; X<sub>7</sub> Is A; X<sub>8</sub> V; X<sub>9</sub> Is F; X<sub>10</sub> Is Y; X<sub>11</sub> Is Y; X<sub>12</sub> Is L; X<sub>13</sub> Is Y; X<sub>14</sub> Is H; X<sub>15</sub> For A. In another aspect, the light chain is further comprised according to the formula: (LC-FR1)-(HVR-L1)-(LC-FR2)-(HVR-L2)-(LC-FR3)-(HVR-L3) -(LC-FR4) HVR sequences juxtaposed between variable region light chain framework sequences. In another aspect, the framework sequence is derived from a human common framework sequence. In another aspect, the framework sequence is a VL κ I common framework. In another aspect, at least one framework sequence is as follows:
LC-FR1 is DIQMTQSPSSLSASVGDRVTITC (SEQ ID NO: 21)
LC-FR2 is WYQQKPGKAPKLLIY (SEQ ID NO: 22)
LC-FR3 is GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC (SEQ ID NO: 23)
LC-FR4 is FGQGTKVEIKR (SEQ ID NO: 24).
In another embodiment, an isolated anti-PDL1 antibody or antigen-binding fragment is provided comprising heavy chain and light chain variable region sequences, wherein
(a) The heavy chain includes HVR-H1, HVR-H2, and HVR-H3, of which:
(i) HVR-H1 sequence is GFTFSX<sub>1</sub> SWIH; (SEQ ID NO: 11)
(ii) HVR-H2 sequence is AWIX<sub>2</sub> PYGGSX<sub>3</sub> YYADSVKG (SEQ ID NO: 12)
(iii) the HVR-H3 sequence is RHWPGGFDY, and (SEQ ID NO: 13)
(b) The light chain includes HVR-L1, HVR-L2 and HVR-L3, of which:
(i) HVR-L1 sequence is RASQX<sub>4</sub> X<sub>5</sub> X<sub>6</sub> TX<sub>7</sub> X<sub>8</sub> A (SEQ ID NO: 18)
(ii) HVR-L2 sequence is SASX<sub>9</sub> LX<sub>10</sub> S; and (SEQ ID NO: 19)
(iii) HVR-L3 sequence is QQX<sub>11</sub> X<sub>12</sub> X<sub>13</sub> X<sub>14</sub> PX<sub>15</sub> T; (SEQ ID NO: 20)
Of which: X<sub>1</sub> D or G; X<sub>2</sub> Is S or L; X<sub>3</sub> T or S; X<sub>4</sub> D or V; X<sub>5</sub> V or I; X<sub>6</sub> Is S or N; X<sub>7</sub> A or F; X<sub>8</sub> V or L; X<sub>9</sub> F or T; X<sub>10</sub> Y or A; X<sub>11</sub> Is Y, G, F or S; X<sub>12</sub> Is L, Y, F or W; X<sub>13</sub> Is Y, N, A, T, G, F or I; X<sub>14</sub> H, V, P, T or I; X<sub>15</sub> It is A, W, R, P or T.
In a particular aspect, X<sub>1</sub> Is D; X<sub>2</sub> Is S and X<sub>3</sub> Is T. In another aspect, X<sub>4</sub> Is D; X<sub>5</sub> V; X<sub>6</sub> Is S; X<sub>7</sub> Is A; X<sub>8</sub> V; X<sub>9</sub> Is F; X<sub>10</sub> Is Y; X<sub>11</sub> Is Y; X<sub>12</sub> Is L; X<sub>13</sub> Is Y; X<sub>14</sub> Is H; X<sub>15</sub> For A. In another aspect, X<sub>1</sub> Is D; X<sub>2</sub> Is S and X<sub>3</sub> Is T; X<sub>4</sub> Is D; X<sub>5</sub> V; X<sub>6</sub> Is S; X<sub>7</sub> Is A; X<sub>8</sub> V; X<sub>9</sub> Is F; X<sub>10</sub> Is Y; X<sub>11</sub> Is Y; X<sub>12</sub> Is L; X<sub>13</sub> Is Y; X<sub>14</sub> H and X<sub>15</sub> For A.
In another aspect, the heavy chain variable region comprises one or more of (HC-FR1)-(HVR-H1)-(HC-FR2)-(HVR-H2)-(HC-FR3)-( HVR-H3)-(HC-FR4) are juxtaposed framework sequences between HVRs, and the light chain variable region contains one or more (HVR-L2)-(LC-FR3)-(HVR-L3)-(LC-FR4). In another aspect, the framework sequence is derived from a human common framework sequence. In another aspect, the heavy chain framework sequence is derived from a Kabat subgroup I, II or III sequence. In another aspect, the heavy chain framework sequence is a VH subgroup III common framework. In another aspect, the one or more heavy chain framework sequences are as follows:
HC-FR1 EVQLVESGGGLVQPGGSLRLSCAAS (SEQ ID NO: 14)
HC-FR2 WVRQAPGKGLEWV (SEQ ID NO: 15)
HC-FR3 RFTISADTSKNTAYLQMNSLRAEDTAVYYCAR (SEQ ID NO: 16)
HC-FR4 WGQGTLVTVSA (SEQ ID NO: 17).
In another aspect, the light chain framework sequence is derived from a Kabat κ I, II, II or IV subgroup sequence. In another aspect, the light chain framework sequence is a VL κ I common framework. In another aspect, one or more light chain framework sequences are as follows:
LC-FR1 DIQMTQSPSSLSASVGDRVTITC (SEQ ID NO: 21)
LC-FR2 WYQQKPGKAPKLLIY (SEQ ID NO: 22)
LC-FR3 GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC (SEQ ID NO: 23)
LC-FR4 FGQGTKVEIKR (SEQ ID NO: 24).
In another specific aspect, the antibody further comprises a human or murine constant region. In another aspect, the human constant region is selected from the group consisting of IgG1, IgG2, IgG2, IgG3, IgG4. In another specific aspect, the human constant region is IgG1. In another aspect, the murine constant region is selected from the group consisting of: IgG1, IgG2A, IgG2B, IgG3. In another aspect, the murine constant region is IgG2A. In another specific aspect, the antibody has a reduced or minimal effector function. In another specific aspect, the minimal effector function is produced by "no effect Fc mutation" or aglycosylation. In another embodiment, fewer effector Fc mutations are made to the N297A or D265A / N297A substitutions in the constant region.
In another embodiment, an anti-PDL1 antibody is provided comprising heavy chain and light chain variable region sequences, wherein:
(a) The heavy chain further comprises HVR-H1, HVR-H2, and HVR-H3 sequences, which have GFTFSDSWIH (SEQ ID NO: 25), AWISPYGGSTYYADSVKG (SEQ ID NO: 26), and RHWPGGFDY (SEQ ID NO: 13), respectively. At least 85% sequence identity, or
(b) The light chain further comprises HVR-L1, HVR-L2, and HVR-L3 sequences, which have RASQDVSTAVA (SEQ ID NO: 27), SASFLYS (SEQ ID NO: 28), and QQYLYHPAT (SEQ ID NO: 29), respectively. At least 85% sequence identity.
In a particular aspect, sequence identity is 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%. In another aspect, the variable region of the heavy chain comprises one or more of the following: HVR-H3)-(HC-FR4) are juxtaposed framework sequences between HVRs, and the light chain variable region contains one or more (HVR-L2)-(LC-FR3)-(HVR-L3)-(LC-FR4). In another aspect, the framework sequence is derived from a human common framework sequence. In another aspect, the heavy chain framework sequence is derived from a Kabat subgroup I, II or III sequence. In another aspect, the heavy chain framework sequence is a VH subgroup III common framework. In another aspect, the one or more heavy chain framework sequences are as follows:
HC-FR1 EVQLVESGGGLVQPGGSLRLSCAAS (SEQ ID NO: 14)
HC-FR2 WVRQAPGKGLEWV (SEQ ID NO: 15)
HC-FR3 RFTISADTSKNTAYLQMNSLRAEDTAVYYCAR (SEQ ID NO: 16)
HC-FR4 WGQGTLVTVSA (SEQ ID NO: 17).
In another aspect, the light chain framework sequence is derived from a Kabat κ I, II, II or IV subgroup sequence. In another aspect, the light chain framework sequence is a VL κ I common framework. In another aspect, one or more light chain framework sequences are as follows:
LC-FR1 DIQMTQSPSSLSASVGDRVTITC (SEQ ID NO: 21)
LC-FR2 WYQQKPGKAPKLLIY (SEQ ID NO: 22)
LC-FR3 GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC (SEQ ID NO: 23)
LC-FR4 FGQGTKVEIKR (SEQ ID NO: 24).
In another specific aspect, the antibody further comprises a human or murine constant region. In another aspect, the human constant region is selected from the group consisting of IgG1, IgG2, IgG2, IgG3, IgG4. In another specific aspect, the human constant region is IgG1. In another aspect, the murine constant region is selected from the group consisting of: IgG1, IgG2A, IgG2B, IgG3. In another aspect, the murine constant region is IgG2A. In another specific aspect, the antibody has a reduced or minimal effector function. In another specific aspect, the minimal effector function is produced by "no effect Fc mutation" or aglycosylation. In another embodiment, fewer effector Fc mutations are made to the N297A or D265A / N297A substitutions in the constant region.
In another embodiment, an isolated anti-PDL1 antibody is provided comprising heavy chain and light chain variable region sequences, wherein:
(a) the heavy chain sequence has at least 85% sequence identity with the heavy chain sequence: EVQLVESGGGLVQPGGSLRLS CAASGFTFSDSWIHWVRQAPGKGLEWVAWISPYGGSTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARRHWPGGFDYWGQGTLVTVSA (SEQ ID NO: 30)
(b) Light chain sequence and light chain sequence: DIQMTQSPSSLSASVGDRVTITCRA SQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYLYHPATFGQGTKVEIKR (SEQ ID NO: 31) has at least 85% sequence identity.
In a specific aspect, the sequence identity is 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%. In another aspect, the heavy chain variable region comprises one or more of (HC-FR1)-(HVR-H1)-(HC-FR2)-(HVR-H2)-(HC-FR3)-( HVR-H3)-(HC-FR4) are juxtaposed framework sequences between HVRs, and the light chain variable region contains one or more (HVR-L2)-(LC-FR3)-(HVR-L3)-(LC-FR4). In another aspect, the framework sequence is derived from a human common framework sequence. In another aspect, the heavy chain framework sequence is derived from a Kabat subgroup I, II or III sequence. In another aspect, the heavy chain framework sequence is a VH subgroup III common framework. In another aspect, the one or more heavy chain framework sequences are as follows:
HC-FR1 EVQLVESGGGLVQPGGSLRLSCAAS (SEQ ID NO: 14)
HC-FR2 WVRQAPGKGLEWV (SEQ ID NO: 15)
HC-FR3 RFTISADTSKNTAYLQMNSLRAEDTAVYYCAR (SEQ ID NO: 16)
HC-FR4 WGQGTLVTVSA (SEQ ID NO: 17).
In another aspect, the light chain framework sequence is derived from a Kabat κ I, II, II or IV subgroup sequence. In another aspect, the light chain framework sequence is a VL κ I common framework. In another aspect, one or more light chain framework sequences are as follows:
LC-FR1 DIQMTQSPSSLSASVGDRVTITC (SEQ ID NO: 21)
LC-FR2 WYQQKPGKAPKLLIY (SEQ ID NO: 22)
LC-FR3 GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC (SEQ ID NO: 23)
LC-FR4 FGQGTKVEIKR (SEQ ID NO: 24).
In another specific aspect, the antibody further comprises a human or murine constant region. In another aspect, the human constant region is selected from the group consisting of IgG1, IgG2, IgG2, IgG3, IgG4. In another specific aspect, the human constant region is IgG1. In another aspect, the murine constant region is selected from the group consisting of: IgG1, IgG2A, IgG2B, IgG3. In another aspect, the murine constant region is IgG2A. In another specific aspect, the antibody has a reduced or minimal effector function. In another specific aspect, the minimal effector function is produced by prokaryotic cells. In another specific aspect, the minimal effector function is produced by "no effect Fc mutation" or aglycosylation. In another embodiment, fewer effector Fc mutations are made to the N297A or D265A / N297A substitutions in the constant region.
In another embodiment, an isolated anti-PDL1 antibody is provided comprising heavy chain and light chain variable region sequences, wherein:
(a) The heavy chain sequence has at least 85% sequence identity with the heavy chain sequence: EVQLVESGGGLVQPGGSLRLS CAASGFTFSDSWIHWVRQAPGKGLEWVAWISPYGGSTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARRHWPGGFDYWGQGTLVTVSS (SEQ ID NO: 32), or
(b) Light chain sequence and light chain sequence: DIQMTQSPSSLSASVGDRVTITCRASQD VSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYLYHPATFGQGTKVEIKR (SEQ ID NO: 31) has at least 85% sequence identity.
In a specific aspect, the sequence identity is 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%. In another aspect, the heavy chain variable region comprises one or more of (HC-FR1)-(HVR-H1)-(HC-FR2)-(HVR-H2)-(HC-FR3)-( HVR-H3)-(HC-FR4) are juxtaposed framework sequences between HVRs, and the light chain variable region contains one or more (HVR-L2)-(LC-FR3)-(HVR-L3)-(LC-FR4). In another aspect, the framework sequence is derived from a human common framework sequence. In another aspect, the heavy chain framework sequence is derived from a Kabat subgroup I, II or III sequence. In another aspect, the heavy chain framework sequence is a VH subgroup III common framework. In another aspect, the one or more heavy chain framework sequences are as follows:
HC-FR1 EVQLVESGGGLVQPGGSLRLSCAAS (SEQ ID NO: 14)
HC-FR2 WVRQAPGKGLEWV (SEQ ID NO: 15)
HC-FR3 RFTISADTSKNTAYLQMNSLRAEDTAVYYCAR (SEQ ID NO: 16)
HC-FR4 WGQGTLVTVSS (SEQ ID NO: 33).
In another aspect, the light chain framework sequence is derived from a Kabat κ I, II, II or IV subgroup sequence. In another aspect, the light chain framework sequence is a VL κ I common framework. In another aspect, one or more light chain framework sequences are as follows:
LC-FR1 DIQMTQSPSSLSASVGDRVTITC (SEQ ID NO: 21)
LC-FR2 WYQQKPGKAPKLLIY (SEQ ID NO: 22)
LC-FR3 GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC (SEQ ID NO: 23)
LC-FR4 FGQGTKVEIKR (SEQ ID NO: 24).
In another specific aspect, the antibody further comprises a human or murine constant region. In another aspect, the human constant region is selected from the group consisting of IgG1, IgG2, IgG2, IgG3, IgG4. In another specific aspect, the human constant region is IgG1. In another aspect, the murine constant region is selected from the group consisting of: IgG1, IgG2A, IgG2B, IgG3. In another aspect, the murine constant region is IgG2A. In another specific aspect, the antibody has a reduced or minimal effector function. In another specific aspect, the minimal effector function is produced by prokaryotic cells. In another specific aspect, the minimal effector function is produced by "no effect Fc mutation" or aglycosylation. In another embodiment, fewer effector Fc mutations are made to the N297A or D265A / N297A substitutions in the constant region.
In another aspect, the variable region of the heavy chain comprises one or more of the following: HVR-H3)-(HC-FR4) are juxtaposed framework sequences between HVRs, and the light chain variable region contains one or more (HVR-L2)-(LC-FR3)-(HVR-L3)-(LC-FR4). In another aspect, the framework sequence is derived from a human common framework sequence. In another aspect, the heavy chain framework sequence is derived from a Kabat subgroup I, II or III sequence. In another aspect, the heavy chain framework sequence is a VH subgroup III common framework. In another aspect, the one or more heavy chain framework sequences are as follows:
HC-FR1 EVQLVESGGGLVQPGGSLRLSCAASGFTFS (SEQ ID NO: 34)
HC-FR2 WVRQAPGKGLEWVA (SEQ ID NO: 35)
HC-FR3 RFTISADTSKNTAYLQMNSLRAEDTAVYYCAR (SEQ ID NO: 16)
HC-FR4 WGQGTLVTVSS (SEQ ID NO: 33).
In another aspect, the light chain framework sequence is derived from a Kabat κ I, II, II or IV subgroup sequence. In another aspect, the light chain framework sequence is a VL κ I common framework. In another aspect, one or more light chain framework sequences are as follows:
LC-FR1 DIQMTQSPSSLSASVGDRVTITC (SEQ ID NO: 21)
LC-FR2 WYQQKPGKAPKLLIY (SEQ ID NO: 22)
LC-FR3 GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC (SEQ ID NO: 23)
LC-FR4 FGQGTKVEIK (SEQ ID NO: 36).
In another specific aspect, the antibody further comprises a human or murine constant region. In another aspect, the human constant region is selected from the group consisting of IgG1, IgG2, IgG2, IgG3, IgG4. In another specific aspect, the human constant region is IgG1. In another aspect, the murine constant region is selected from the group consisting of: IgG1, IgG2A, IgG2B, IgG3. In another aspect, the murine constant region is IgG2A. In another specific aspect, the antibody has a reduced or minimal effector function. In another specific aspect, the minimal effector function is produced by "no effect Fc mutation" or aglycosylation. In another embodiment, fewer effector Fc mutations are made to the N297A or D265A / N297A substitutions in the constant region.
In another embodiment, an anti-PDL1 antibody is provided comprising heavy chain and light chain variable region sequences, wherein:
(c) The heavy chain further comprises HVR-H1, HVR-H2, and HVR-H3 sequences, which have GFTFSDSWIH (SEQ ID NO: 4), AWISPYGGSTYYADSVKG (SEQ ID NO: 5), and RHWPGGFDY (SEQ ID NO: 6) respectively. At least 85% sequence identity, or
(d) The light chain further comprises HVR-L1, HVR-L2, and HVR-L3 sequences, which have RASQDVSTAVA (SEQ ID NO: 1), SASFLYS (SEQ ID NO: 2), and QQYLYHPAT (SEQ ID NO: 3), respectively. At least 85% sequence identity.
In a specific aspect, the sequence identity is 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%. In another aspect, the heavy chain variable region comprises one or more of (HC-FR1)-(HVR-H1)-(HC-FR2)-(HVR-H2)-(HC-FR3)-( HVR-H3)-(HC-FR4) are juxtaposed framework sequences between HVRs, and the light chain variable region contains one or more (HVR-L2)-(LC-FR3)-(HVR-L3)-(LC-FR4). In another aspect, the framework sequence is derived from a human common framework sequence. In another aspect, the heavy chain framework sequence is derived from a Kabat subgroup I, II or III sequence. In another aspect, the heavy chain framework sequence is a VH subgroup III common framework. In another aspect, the one or more heavy chain framework sequences are as follows:
HC-FR1 EVQLVESGGGLVQPGGSLRLSCAAS (SEQ ID NO: 34)
HC-FR2 WVRQAPGKGLEWV (SEQ ID NO: 35)
HC-FR3 RFTISADTSKNTAYLQMNSLRAEDTAVYYCAR (SEQ ID NO: 16)
HC-FR4 WGQGTLVTVSSASTK (SEQ ID NO: 33).
In another aspect, the light chain framework sequence is derived from a Kabat κ I, II, II or IV subgroup sequence. In another aspect, the light chain framework sequence is a VL κ I common framework. In another aspect, one or more light chain framework sequences are as follows:
LC-FR1 DIQMTQSPSSLSASVGDRVTITC (SEQ ID NO: 21)
LC-FR2 WYQQKPGKAPKLLIY (SEQ ID NO: 22)
LC-FR3 GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC (SEQ ID NO: 23)
LC-FR4 FGQGTKVEIKR (SEQ ID NO: 24).
In another specific aspect, the antibody further comprises a human or murine constant region. In another aspect, the human constant region is selected from the group consisting of IgG1, IgG2, IgG2, IgG3, IgG4. In another specific aspect, the human constant region is IgG1. In another aspect, the murine constant region is selected from the group consisting of: IgG1, IgG2A, IgG2B, IgG3. In another aspect, the murine constant region is IgG2A. In another specific aspect, the antibody has a reduced or minimal effector function. In another specific aspect, the minimal effector function is produced by "no effect Fc mutation" or aglycosylation. In another embodiment, fewer effector Fc mutations are made to the N297A or D265A / N297A substitutions in the constant region.
In another embodiment, an isolated anti-PDL1 antibody is provided comprising heavy chain and light chain variable region sequences, wherein:
(a) The heavy chain sequence has at least 85% sequence identity with the heavy chain sequence: EVQLVESGGGLVQPGGSLRLS CAASGFTFSDSWIHWVRQAPGKGLEWVAWISPYGGSTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARRHWPGGFDYWGQGTLVTVSSASTK (SEQ ID NO: 8), or
(b) Light chain sequence and light chain sequence: DIQMTQSPSSLSASVGDRVTITCRASQ DVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYLYHPATFGQGTKVEIKR (SEQ ID NO: 7) has at least 85% sequence identity.
In some embodiments, an isolated anti-PDL1 antibody comprising heavy and light chain variable region sequences is provided, wherein the light chain variable region sequence and the amino acid sequence of SEQ ID NO: 7 have at least 85%, at least 86%, At least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99 % Sequence identity. In some embodiments, an isolated anti-PDL1 antibody comprising heavy chain and light chain variable region sequences is provided, wherein the heavy chain variable region sequence has at least 85%, at least 86%, at least 87%, SEQ ID NO: 8, At least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity . In some embodiments, an isolated anti-PDL1 antibody comprising heavy chain and light chain variable region sequences is provided, wherein the light chain variable region sequence has at least 85%, at least 86%, an amino acid sequence of SEQ ID NO: 7, At least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99 % Sequence identity and the heavy chain variable region sequence has at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, At least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity.
In another embodiment, an isolated anti-PDL1 antibody comprising heavy and light chain sequences is provided, wherein:
(A) heavy chain sequence and a heavy chain having the sequence: EVQLVESGGGLVQPGGSLRL SCAASGFTFSDSWIHWVRQAPGKGLEWVAWISPYGGSTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARRHWPGGFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 10) 85% sequence identity at least, or
(B) a light chain sequence and light chain sequence: DIQMTQSPSSLSASVGDRVTI TCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYLYHPATFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 9) at least 85% sequence identity.
In some embodiments, an isolated anti-PDL1 antibody comprising heavy and light chain sequences is provided, wherein the light chain sequence and the amino acid sequence SEQ ID NO: 9 have at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity. In some embodiments, an isolated anti-PDL1 antibody comprising a heavy chain and a light chain sequence is provided, wherein the heavy chain sequence has at least 85%, at least 86%, at least 87%, at least 88%, at least 89% of SEQ ID NO: 10 %, At least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity. In some embodiments, an isolated anti-PDL1 antibody comprising a heavy chain and a light chain sequence is provided, wherein the light chain sequence has at least 85%, at least 86%, at least 87%, at least 88, and at least 88% of the amino acid sequence SEQ ID NO: 9 %, At least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% of the sequence identity and weight The chain sequence has at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 85% of the amino acid sequence SEQ ID NO: 10 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity.
In some embodiments, the isolated anti-PDL1 antibody is an oxidized monoclonal antibody. In some embodiments, the oxidized monoclonal antibody in the formulation comprises a light chain comprising an amino acid sequence of SEQ ID NO: 9 and a heavy chain comprising an amino acid sequence of SEQ ID NO: 10. In some embodiments, the oxidized monoclonal antibody in the formulation comprises a heavy chain comprising an amino acid sequence of SEQ ID NO: 10, wherein one or more of W33, W50, or W101 is oxidized. In some embodiments, the oxidized monoclonal antibody in the formulation comprises a heavy chain comprising an amino acid sequence of SEQ ID NO: 10, wherein one or more of M253 and M429 are oxidized. In some embodiments, the oxidized monoclonal antibody retains at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, or at least about 95% % Its biological activity (eg, binding to the target or therapeutic efficacy) before storage (ie, when the pharmaceutical formulation is prepared).
In some embodiments, the isolated anti-PDL1 antibody is a glycosylated monoclonal antibody. In some embodiments, the glycosylated monoclonal antibody in the formulation comprises a light chain comprising an amino acid sequence of SEQ ID NO: 9 and a heavy chain comprising an amino acid sequence of SEQ ID NO: 10. In some embodiments, the glycosylated monoclonal antibody in the formulation comprises a heavy chain comprising an amino acid sequence of SEQ ID NO: 10, wherein one or more lysines are glycosylated. In some embodiments, the glycosylated monoclonal antibody in the formulation comprises a heavy chain comprising an amino acid sequence of SEQ ID NO: 10, wherein K65 is glycosylated.
In some embodiments, the isolated anti-PDL1 antibody is deglycosylated.
In any of the embodiments herein, the isolated anti-PDL1 antibody can bind to human PD-L1, such as human PD-L1 shown in UniProtKB / Swiss-Prot Accession No. Q9NZQ7.1, or a variant thereof.
In another embodiment, an isolated nucleic acid encoding any of the antibodies described herein is provided. In some embodiments, the nucleic acid further comprises a vector suitable for expressing a nucleic acid of any of the anti-PDL1 antibodies described above. In another specific aspect, the vector is in a host cell suitable for expression of a nucleic acid. In another specific aspect, the host cell is a eukaryotic cell or a prokaryotic cell. In another specific aspect, the eukaryotic cells are mammalian cells, such as Chinese Hamster Ovary (CHO).
The antibody or antigen-binding fragment thereof can be produced using methods known in the art (e.g., by a method comprising culturing a host cell containing a nucleic acid encoding any of the anti-PDL1 antibodies or antigen-binding fragments described above). Such antibodies or fragments and the conditions under which the antibodies or fragments are recovered are prepared in a form suitable for expression.
B. Antibody preparation
Exemplary methods for preparing antibodies in formulations using techniques available in the art for antibody production are described in more detail in the following sections.
The antibody system is directed against the antigen of interest (ie PD-L1, such as human PD-L1). The antigen is preferably a biologically important polypeptide, and administration of an antibody to a mammal suffering from a disorder can produce a therapeutic benefit in that mammal.
(i) Antigen preparation
Soluble antigens or fragments thereof optionally bound to other molecules can be used as immunogens for antibody production. For transmembrane molecules such as receptors, fragments thereof (e.g., the extracellular domain of the receptor) can be used as immunogens. Alternatively, cells expressing transmembrane molecules can be used as immunogens. Such cells may be derived from natural sources (e.g., cancer cell lines) or may be cells that have been transformed by recombinant techniques to express transmembrane molecules. Other antigens and forms suitable for use in the preparation of antibodies will be readily apparent to those skilled in the art.
(ii) Certain antibody-based methods
Multiple strains of antibodies are preferably produced in animals by multiple subcutaneous (sc) or intraperitoneal (ip) injections of the relevant antigen and adjuvant. It can be used to bind relevant antigens to proteins that are immunogenic to the species to be immunized, such as keyhole snail hemocyanin, serum albumin, bovine thyroglobulin, or soybean trypsin inhibitors, which use bifunctional or derivatized agents Carry out, for example, maleimidine imine benzamidine thiosuccinimide (bound through cysteine residues), N-hydroxysuccinimide (through lysine residues), glutaraldehyde , Succinic anhydride, SOCl<sub>2</sub> Or R<sup>1</sup> N = C = NR, where R and R<sup>1</sup> For different alkyl groups.
By combining, for example, 100 μg or 5 μg of protein or conjugate (for rabbits or mice, respectively) with 3 volumes of Freund's complete adjuvant and injecting the solution intradermally at multiple sites, the animal is exposed to the antigen, Immunogenic conjugates or derivatives. One month later, animals were subcutaneously injected at multiple sites with peptides or conjugates in Freund's complete adjuvant in an original amount of 1/5 to 1/10. After 7 to 14 days, the animals were bled and analyzed for serum antibody titers. The animals are beaten until the price of power is stable. Preferably, the animals are beaten with a combination of the same antigen (but the antigen is bound to a different protein and / or to a different cross-linking agent). The conjugate can also be produced as a protein fusion in recombinant cell culture. Similarly, aggregating agents such as alum are suitable for boosting the immune response.
The individual antibodies of the present invention may be first developed by Kohler et al. Using a fusion tumor method.Nature , 256: 495 (1975), and further described, for example, in Hongo et al. On human-human fusion tumors,Hybridoma , 14 (3): 253-260 (1995); Harlow et al.,Antibodies: A Laboratory Manual , (Cold Spring Harbor Laboratory Press, 2nd edition. 1988); Hammerling et al.,Monoclonal Antibodies and T-Cell Hybridomas 563-681 (Elsevier, N.Y., 1981); and Ni,Xiandai Mianyixue , 26 (4): 265-268 (2006). Other methods include, for example, those described in U.S. Patent No. 7,189,826 for the production of a single human natural IgM antibody from a fused tumor cell line. Human fusion tumor technology (Trioma technology) also describes Vollmers and Brandlein,Histology and Histopathology 20 (3): 927-937 (2005) and Vollmers and Brandlein,Methods and Findings in Experimental and Clinical Pharmacology 27 (3): 185-91 (2005).
For various other fusion tumor technologies, see, for example, US 2006/258841; US 2006/183887 (fully human antibodies); US 2006/059575; US 2005/287149; US 2005/100546; US 2005/026229; and US Patent Nos. 7,078,492 and No. No. 7,153,507. An exemplary protocol for making monoclonal antibodies using the fusion tumor method is described below. In one embodiment, a mouse or other suitable host animal, such as a hamster, is immunized to cause lymphocytes that produce or are capable of producing antibodies that specifically bind to the protein used for immunization. By multiple subcutaneous (sc) or intraperitoneal (ip) injections of the polypeptides or fragments thereof of the present invention and adjuvants such as monophosphoryl lipid A (MPL) / trehalose dicyanurate (TDM) ( Ribi Immunochem. Research, Inc., Hamilton, Mont.)) And produce antibodies in animals. The polypeptides (eg, antigens) or fragments thereof of the invention can be prepared using methods well known in the art, such as recombinant methods, some of which are further described herein. Anti-antigen antibodies in sera from immunized animals were analyzed and, optionally, boosted. Lymphocytes were isolated from animals producing anti-antigen antibodies. Alternatively, lymphocytes can be immunized in vitro.
Lymphocytes are then fused with myeloma cells using a suitable fusion agent, such as polyethylene glycol, to form fused tumor cells. See e.g. Goding,Monoclonal Antibodies: Principles and Practice , Pp. 59-103 (Academic Press, 1986). Myeloma cells that are effective for fusion, support stable high-level production of antibodies by selected antibody-producing cells, and are sensitive to media such as HAT media can be used. Exemplary myeloma cells include, but are not limited to, murine myeloma cell lines such as those derived from MOPC-21 and MPC-11 mouse tumors obtained from Salk Institute Cell Distribution Center, San Diego, Calif. USA, and American Type Culture Collection, Rockville, Md. USA with SP-2 or X63-Ag8-653 cells. Human myeloma and mouse-human hybrid myeloma cell lines (Kozbor,J. Immunol. 133: 3001 (1984); Brodeur et al., Monoclonal Antibody Production Techniques and Applications, pp. 51-63 (Marcel Dekker, Inc., New York, 1987)).
The fused tumor cells thus prepared are seeded and allowed to grow in a suitable medium (for example, a medium containing one or more substances that inhibit the growth or survival of unfused parental myeloma cells). For example, if the parental myeloma cells lack the enzyme hypoxanthine guanine phosphoribosyltransferase (HGPRT or HPRT), the medium used for fusion tumors will typically include hypoxanthine, aminopterin, and thymidine ( HAT medium), these substances prevent the growth of HGPRT-deficient cells. Preferably, such as, for example, Even et al.,Trends in Biotechnology , 24 (3), 105-108 (2006), describes the use of serum-free fusion tumor cell culture methods to reduce the use of animal-derived serum, such as fetal bovine serum.
The oligopeptides used as a tool to increase the production rate of fused tumor cell cultures are described in Franek,Trends in Monoclonal Antibody Research 111-122 (2005). In particular, the standard medium is rich in certain amino acids (alanine, serine, asparagine, proline) or protein hydrolysate fractions, and can be removed by three to six amino acid residues Synthetic oligopeptides based on the base significantly inhibit cell death. The peptides are present at millimolar concentrations or higher.
The production of monoclonal antibodies that bind to the antibodies of the invention in the medium in which the fusion tumor cells are grown can be analyzed. The binding specificity of a monoclonal antibody produced by a fusion tumor cell can be determined by immunoprecipitation or by in vitro binding assays such as radioimmunoassay (RIA) or enzyme-linked immunosorbent assay (ELISA). The binding affinity of a monoclonal antibody can be determined by, for example, Scatchard analysis. See, for example, Munson et al.Anal. Biochem. J. 107: 220 (1980).
After identifying the fusion tumor cells that produce antibodies with the desired specificity, affinity and / or activity, the pure lines can be sub-selected by a limiting dilution procedure and allowed to grow by standard methods. See, for example, Goding, supra. Suitable media suitable for this purpose include, for example, D-MEM or RPMI-1640 media. In addition, fused tumor cells can be cultured in vivo as ascites tumors in animals. Monoclonal antibody systems secreted by subpure lines are appropriately linked to the culture medium by conventional immunoglobulin purification procedures (such as protein A-agarose gel, hydroxyapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography). Ascites fluid or serum isolated. A procedure for separating proteins from fusion tumor cells is described in US 2005/176122 and US Patent No. 6,919,436. This method involves the use of minimal salts (such as soluble salts) during the bonding process and also preferably a small amount of organic solvent during the dissolution process.
(iii) Certain library screening methods
The antibodies of the invention can be prepared by screening combinatorial libraries for antibodies having the desired activity. For example, a number of methods are known in the art that can be used to generate phage presentation libraries and to screen such libraries for antibodies with the desired binding characteristics. Such methods are generally described in Hoogenboom et al.Methods in Molecular Biology 178: 1-37 (ed. O'Brien et al., Human Press, Totowa, NJ, 2001). For example, like Lee et al.,J. Mol. Biol. (2004), 340 (5): 1073-93, a method of generating antibodies of interest is performed by using a phage antibody library.
In general, a pure line of synthetic antibodies is selected by screening a phage library containing phages that exhibit various fragments of antibody variable regions (Fv) fused to phage sheath proteins. Such phage libraries are screened by affinity chromatography of the desired antigen. A pure line expressing an Fv fragment capable of binding to the desired antigen is adsorbed to the antigen and thus separated from the unbound pure line in the library. The bound pure line is then lysed from the antigen and can be further enriched by an additional antigen adsorption / dissolution cycle. Selection of a suitable phage clone of interest by designing a suitable antigen screening procedure, followed by the use of Fv sequences and Kabat from the phage clone of interestWait, Sequences of Proteins of Immunological Interest , 5th ed., NIH Publication 91-3242, Bethesda MD (1991), Vols. 1-3. Suitable constant region (Fc) sequences are used to construct a full-length antibody lineage to obtain any antibody of the invention.
In certain embodiments, the antigen-binding domain of an antibody is formed by two variable (V) regions having about 110 amino acids, each from a light chain (VL) and a heavy chain (VH), both of which are Presents three hypervariable loops (HVR) or complementarity determining regions (CDRs). Variable domains can be, for example, single-chain Fv (scFv) fragments (where VH and VL are linked by covalent bonds via flexible short peptides) or Fab fragments (where VH and VL are each fused to a constant domain and interact with non-covalent bonds) Functionally presented on phage, such as Winter et al.,Ann. Rev. Immunol. , 12: 433-455 (1994). As used herein, a scFv-encoding phage pure line and a Fab-encoding phage pure line are referred to as "Fv phage pure line" or "Fv pure line".
The VH and VL gene libraries can be separately selected by polymerase chain reaction (PCR), and randomly recombined in the phage library, and then the antigen-binding pure lines can be searched, such as Winter et al.,Ann. Rev. Immunol. , 12: 433-455 (1994). Libraries from immunized sources can provide high-affinity antibodies to immunogens without constructing fusion tumors. Alternatively, natural libraries can be selected to provide a single source of human antibodies to a wide range of non-autogenous antigens and autoantigens without any immune effect, such as Griffiths et al.,EMBO J, 12: 725-734 (1993). Finally, natural libraries can also be synthesized by selecting unrearranged V-gene fragments from stem cells, using PCR primers containing random sequences to encode highly variable CDR3 regions, and completing in vitro rearrangements, such as Hoogenboom and Winter,J. Mol. Biol. 227: 381-388 (1992).
In some embodiments, filamentous phage is used to present antibody fragments by fusing to the minor sheath protein pIII. These antibody fragments can be presented as single-chain Fv fragments, in which the VH domain and the VL domain are linked to the same polypeptide chain by a flexible polypeptide spacer, such as Marks et al.,J. Mol. Biol. , 222: 581-597 (1991); or presented as a Fab fragment in which one strand is fused to pIII and the other is secreted into the periplasm of the bacterial host cell, in which the wild-type exosome is replaced by replacement A part of the protein assembles the Fab-coat protein structure present on the surface of the phage, such as Hoogenboom et al.Nucl. Acids Res., 19 : 4133-4137 (1991).
In general, nucleic acids encoding antibody gene fragments can be obtained from immune cells collected from humans or animals. If a library focused on pure anti-antigens is needed, the individual is immunized with the antigen to generate an antibody response, and spleen cells and / or circulating B cells and other peripheral blood lymphocytes (PBL) can be recovered for library construction. In one embodiment, an anti-antigen pure human antibody gene fragment library is obtained by transgenic mice carrying a functional human immunoglobulin gene array (and lacking a functional endogenous antibody production system). The anti-antigen antibody response is obtained in order to obtain antigens by immunizing human cells with anti-antigens. The production of transgenic mice producing human antibodies will be described below.
B cells expressing antigen-specific membrane-bound antibodies can be isolated by using a suitable screening procedure (e.g., by isolating cells with antigen affinity chromatography or attaching the cells to a fluorescently labeled antigen followed by flow-activated cell sorting ( FACS)) to obtain additional enrichment of the anti-antigen-responsive cell population.
Alternatively, the use of spleen cells and / or B cells or other PBLs from an unimmunized donor for better presentation of possible antibody profiles, and also allows the use of any animal (human or non-human) species with non-antigenic antigens Construction of antibody libraries. For libraries incorporating antibody gene constructs in vitro, stem cells are collected from individuals to provide nucleic acids encoding unrearranged antibody gene segments. The immune cells of interest can be obtained from a variety of animal species, such as human, mouse, rat, rabbit, wolf, canine, feline, pig, cattle, horse, and bird species.
Nucleic acid encoding antibody variable gene segments (including VH and VL segments) is recovered from the cells of interest and allowed to expand. In the case of rearranged VH and VL gene libraries, the desired DNA can be obtained by isolating genomic DNA or mRNA from lymphocytes, and reusing primers matching the 5 'and 3' ends of rearranged VH and VL genes. Obtained by polymerase chain reaction (PCR), such as Orlando et al.,Proc. Natl. Acad. Sci. (USA), 86: 3833-3837 (1989) to obtain various V gene libraries for expression. The V gene can be amplified from cDNA and genomic DNA using backward primers encoding the 5 'end of the mature V-domain exons and forward primers located inside the J-segment, such as Orlando et al. (1989) And Ward et al.Nature 341: 544-546 (1989). However, for self-cDNA amplification, backward primers can also be located in leading exons, such as Jones et al.,Biotechnol. , 9: 88-89 (1991), and forward primers can also be located inside the constant region, as in Sastry et al.Proc. Natl. Acad. Sci. (USA) , 86: 5728-5732 (1989). To maximize complementarity, degenerates can be integrated into these primers, as described in Orlandi et al. (1989) or Sastry et al. (1989). In some embodiments, library diversity can be maximized by using PCR primers that target each V-gene family in order to increase all available VH and VL alignments present in immune cell nucleic acid samples, such as, for example, Marks Wait,J. Mol. Biol. , 222: 581-597 (1991), or as Orum et al.,Nucleic Acids Res. , 21: 4491-4498 (1993). For the colonization of amplified DNA into expression vectors, rare restriction sites can be introduced into the PCR primers as markers at one end, as described in Orlando et al. (1989); or other PCR amplifications can be performed using marker primers. Zeng, like Clackson and others,Nature , 352: 624-628 (1991).
Synthetic rearranged V gene libraries can be obtained in vitro from V gene segments. Most of the human VH-gene segments have been selected and sequenced (reported by Tomlinson et al.,J. Mol. Biol. , 227: 776-798 (1992)), and a map has been drawn (reported by Matsuda et al.,Nature Genet. ,3 : 88-94 (1993)); these breeding segments (including all major configurations of H1 and H2 loops) and PCR primers encoding H3 loops of various sequences and lengths can be used to generate various VH gene libraries, such as Hoogenboom And Winter,J. Mol. Biol. 227: 381-388 (1992). VH libraries with all sequence diversity focusing on single-length long H3 loops can also be obtained, such as Barbas et al.,Proc. Natl. Acad. Sci. USA, 89: 4457-4461 (1992). Human Vκ and Vλ segments have been selected and sequenced (reported by Williams and Winter,Eur. J. Immunol. , 23: 1456-1461 (1993)) and can be used to obtain synthetic light chain libraries. Based on a range of VH and VL folds and L3 and H3 length synthesis, the V gene library will encode antibodies with a large amount of structural diversity. After amplifying the V-gene encoding DNA, the germline V-gene segment can be determined according to Hoogenboom and Winter,J. Mol. Biol. , 227: 381-388 (1992).
Several methods can be used to construct a library of antibody fragments by combining VH and VL gene libraries. Each library can be produced in a different vector, and the vector can be recombined in vitro (for example, Hogrefe et al.,Gene , 128: 119-126 (1993)) or recombined in vivo by combination infection (e.g. Waterhouse et al.,Nucl. Acids Res. , 21: 2265-2266 (1993), loxP system). The in vivo recombination method uses the double-stranded nature of Fab fragments to overcome the restriction on library size imposed by E. coli transformation power. Native VH and VL libraries were individually cloned, one cloned into a phagemid and the other into a phage vector. The two libraries are then combined by phage infection of bacteria containing phagemids so that each cell contains a different combination and the size of the library is limited only by the number of cells present (about 10<sup>12</sup> A pure line) restrictions. Both vectors contain in vivo recombination signals so that VH and VL genes are recombined on a single replicon and co-packaged in phage virions. These large libraries provide large quantities with good affinity (K<sub>d</sub> <sup>-1</sup> For about 10<sup>-8</sup> M) Multiple antibodies.
Alternatively, the libraries can be sequentially selected into the same vector, such as Barbas et al.,Proc. Natl. Acad. Sci. USA, 88: 7978-7982 (1991); or assembled together by PCR and then selected, such as Clackson et al.,Nature, 352: 624-628 (1991). PCR assembly can also be used to link VH and VL DNA to DNA encoding flexible peptide spacers to form a single-chain Fv (scFv) library. In another technique, "in a cellular PCR assembly" is used to combine VH and VL genes by PCR in lymphocytes, and then as Embleton et al.,Nucl. Acids Res. , 20: 3831-3837 (1992).
Antibodies (natural or synthetic) produced by native libraries may have a moderate affinity (about 10<sup>6</sup> Up to 10<sup>7</sup> M<sup>-1</sup> K<sub>d</sub> <sup>-1</sup> ), But affinity maturity can also be simulated by constructing a second library and choosing from it, as described by Winter et al. (1994) (same as above). For example, Hawkins et al., J. Mol. Biol., 226: 889-896 (1992) can be used by using error-prone polymerase (reported in Leung et al., Technology 1: 11-15 (1989)). Methods or methods of Gram et al., Proc. Natl. Acad. Sci USA, 89: 3576-3580 (1992) introduce mutations in vitro at random locations. In addition, affinity maturation can be performed, for example, by using PCR with primers carrying random sequences spanning the CDRs of interest to randomly mutate one or more CDRs in selected individual Fv pure lines and screen higher affinity pure lines. WO 9607754 (published on March 14, 1996) describes a method for inducing mutations in the complementarity determining region of an immunoglobulin light chain to form a light chain gene library. Another effective method is to recombine the selected VH domain or VL domain by phage presentation with a naturally occurring V domain variant library obtained from an unimmunized donor and screen for higher affinity with several rounds of shuffle, such as Marks et al ,Biotechnol. , 10: 779-783 (1992). This technique makes it possible to generate an affinity of about 10<sup>-9</sup> M or 10<sup>-9</sup> Antibodies and antibody fragments below M.
Libraries can be screened by a variety of techniques known in the art. For example, the wells of an adsorption plate can be coated with antigen, expressed on host cells attached to the adsorption plate or used for cell sorting, or combined with biotin for capture of streptavidin-coated beads , Or used in any other method of panning phage presentation libraries.
The phage library sample is contacted with the immobilized antigen under conditions suitable for binding at least a portion of the phage particles to an adsorbent. In general, conditions including pH, ionic strength, temperature, and the like are selected to simulate physiological conditions. The solid-bound phage is washed and then lysed by acid, such as Barbas et al.,Proc. Natl. Acad. Sci USA , 88: 7978-7982 (1991); or by alkali dissolution, such as Marks et al.,J. Mol. Biol. , 222: 581-597 (1991); or by antigen competition (e.g., with Clackson et al.,Nature , 352: 624-628 (1991). Phages can be enriched 20-1,000 times in a single round of selection. In addition, the enriched phage can be allowed to grow in bacterial culture and undergo another round of selection.
Selection efficiency depends on many factors, including dissociation kinetics during washing and whether multiple antibody fragments on a single phage can simultaneously bind to the antigen. Antibodies with fast dissociation kinetics (and weak binding affinity) can be retained by using short wash times, multivalent phage presentation, and high coating density of the antigen in the solid phase. The high density not only stabilizes the phage through multivalent interactions, but also facilitates the recombination of the dissociated phage. Antibody selection with slow dissociation kinetics (and good binding affinity) can be achieved through the use of prolonged washing and monovalent phage presentation (eg, Bass et al.,Proteins , 8: 309-314 (1990) and WO 92/09690) and low antigen coating density (as described in Marks et al., Biotechnol., 10: 779-783 (1992)).
It is possible to choose between phage antibodies that have different affinities, even slightly different affinities to an antigen. However, random mutations of the selected antibodies (e.g., as performed in some affinity maturation techniques) may produce many mutants, most of which bind to the antigen and a few have higher affinity. The use of restricted antigens can competitively eliminate very few high-affinity phages. In order to retain all higher affinity mutants, phage can be incubated with excess biotin-labeled antigen, but the molar concentration of the biotin-labeled antigen is lower than the target's target molar affinity constant. High-affinity bound phages can then be captured by streptavidin-coated paramagnetic beads. Such "equilibrium capture" allows antibodies to be selected based on their binding affinity, and its sensitivity allows isolation of only twice as high affinity mutant pure lines from a significant excess of phage with lower affinity. The conditions used in washing and solid-phase bound phages can also be manipulated to distinguish based on dissociation kinetics.
Anti-antigen pure lines can be selected based on activity. In certain embodiments, the invention provides anti-antigen antibodies that bind to living cells that naturally express the antigen or to free-floating antigens or antigens linked to other cellular structures. Fv pure lines corresponding to such anti-antigen antibodies can be selected by the following steps: (1) Isolate the anti-antigen pure lines from the autophage library as described above, and optionally expand the population by breeding the population in a suitable bacterial host Isolated populations of pure phage clones; (2) Selecting antigens and second proteins for blocking and non-blocking activities, respectively; (3) Adsorbing anti-antigen phage pure lines to immobilized antigens; (4) Use excess The second protein dissociates any undesired pure lines that recognize an antigen binding determinant that overlaps or shares the binding determinant of the second protein; and (5) the pure lines that are still adsorbed after the dissolution step (4) is completed. Optionally, pure lines with the desired blocking / non-blocking properties can be further enriched by repeating the selection procedure described herein one or more times.
Easily isolate DNA encoding a fusion antibody-derived monoclonal antibody or phage of the present invention that exhibits Fv-pure DNA, and use conventional procedures (e.g., by using specific designed to amplify the relevant heavy chain from the fusion tumor or phage DNA template and The oligonucleotide primers of the light chain coding region) were sequenced. After isolation, the DNA can be placed in a expression vector, and the expression vector can then be transfected into host cells (such as E. coli cells, simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulins). ) In order to obtain the desired monoclonal antibody in recombinant host cells. Commentary on recombinant expression of DNA encoding antibodies in bacteria includes Skera et al.,Curr. Opinion in Immunol. 5: 256 (1993) and Pluckthun,Immunol. Revs 130: 151 (1992).
DNA encoding a pure Fv line of the present invention can be combined with DNA sequences known to encode constant regions of the heavy and / or light chains (e.g., suitable DNA sequences can be obtained from Kabat et al. (Above)) to form a full-length or partially-length heavy chain And / or light chain pure. It should be understood that any isotype constant region can be used to achieve this, including IgG, IgM, IgA, IgD, and IgE constant regions, and such constant regions can be obtained from any human or animal species. Fv clones derived from variable domain DNA of one animal (such as human) species and subsequently fused with constant region DNA of another animal species to form a "hybrid" full-length heavy and / or light chain coding sequence are included as used herein The definition of "chimeric" and "hybrid" antibodies. In certain embodiments, Fv pure lines derived from human variable DNA are fused to human constant region DNA to form a full-length or partial-length human heavy and / or light chain coding sequence.
The DNA encoding the hybridoma-derived anti-antigen antibody of the present invention may also be modified, such as replacing the homologous murine sequences derived from the pure line of the hybridoma with human heavy chain constant domain and light chain constant domain coding sequences (for example, with Morrison and others,Proc. Natl. Acad. Sci. USA , 81: 6851-6855 (1984)). DNA encoding an antibody or fragment derived from a fusion tumor or Fv pure line can be further modified by covalently joining all or part of the coding sequence of a non-immunoglobulin polypeptide to the immunoglobulin coding sequence. A "chimeric" or "hybrid" antibody having the binding specificity of the Fv pure line of the present invention or the binding specificity of an antibody derived from a hybridoma pure line can be prepared in this manner.
(iv) Humanization and human antibodies
Various methods of humanizing non-human antibodies are known in the art. For example, a humanized antibody has one or more amino acid residues introduced into it from a non-human source. These non-human amino acid residues are often referred to as "import" residues, which are typically taken from an "import" variable domain. Humanization can basically follow the approach of Winter and collaborators (Jones et al.,Nature , 321: 522-525 (1986); Riechmann et al.,Nature , 332: 323-327 (1988); Verhoeyen et al.,Science 239: 1534-1536 (1988)), by replacing the corresponding sequence of a human antibody with a rodent CDR or CDR sequence. Therefore, such "humanized" antibodies are chimeric antibodies (U.S. Patent No. 4,816,567) in which variable domains that are substantially less than the entire human variable domain are replaced with corresponding sequences from non-human species. In fact, humanized antibodies are generally human antibodies in which some CDR residues and possibly some FR residues are replaced with residues from similar sites in rodent antibodies.
Candidates for the human variable domains (light and heavy chains) intended to make humanized antibodies are extremely important for reducing antigenicity. According to the so-called "best fit" method, the variable domain sequence of a rodent antibody is screened against the entire known human variable domain sequence library. The human sequence closest to the rodent sequence is then accepted as the human framework (FR) of the humanized antibody (see Sims et al.,J. Immunol ., 151: 2296 (1993); Chothia et al.,J. Mol. Biol ., 196: 901 (1987)). Another method uses a specific framework obtained from the common sequence of all human antibodies with a specific light or heavy chain subgroup. The same framework can be used for several different humanized antibodies (Carter et al.,Proc. Natl. Acad Sci. USA , 89: 4285 (1992); Presta et al.,J. Immunol. 151: 2623 (1993)).
More importantly, humanize the antibody and retain high affinity for the antigen and other beneficial biological properties. To achieve this, according to one embodiment of the method, a humanized antibody is prepared by analyzing a parental sequence and various conceptually humanized products using a three-dimensional model of the parental sequence and the humanized sequence. Three-dimensional immunoglobulin models are generally available and familiar to those skilled in the art. Computer programs are available that illustrate and present probable three-dimensional conformations of selected candidate immunoglobulin sequences. Examination of these presentations allows analysis of possible roles of residues in the functioning of the candidate immunoglobulin sequence, that is, analysis of residues that affect the ability of the candidate immunoglobulin to bind its antigen. In this way, FR residues can be selected from the recipient and input sequence and combined with the recipient and input sequence in order to obtain the desired antibody characteristics, such as increased affinity for the target antigen. In general, hypervariable region residues are directly and mostly involved in affecting antigen binding.
The human antibodies of the present invention can be constructed by combining Fv pure line variable domain sequences selected from human-derived phage presentation libraries with known human constant domain sequences as described above. Alternatively, the human monoclonal antibody of the present invention can be prepared by a fusion tumor method. Human myeloma and mouse-human hybrid myeloma cell lines used to make human monoclonal antibodies have been, for example, manufactured by KozborJ. Immunol. , 133: 3001 (1984); Brodeur et al.,Monoclonal Antibody Production Techniques and Applications , Pages 51-63 (Marcel Dekker, Inc., New York, 1987); and Boerner et al.,J. Immunol. 147: 86 (1991).
It is possible to produce transgenic animals (such as mice) that can produce a full-length library of human antibodies upon immunization in the absence of endogenous immunoglobulin production. For example, antibody heavy chain junction regions have been described in chimeric and germline mutant mice (J<sub>H</sub> ) The homozygous deletion of the gene results in complete suppression of endogenous antibody production. The transfer of human germline immunoglobulin gene arrays to such germline mutant mice will cause the production of human antibodies after antigen challenge. See e.g. Jakobovits et al.Proc. Natl. Acad. Sci. USA , 90: 2551 (1993); Jakobovits et al.,Nature , 362: 255-258 (1993); Bruggermann et al.,Year in Immuno. , 7:33 (1993); and Duchosal et al.,Nature 355: 258 (1992).
Human antibodies can also be obtained from non-human (e.g., rodent) antibodies using gene shuffling, where human antibodies have affinity and specificity similar to the original non-human antibodies. According to this method, also known as "antigenic determinant imprinting", the heavy or light chain variable region of a non-human antibody fragment obtained by phage presentation technology as described herein is replaced by a human V domain gene library to form a non-human chain / Population of human chain scFv or Fab chimeras. Selection using an antigen can result in the separation of a non-human chain / human chain chimeric scFv or Fab, in which the human chain recovers and removes the damaged antigen-binding site when the primary phage presents the corresponding non-human chain in the pure line, that is, the epitope determines (Impression) Selection of human chain collocation. When the method is repeated to replace the remaining non-human chains, human antibodies are obtained (see PCT WO 93/06213, published on April 1, 1993). Unlike the traditional humanization of transplanting non-human antibodies by CDRs, this technology provides complete human antibodies without FR or CDR residues of non-human origin.
(v) Antibody fragments
Antibody fragments can be produced by conventional means (such as enzymatic digestion) or by recombinant techniques. In some cases, it is advantageous to use antibody fragments rather than whole antibodies. Smaller size fragments allow for rapid clearance and can lead to improvements in access to solid tumors. For a review of certain antibody fragments see Hudson et al. (2003)Nat. Med. 9: 129-134.
Various techniques have been developed for the production of antibody fragments. Traditionally, such fragments can be obtained by proteolytic digestion of intact antibodies (see, for example, Morimoto et al.,Journal of Biochemical and Biophysical Methods 24: 107-117 (1992); and Brennan et al.,Science , 229: 81 (1985)). However, these fragments can now be produced directly by recombinant host cells. Fab, Fv, and ScFv antibody fragments can all be expressed in and secreted from E. coli, thus allowing easy production of large numbers of these fragments. Antibody fragments can be isolated from antibody phage libraries discussed above. Alternatively, the Fab'-SH fragment can be recovered directly from E. coli and chemically coupled to form F (ab ')<sub>2</sub> Fragments (Carter et al.,Bio / Technology 10: 163-167 (1992)). According to another method, F (ab ')<sub>2</sub> Fragments can be isolated directly from recombinant host cell culture. Fab and F (ab ') with extended half-life in vivo and containing rescue receptor binding epitope residues<sub>2</sub> Fragments are described in US Patent No. 5,869,046. Skilled practitioners will readily know other manufacturing techniques for antibody fragments. In certain embodiments, the antibody is a single-chain Fv fragment (scFv). See WO 93/16185, U.S. Patent Nos. 5,571,894 and 5,587,458. Fv and scFv are the only substances with a complete binding site without a constant region; therefore, they may be suitable for reducing non-specific binding during use in vivo. The scFv fusion protein can be constructed such that the effector protein is fused to the amine or carboxy terminus of the scFv. SeeAntibody Engineering Edited by Borrebaeck, supra. The antibody fragment may also be, for example, a "linear antibody" as described in US Patent No. 5,641,870. Such linear antibodies may be monospecific or bispecific antibodies.
(vi) Multispecific antibodies
Multispecific antibodies have binding specificities for at least two different epitopes, where the epitopes are usually derived from different antigens. Although such molecules typically bind only two different epitopes (i.e., bispecific antibodies, BsAb), antibodies with additional specificity, such as trispecific antibodies, are encompassed by this expression when used herein . Bispecific antibodies (e.g. F (ab ')) can be prepared in the form of full-length antibodies or antibody fragments<sub>2</sub> Bispecific antibodies).
Methods for making bispecific antibodies are known in the art. Traditionally, full-length bispecific antibodies are produced based on the co-expression of two immunoglobulin heavy-light chain pairs, where the two chains have different specificities (Millstein et al.,Nature 305: 537-539 (1983)). Due to the random allocation of immunoglobulin heavy and light chains, these fusion tumors (four-source fusion tumors) produce a potential mixture of 10 different antibody molecules, of which only one has the correct bispecific structure. Purification of the correct molecules by affinity chromatography steps is generally cumbersome and yields low. Similar procedures are disclosed in WO 93/08829 and Traunecker et al.EMBO J. , 10: 3655-3659 (1991).
According to different methods, an antibody variable domain (antibody-antigen binding site) having a desired binding specificity is fused to an immunoglobulin constant domain sequence. The fusion is preferably a fusion with an immunoglobulin heavy chain constant domain comprising at least a portion of the hinge region, CH2 and CH3 regions. The first heavy chain constant region (CH1) present in at least one of these fusions is typically made to contain the necessary sites for binding to the light chain. The DNA encoding the immunoglobulin heavy chain fusion and, if necessary, the immunoglobulin light chain is inserted into a separate expression vector and co-transfected into a suitable host organism. This provides great flexibility in adjusting the mutual ratio of the three polypeptide fragments in the examples when the unequal ratios of the three polypeptide chains used in the construction provide the best yield. However, when the performance of at least two polypeptide chains in equal ratios results in high yields or when the ratio is not particularly important, the coding sequences of two or all three polypeptide chains may be inserted into one performance vector.
In one embodiment of this method, the bispecific antibody consists of a hybrid immunoglobulin heavy chain with a first binding specificity in one arm and a hybrid immunoglobulin heavy chain-light chain pair (provided in the other arm) (Second binding specificity) composition. It has been found that the presence of an immunoglobulin light chain in only half of the bispecific molecules provides a convenient means of separation, and this asymmetric structure facilitates the separation of the desired bispecific compound from the undesired immunoglobulin chain combination. This method is disclosed in WO 94/04690. For further details on the production of bispecific antibodies see, for example, Suresh et al.Methods in Enzymology 121: 210 (1986).
According to another method described in WO96 / 27011, the interface between a pair of antibody molecules can be engineered to maximize the percentage of heterodimers recovered from the recombinant cell culture. C-domain<sub>H</sub> At least part of a 3 domain. In this way, one or more small amino acid side chains of the interface of the first antibody molecule are replaced with larger side chains (such as tyrosine or tryptophan). A complementary "cavity" of the same or similar size as the large side chain is formed at the interface of the second antibody molecule by replacing the large amino acid side chain with a smaller amino acid side chain (such as alanine or threonine). This provides a mechanism to increase the yield of heterodimers over other undesirable end products such as homodimers.
Bispecific antibodies include cross-linked or "heterologous" antibodies. For example, one of the antibodies in the form of a heteroconjugate may be coupled to avidin and the other to biotin. For example, such antibodies have been proposed to target immune system cells to unwanted cells (U.S. Patent No. 4,676,980) and are used to treat HIV infection (WO 91/00360, WO 92/200373, and EP 03089). Heteroconjugate antibodies can be made using any convenient cross-linking method. Suitable cross-linking agents as well as many cross-linking techniques are well known in the art and are disclosed in US Patent No. 4,676,980.
Techniques for generating bispecific antibodies from antibody fragments have also been described in the literature. For example, chemical linkages can be used to make bispecific antibodies. Brennan and others,Science , 229: 81 (1985) describe a method in which intact antibodies are cleaved by protein to produce F (ab ')<sub>2</sub> Fragment program. These fragments are reduced in the presence of the dithiol complexing agent sodium arsenite to stabilize adjacent dithiols and prevent intermolecular disulfide formation. The resulting Fab 'fragment is then converted into a thionitrobenzoate (TNB) derivative. One Fab'-TNB derivative is then reconverted to Fab'-thiol by reduction with mercaptoethylamine, and mixed with an equimolar amount of another Fab'-TNB derivative to form a bispecific antibody. The bispecific antibody produced can be used as a reagent for selective immobilization of an enzyme.
Recent developments have facilitated the direct recovery of Fab'-SH fragments from E. coli, which can be chemically coupled to form bispecific antibodies. Shalaby and others,J. Exp. Med. , 175: 217-225 (1992) describes a fully humanized bispecific antibody F (ab ')<sub>2</sub> Preparation of molecules. Each Fab 'fragment was separately secreted from E. coli and subjected to directed chemical coupling in vitro to form a bispecific antibody.
Various techniques have also been described for the preparation and isolation of bispecific antibody fragments directly from recombinant cell cultures. For example, bispecific antibodies have been generated using leucine zipper. Kostelny and others,J. Immunol., 148 (5): 1547-1553 (1992). The leucine zipper peptides from Fos and Jun proteins were linked to the Fab 'portion of two different antibodies by gene fusion. The antibody homodimer is reduced at the hinge region to form a monomer, and then it is reoxidized to form an antibody heterodimer. This method can also be used to produce antibody homodimers. Hollinger and others,Proc. Natl. Acad. Sci. USA, 90: 6444-6448 (1993), the "bifunctional antibody" technology provides an alternative mechanism for the preparation of bispecific antibody fragments. These fragments include a linker linked to a light chain variable domain (V<sub>L</sub> ) Heavy chain variable domain (V<sub>H</sub> ), The linker is too short to allow pairing between the two domains on the same chain. So forcing a fragment of V<sub>H</sub> And V<sub>L</sub> Domain complementary to another fragment V<sub>L</sub> And V<sub>H</sub> The domains are paired, thereby forming two antigen-binding sites. Another strategy for preparing bispecific antibody fragments by using single-chain Fv (sFv) dimers has also been reported. See Gruber et al.J. Immunol. 152: 5368 (1994).
Antibodies with more than two valences are also considered. For example, trispecific antibodies can be made.Tuft Wait. J. Immunol. 147: 60 (1991).
(vii) Single domain antibodies
In some embodiments, the antibodies of the invention are single domain antibodies. A single domain antibody is a single polypeptide chain comprising all or part of the heavy chain variable domain or all or part of the light chain variable domain of an antibody. In certain embodiments, the single domain antibody is a human single domain antibody (Domantis, Inc., Waltham, Mass .; see, eg, US Patent No. 6,248,516 B1). In one embodiment, a single domain antibody consists of all or part of the heavy chain variable domain of an antibody.
(viii) Antibody variants
In some embodiments, amino acid sequence modifications of the antibodies described herein are encompassed. For example, it may be desirable to improve the binding affinity and / or other biological properties of the antibody. Amino acid sequence variants of antibodies can be prepared by introducing appropriate changes into the nucleotide sequence encoding the antibody or by peptide synthesis. Such modifications include, for example, deletions and / or insertions and / or substitutions of residues within the amino acid sequence of the antibody. Any combination of deletions, insertions, and substitutions can be performed to obtain the final structure, with the limitation that the final structure has the required characteristics. Amino acid changes can be introduced into the target antibody amino acid sequence when the sequence is made.
(ix) Antibody derivatives
The antibodies of the invention may be further modified to contain additional non-proteinaceous moieties known in the art and readily available. In certain embodiments, the portion suitable for derivatizing the antibody is a water-soluble polymer. Non-limiting examples of water-soluble polymers include, but are not limited to, polyethylene glycol (PEG), ethylene glycol / propylene glycol copolymers, carboxymethyl cellulose, dextran, polyvinyl alcohol, polyvinyl pyrrolidone , Poly-1,3-dioxolane, poly-1,3,6-trioxane, ethylene / maleic anhydride copolymer, polyamino acid (homopolymer or random copolymer) And dextran or poly (n-vinylpyrrolidone) polyethylene glycol, propylene glycol homopolymer, polyoxypropylene / ethylene oxide copolymer, polyoxyethylene polyol (such as glycerol), polyvinyl alcohol, and mixtures thereof. Polyethylene glycol propionaldehyde has advantages in manufacturing due to its stability in water. The polymer may have any molecular weight and may be branched or unbranched. The number of polymers attached to the antibody can vary, and if more than one polymer is attached, the polymers can be the same or different molecules. In general, the number and / or type of polymers used for derivatization can be determined based on considerations including, but not limited to, the special characteristics or functions of the antibody to be improved, whether the antibody derivative will be used in therapy under specified conditions, etc .
(x) Vector, host cell and recombination method
Antibodies can also be produced using recombinant methods. To produce an anti-antigen antibody recombinantly, the nucleic acid encoding the antibody is isolated and inserted into a replicable vector for further selection (amplified DNA) or for expression. The DNA encoding the antibody can be easily isolated and sequenced using conventional procedures, such as by using oligonucleotide probes that specifically bind to genes encoding the heavy and light chains of the antibody. A variety of vectors are available. Vector components generally include, but are not limited to, one or more of the following: a signal sequence, an origin of replication, one or more marker genes, an enhancer component, a promoter, and a transcription termination sequence.
(a) Signal sequence components
The antibodies of the present invention can be produced not only directly recombinantly, but also in the form of a fusion polypeptide fused to a heterologous polypeptide. The heterologous polypeptide is preferably a signal sequence or one having a specific cleavage site at the N-terminus of the mature protein or polypeptide. Other peptides. The selected heterologous signal sequence is preferably a signal sequence that can be recognized and processed by the host cell (ie, cleaved by a signal peptidase). For prokaryotic host cells that do not recognize and process the native antibody signal sequence, the signal sequence is replaced with, for example, a prokaryotic signal sequence selected from the group of alkaline phosphatase, penicillinase, lpp, or a thermostable enterotoxin II leader sequence. For yeast secretion, the native signal sequence can be replaced by, for example, a yeast invertase leader sequence, a factor leader sequence (including yeast (Saccharomyces KluyveromycesKluyveromyces ) α-factor leader sequence) or acid phosphatase leader sequence, Candida albicans (C. albicans ) Glucoamylase leader sequence or signal described in WO 90/13646. In mammalian cell expression, mammalian signal sequences and viral secretion leader sequences (eg, herpes simplex gD signal) can be used.
(b) Starting point of reproduction
Both expression and selection vectors contain nucleic acid sequences that enable the vector to replicate in one or more selected host cells. Generally, in a selection vector, this sequence is a sequence that enables the vector to replicate independently of the host chromosomal DNA, and includes an origin of replication or an autonomously replicating sequence. Such sequences are well known for a variety of bacteria, yeast, and viruses. The origin of replication from plastid pBR322 is suitable for most Gram-negative bacteria, the 2μ origin of plastid is suitable for yeast, and various viral origins (SV40, polyoma virus, adenovirus, VSV or BPV) are suitable For the selection of vectors in mammalian cells. In general, mammalian expression vectors do not require an origin of replication component (because the SV40 origin contains an early promoter, this origin can usually be used only).
(c) Selection of genetic components
The expression and selection vector may contain a selection gene, also known as a selectable marker. Typical selection genes encode the following proteins: (a) conferring resistance to antibiotics or other toxins such as ampicillin, neomycin, methotrexate, or tetracycline, ( b) lack of supplementary nutritional deficiencies, or (c) supply of critical nutrients that cannot be obtained from complex media, such as the gene encoding D-alanine racemase from Bacillus.
An example of a selection process uses drugs to halt the growth of host cells. Those cells that have been successfully transformed with a heterologous gene produce a protein that exhibits resistance and thus survives the selection scheme. Examples of such dominant selections use the drugs neomycin, mycophenolic acid, and hygromycin.
Another example of suitable selectable markers for mammalian cells is their ability to identify cells capable of receiving nucleic acids encoding antibodies, such as DHFR, glutamate synthase (GS), thymidine kinase, metals Thioprotein-I and metallothionein-II (preferably a primate metallothionein gene), adenosine deaminase, ornithine decarboxylase, and the like.
For example, transformants are identified by culturing cells transformed with the DHFR gene in a medium containing methotrexate (Mtx), a competitive antagonist of DHFR. Under these conditions, the DHFR gene is amplified with any other co-transformed nucleic acid. Chinese hamster ovary (CHO) cell lines (eg ATCC CRL-9096) lacking endogenous DHFR activity can be used.
Alternatively, cells transformed with the GS gene can be identified by culturing the transformants in a medium containing L-methionine sulfonylimide (Msx) (an inhibitor of GS). Under these conditions, the GS gene is amplified with any other co-transformed nucleic acid. The GS selection / amplification system can be used in combination with the DHFR selection / amplification system as described above.
Alternatively, the one encoding the antibody of interest can be selected by cell growth in a medium containing a selection agent for a selectable marker, such as an aminoglycoside antibiotic, such as kanamycin, neomycin, or G418. Host cells (especially wild-type hosts containing endogenous DHFR) transformed or co-transformed with the DNA sequence, wild-type DHFR gene, and another selectable marker (such as aminoglycoside 3'-phosphotransferase (APH)) . See US Patent No. 4,965,199.
Selection genes suitable for use in yeast are those present in yeast plastid YRp7trp 1 gene (Stinchcomb et al.,Nature 282: 39 (1979)).trp The 1 gene provides a selectable marker for mutant yeast strains (such as ATCC number 44076 or PEP4-1) that cannot grow in tryptophan. Jones,Genetics 85:12 (1977). In the yeast host cell genometrp 1 The presence of dysfunction provides an effective environment for detecting transformation by culturing in the presence of tryptophan. Similarly,Leu 2 defective yeast strains (ATCC 20,622 or 38,626) are carried byLeu 2 genes of known plastid supplementation.
In addition, a vector derived from a 1.6 μm circular plastid pKD1 can be used for Kluyveromyces transformation. Alternatively, a performance system for large-scale production of recombinant bovine chymosin has been reported for Kluyveromyces lactis. Van den Berg,Bio / Technology , 8: 135 (1990). A stable multi-replica expression vector for secreting mature recombinant human serum albumin using an industrial Kluyveromyces strain has also been disclosed. Fleer and others,Bio / Technology , 9: 968-975 (1991).
(d) Promoter components
Expression and selection vectors typically contain a promoter recognized by the host organism and operably linked to a nucleic acid encoding an antibody. Promoters suitable for use in prokaryotic hosts includepho A promoter, β-lactamase and lactose promoter, alkaline phosphatase promoter, tryptophan (trp) promoter, and hybrid promoter (such as tac promoter). However, other known bacterial promoters are also suitable. Promoters used in bacterial systems will also contain Shine-Dalgarno (S.D.) sequences operably linked to DNA encoding the antibody.
Promoter sequences are known for use in eukaryotes. Virtually all eukaryotic genes have an AT-enriched region located approximately 25 to 30 bases upstream of the transcription start site. Another sequence found 70 to 80 bases upstream of the start of transcription of various genes is the CNCAAT region, where N can be any nucleotide. The 3 'end of most eukaryotic genes is an AATAAA sequence, which can be a signal that adds a poly A tail to the 3' end of the coding sequence. All of these sequences are suitable for insertion into a eukaryotic expression vector.
Examples of promoter sequences suitable for use in yeast hosts include promoters of 3-phosphoglycerate kinase or other glycolytic enzymes such as enolase, glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, Phosphofructokinase, glucose-6-phosphate isomerase, 3-phosphoglycerate dismutase, pyruvate kinase, triose phosphate isomerase, phosphoglucose isomerase, and glucokinase.
Other yeast promoters with inducible promoters that have the additional advantage of being controlled by growth conditions are promoter regions for the following: alcohol dehydrogenase 2, isocytochrome C, acid phosphatase, degrading enzymes related to nitrogen metabolism , Metallothionein, glyceraldehyde-3-phosphate dehydrogenase and enzymes responsible for utilization of maltose and galactose. Vectors and promoters suitable for use in yeast performance are further described in EP 73,657. Yeast enhancers should also be used with yeast promoters.
Antibody transcription from vectors in mammalian host cells can be controlled, for example, by promoters obtained from: such as polymorphoma virus, fowlpox virus, adenovirus (such as adenovirus 2), bovine papilloma virus, avian sarcoma virus , Cytomegalovirus, retrovirus, hepatitis B virus, simian virus 40 (SV40) virus genome; or a heterologous mammalian promoter (such as an actin promoter or an immunoglobulin promoter); heat shock activation Promoters, the restriction being that the promoters are compatible with the host cell system.
The early and late promoters of SV40 virus are conveniently obtained as SV40 restriction fragments that also contain the origin of SV40 virus replication. The immediate early promoter of human cytomegalovirus is conveniently obtained as a HindIII E restriction fragment. A system for expressing DNA using a bovine papilloma virus as a vector in a mammalian host is disclosed in US Patent No. 4,419,446. A modification of this system is described in US Patent No. 4,601,978. The expression of human β-interferon cDNA in mouse cells under the control of the thymidine kinase promoter from herpes simplex virus is also described in Reyes et al.,Nature 297: 598-601 (1982). Alternatively, a long terminal repeat of Rous Sarcoma Virus can be used as a promoter.
(e) Enhancer element components
Transcription of DNA encoding an antibody of the invention from higher eukaryotes is usually increased by inserting the enhancer sequence into a vector. A number of enhancer sequences from mammalian genes (hemoglobin, elastase, albumin, alpha-fetoprotein, and insulin) are now known. However, we usually use enhancers from eukaryotic cells. Examples include SV40 enhancer (bp 100-270) behind the origin of replication, cytomegalovirus early promoter enhancer, polyoma virus enhancer behind the origin of replication, and adenovirus enhancer. See also Yaniv for enhancement elements used to activate eukaryotic promoters,Nature 297: 17-18 (1982). The enhancer can be spliced to the 5 'or 3' position of the antibody coding sequence in the vector, but is preferably located at the 5 'position of the promoter.
(f) Transcription termination component
Performance vectors for eukaryotic host cells (yeast, fungi, insects, plants, animals, humans or nucleated cells from other multicellular organisms) also contain sequences necessary to terminate transcription and stabilize mRNA. Such sequences are generally available from the 5 'and sometimes 3' untranslated regions of eukaryotic or viral DNA or cDNA. These regions contain nucleotide segments transcribed as polyadenylated fragments in the untranslated portion of the mRNA encoding the antibody. A suitable transcription termination component is the bovine growth hormone polyadenylation region. See WO94 / 11026 and the expression vectors disclosed therein.
(g) Selection and transformation of host cells
Suitable host cells for the selection or expression of DNA in the vectors herein are prokaryotic, yeast or higher eukaryotic cells as described above. Prokaryotes suitable for this purpose include Eubacteria, such as Gram-negative or Gram-positive organisms, such as Enterobacteriaceae, such as Escherichia (Escherichia ) (E.g. E. coli), Enterobacteria (Enterobacter ), Erwinia (Erwinia ), Klebsiella (Klebsiella ProteusProteus ), Salmonella (Salmonella ) (E.g. Salmonella typhimurium (Salmonella typhimurium )), Serratia (Serratia ) (E.g. Serratia marcescens (Serratia marcescans )) And Shigella (Shigella ) And Bacillus (Bacilli ) (Such as Bacillus subtilis (B. subtilis ) And Bacillus licheniformis (B. licheniformis ) (Such as B. licheniformis 41P disclosed in DD 266,710 published on April 12, 1989), Pseudomonas (Pseudomonas ) (Such as P. aeruginosaP. aeruginosa )) And StreptomycesStreptomyces ). Although other strains such as E. coli B, E. coli X1776 (ATCC 31,537), and E. coli W3110 (ATCC 27,325) are also suitable, a preferred E. coli breeding host is E. coli 294 (ATCC 31,446). These examples are illustrative and not restrictive.
Can produce full-length antibodies, antibody fusion proteins, and antibody fragments in bacteria, especially when glycosylation and Fc effector functions are not required, such as when the therapeutic antibody is combined with a cytotoxic agent (e.g., a toxin) that exhibits its own ability to destroy tumor cells Time. Full-length antibodies have a longer half-life in circulation. Production is faster and more cost effective in E. coli. For the expression of antibody fragments and polypeptides in bacteria, see, for example, U.S. Patent No. 5,648,237 (Carter et al.), U.S. Patent No. 5,789,199 (Joly et al.), And U.S. Patent No. 5,840,523 (Simmons et. Secrets the best translation initiation region (TIR) and signal sequence. See also Charlton,Methods in Molecular Biology Vol. 248 (ed. B. K. C. Lo, Humana Press, Totowa, N.J., 2003), p. 245-p. 254, describes the expression of antibody fragments in E. coli. After expression, the antibodies in the soluble fraction can be separated from the E. coli cell paste and can be purified by, for example, a protein A or G column depending on the isotype. Final purification can be performed in a similar manner to the purification of antibodies expressed in CHO cells, for example.
In addition to prokaryotes, eukaryotic microorganisms such as filamentous fungi or yeast are suitable breeding or performance hosts for vectors encoding antibodies. Saccharomyces cerevisiae is most commonly used in lower eukaryotic host microorganisms (Saccharomyces cerevisiae ) Or baker's yeast. However, many other genera, species, and virus strains are generally available and suitable for use here, such as Schizosaccharomyces pombe (Schizosaccharomyces pombe ); Kluyveromyces hosts, such as Kluyveromyces lactis, Kluyveromyces fragilis (K. fragilis ) (ATCC 12,424), Kluyveromyces bulgaricus (K. bulgaricus ) (ATCC 16,045), Wick Kluyveromyces (K. wickeramii ) (ATCC 24,178), Kluyveromyces (K. waltii ) (ATCC 56,500), Gouni Kluyveromyces (K. drosophilarum ) (ATCC 36,906), Kluyveromyces thermotolerance (K. thermotolerans ) And Max Kluyveromyces (K. marxianus ); Yarrowiayarrowia ) (EP 402,226); methanol yeast (Pichia pastoris ) (EP 183,070); Candida (Candida ); Trichoderma reesei (Trichoderma reesia ) (EP 244,234);Neurospora crassa ); Schiff ’s yeast (Schwanniomyces ), Such as Schwann yeast (Schwanniomyces occidentalis ); And filamentous fungi such as Rhodococcus (Neurospora ), Penicillium (Penicillium ), CurvulariaTolypocladium ) And AspergillusAspergillus ) Host, such as Aspergillus nidulans (A. nidulans ) And Aspergillus niger (A. niger ). For a review of the use of yeast and filamentous fungi for the manufacture of therapeutic proteins, see e.g. Gerngross,Nat. Biotech. 22: 1409-1414 (2004).
Certain fungal and yeast strains can be selected, in which the glycosylation pathway has been "humanized", resulting in the production of antibodies with partial or complete human glycosylation patterns. See, for example, Li et al.Nat. Biotech. 24: 210-215 (2006) (Describes the humanization of glycosylation pathways in methanol yeast); and Gerngross et al., Supra.
Host cells suitable for expressing glycosylated antibodies can also be obtained from multicellular organisms (invertebrates and vertebrates). Examples of invertebrate cells include plant and insect cells. A variety of baculovirus strains and variants have been identified, as well asSpodoptera frugiperda ) (Caterpillar), Aedes aegypti (Aedes aegypti ) (Mosquito), Aedes albopictus (Aedes albopictus ) (Mosquito), Drosophila melanogaster (Drosophila melanogaster ) (Drosophila) and Silkworm (Bombyx mori ) Corresponding host of the insect host cell. A number of virus strains for transfection are publicly available, such as SativaAutographa californica L-1 variant of NPV and Bm-5 virus strain of silkworm NPV, and the viruses according to the present invention can be used as viruses herein, especially for transfection of grassland armyworm cells.
Cotton, corn, potato, soybean, petunia, tomato, duckweed (Lemnaaceae (Lemnaceae )), Alfalfa (Tribulus alfalfa (M. truncatula )) And tobacco plant cell cultures can also be used as hosts. See, e.g., U.S. Pat.Nos. 5,959,177, 6,040,498, 6,420,548, 7,125,978, and 6,417,429 (Describes PLANTIBODIES for the production of antibodies in specialized genetic plants<sup>TM</sup> technology).
Vertebrate cells can be used as hosts, and proliferation of vertebrate cells in culture (tissue culture) has become a routine procedure. Examples of suitable mammalian host cell lines are monkey kidney CV1 cell lines (COS-7, ATCC CRL 1651) transformed with SV40; human embryonic kidney cell lines (293 cells or subcultured for growth in suspension culture) 293 cells, Graham et al.,J. Gen Virol. 36:59 36:59 (1977)); baby hamster kidney cells (BHK, ATCC CCL 10); mouse supporter cells (TM4, Mather,Biol. Reprod. 23: 243-251 (1980)); monkey kidney cells (CV1 ATCC CCL 70); African green monkey kidney cells (VERO-76, ATCC CRL-1587); human cervical cancer cells (HELA ATCC CCL 2); dog kidney cells (MDCK, ATCC CCL 34); buffalo rat liver cells (BRL 3A, ATCC CRL 1442); human lung cells (W138, ATCC CCL 75); Human hepatocytes (Hep G2, HB 8065); mouse breast tumors (MMT 060562, ATCC CCL51); TRI cells (Mather et al.,Annals NY Acad. Sci. 383: 44-68 (1982)); MRC 5 cells; FS4 cells; and human liver cancer cell lines (Hep G2). Other suitable mammalian host cell lines include Chinese Hamster Ovary (CHO) cells, including DHFR<sup>-</sup> CHO cells (Urlaub et al., Proc. Natl. Acad. Sci. USA 77: 4216 (1980)); and myeloma cell lines such as NS0 and Sp2 / 0. For comments on certain mammalian host cell lines suitable for antibody production see, e.g., Yazaki and Wu,Methods in Molecular Biology Vol. 248 (ed. B. K. C. Lo, edited by Humana Press, Totowa, N.J., 2003), pp. 255-268.
Host cells are transformed with the expression or colony vectors described above for antibody production and cultured in conventional nutrient media modified to suit the induction of promoters, selection of transformants, or amplification of genes encoding desired sequences .
(h) Culture host cells
The host cells used to produce the antibodies of the invention can be cultured in a variety of media. Commercially available media such as Ham's F10 (Sigma), Minimum Essential Media (MEM) (Sigma), RPMI-1640 (Sigma), and Dulbecco's Modified Eagle's Medium (DMEM) ) (Sigma), suitable for culturing host cells. In addition, any of the media described in the following documents can be used as media for such host cells: Ham et al.,Meth. Enz. 58:44 (1979); Barnes et al.,Anal. Biochem. 102: 255 (1980); U.S. Patent Nos. 4,767,704; 4,657,866; 4,927,762; 4,560,655; or 5,122,469; WO 90/03430; WO 87/00195; or US Patent Re. 30,985. Any of these media can be supplemented with hormones and / or other growth factors (such as insulin, transferrin, or epidermal growth factor), salts (such as sodium chloride, calcium, magnesium, and phosphate), buffers (such as HEPES), Nucleotides (such as adenosine and thymidine), antibiotics (such as GENTAMYCIN)<sup>TM</sup> Drugs), trace elements (defined as inorganic compounds, usually present at a final concentration in the micromolar range), and glucose or equivalent energy sources. Any other necessary supplements may also be included at appropriate concentrations known to those skilled in the art. Culture conditions (such as temperature, pH, and the like) are the conditions previously used for host cells selected for performance, and will be readily apparent to those of ordinary skill.
(xi) Antibody purification
When recombinant technology is used, antibodies can be produced intracellularly, in the periplasmic space, or secreted directly into the culture medium. If the antibody is produced intracellularly, it is used as a first step, such as removing host cells or particulate fragments of lysed fragments by centrifugation or ultrafiltration. Carter et al.,Bio / Technology 10: 163-167 (1992) describes a procedure for isolating antibodies secreted into the periplasmic space of E. coli. Briefly, the cell paste was thawed in the presence of sodium acetate (pH 3.5), EDTA, and phenylmethylsulfonium fluoride (PMSF) for about 30 minutes. Cell debris can be removed by centrifugation. In cases where antibodies are secreted into the culture medium, the supernatant of these performance systems is usually first concentrated using a commercially available protein concentration filter (such as an Amicon or Millipore Pellicon ultrafiltration unit). Protease inhibitors such as PMSF may be included in any previous steps to inhibit proteolysis, and antibiotics may be included to prevent the growth of foreign contaminants.
Antibody compositions made from cells can be purified using, for example, hydroxyapatite chromatography, hydrophobic interaction chromatography, gel electrophoresis, dialysis, and affinity chromatography, and affinity chromatography is one of the generally preferred purification steps. The suitability of protein A as an affinity ligand depends on the species and the isotype of any immunoglobulin Fc domain present in the antibody. Protein A can be used to purify human γ1, γ2, or γ4 heavy chain-based antibodies (Lindmark et al.,J. Immunol. Meth. 62: 1-13 (1983)). Protein G is recommended for all mouse isotypes and human γ3 (Guss et al.,EMBO J. 5: 15671575 (1986)). Although the matrix to which the affinity ligand is attached is most often agarose, other matrices can be used. Compared to the flow rates and processing times achievable with agarose, mechanically stable matrices (such as controlled porosity glass or poly (styrenedivinyl) benzene) have faster flow rates and shorter processing times. When the antibody contains C<sub>H</sub> 3 domains, Bakerbond ABX<sup>TM</sup> Resin (J. T. Baker; Phillipsburg, N.J.) is suitable for purification. Depending on the antibody to be recovered, other techniques for protein purification such as ion exchange column fractionation, ethanol deposition, reverse phase HPLC, silica chromatography, heparin SEPHAROSE ™ chromatography, anion or cation exchange resins (such as Polyaspartic acid column) chromatography, chromatography focus, SDS-PAGE and ammonium sulfate precipitation.
In general, the various methods used to prepare antibodies for research, testing, and clinical use are well established in the technology, are consistent with the methods described above, and / or are considered suitable for the particular antibody of interest by those skilled in the art .
C. Select bioactive antibodies
One or more "biological activity" assays can be performed on the antibodies produced as described above to select antibodies with beneficial properties from a therapeutic standpoint or to select formulations and conditions that retain the biological activity of the antibodies. The ability of an antibody to bind to an elevated antigen can be tested. For example, for anti-PDL1 antibodies, the antigen-binding properties of the antibodies can be assessed in an assay that detects the ability to bind to PDL1. In some embodiments, antibody binding can be determined by saturation binding; ELISA; and / or competition analysis (eg, RIA's). Similarly, other biological activity assays can be performed on the antibody, for example to evaluate its effectiveness as a therapeutic agent. Such assays are known in the art and depend on the intended use of the target antigens and antibodies. For example, the biological effects of PD-L1 blocked by antibodies can be in CD8 + T cells, mouse models of lymphocytic choroid plexus meningitis virus (LCMV), and / or homologous tumor models (e.g., as described in US Patent 8,217,149) Assessment.
To screen for antibodies that bind to a particular epitope on the antigen of interest (e.g., blocking an example of an anti-PDL1 antibody that binds PD-L1), conventional cross-blocking assays such asAntibodies, A Laboratory Manual , Cold Spring Harbor Laboratory, Ed Harlow and David Lane (1988). Alternatively, for example, such as Champe et al.,J. Biol. Chem. 270: 1388-1394 (1995) describes epitope mapping to determine whether an antibody binds to the relevant epitope.
D. Preparation of formulations
After preparing the relevant antibodies (eg, techniques for making antibodies that can be formulated as disclosed herein will be detailed below and known in the art), pharmaceutical formulations comprising the same are prepared. In certain embodiments, the antibody to be formulated is not pre-lyophilized and the relevant formulation herein is an aqueous formulation. In certain embodiments, the antibody is a full-length antibody. In one embodiment, the antibody in the formulation is an antibody fragment, such as F (ab ')<sub>2</sub> It may be necessary to address issues where full-length antibodies do not occur in this case (such as antibody splicing into Fab). The therapeutically effective amount of the antibody present in the formulation is determined by considering, for example, the required dose volume and mode of administration. About 25 mg / mL to about 150 mg / mL, or about 30 mg / mL to about 140 mg / mL, or about 35 mg / mL to about 130 mg / mL, or about 40 mg / mL to about 120 mg / mL , Or about 50 mg / mL to about 130 mg / mL, or about 50 mg / mL to about 125 mg / mL, or about 50 mg / mL to about 120 mg / mL, or about 50 mg / mL to about 110 mg / mL, or about 50 mg / mL to about 100 mg / mL, or about 50 mg / mL to about 90 mg / mL, or about 50 mg / mL to about 80 mg / mL, or about 54 mg / mL to about 66 mg / mL is an exemplary antibody concentration in the formulation.
An aqueous formulation of the antibody is prepared containing a pH buffer solution. The buffer of the present invention has a pH in the range of about 5.0 to about 7.0. In certain embodiments, the pH is in the range of about 5.0 to about 6.5, the pH is in the range of about 5.0 to about 6.4, the range of about 5.0 to about 6.3, the pH is in the range of about 5.0 to about 6.2, and the pH is in the range of about 5.0 In the range of about 6.1, the pH is in the range of about 5.5 to about 6.1, the pH is in the range of about 5.0 to about 6.0, the pH is in the range of about 5.0 to about 5.9, the pH is in the range of about 5.0 to about 5.8, and the pH is about 5.1 In the range of about 6.0, the pH is in the range of about 5.2 to about 6.0, the pH is in the range of about 5.3 to about 6.0, the pH is in the range of about 5.4 to about 6.0, the pH is in the range of about 5.5 to about 6.0, and the pH is about 5.6 In the range of about 6.0, the pH is in the range of about 5.7 to about 6.0, or the pH is in the range of about 5.8 to about 6.0. In certain embodiments of the invention, the formulation has a pH of 6.0 or about 6.0. In certain embodiments of the invention, the formulation has a pH of 5.9 or about 5.9. In certain embodiments of the invention, the formulation has a pH of 5.8 or about 5.8. In certain embodiments of the invention, the formulation has a pH of 5.7 or about 5.7. In certain embodiments of the invention, the formulation has a pH of 5.6 or about 5.6. In certain embodiments of the invention, the formulation has a pH of 5.5 or about 5.5. In certain embodiments of the invention, the formulation has a pH of 5.4 or about 5.4. In certain embodiments of the invention, the formulation has a pH of 5.3 or about 5.3. In certain embodiments of the invention, the formulation has a pH of 5.2 or about 5.2. Examples of buffers for controlling the pH in this range include histidine (such as L-histidine) or sodium acetate. In certain embodiments, the buffer contains histidine acetate or sodium acetate at a concentration of about 15 mM to about 25 mM. In certain embodiments of the invention, the buffer contains a concentration of about 15 mM to about 25 mM, about 16 mM to about 25 mM, about 17 mM to about 25 mM, about 18 mM to about 25 mM, about 19 mM To about 25 mM, about 20 mM to about 25 mM, about 21 mM to about 25 mM, about 22 mM to about 25 mM, about 15 mM, about 16 mM, about 17 mM, about 18 mM, about 19 mM, about 20 mM, about 21 mM, about 22 mM, about 23 mM, about 24 mM, or about 25 mM histidine acetate or sodium acetate. In one embodiment, the buffer is histidine acetate or sodium acetate in an amount of about 20 mM, pH 5.0. In one embodiment, the buffer is histidine acetate or sodium acetate in an amount of about 20 mM, pH 5.1. In one embodiment, the buffer is histidine acetate or sodium acetate in an amount of about 20 mM, pH 5.2. In one embodiment, the buffer is histidine acetate or sodium acetate in an amount of about 20 mM, pH 5.3. In one embodiment, the buffer is histidine acetate or sodium acetate in an amount of about 20 mM, pH 5.4. In one embodiment, the buffer is histidine acetate or sodium acetate in an amount of about 20 mM, pH 5.5. In one embodiment, the buffer is histidine acetate or sodium acetate in an amount of about 20 mM, pH 5.6. In one embodiment, the buffer is histidine acetate or sodium acetate in an amount of about 20 mM, pH 5.7. In one embodiment, the buffer is histidine acetate or sodium acetate in an amount of about 20 mM, pH 5.8. In one embodiment, the buffer is histidine acetate or sodium acetate in an amount of about 20 mM, pH 5.9. In one embodiment, the buffer is histidine acetate or sodium acetate in an amount of about 20 mM, pH 6.0. In one embodiment, the buffer is histidine acetate or sodium acetate in an amount of about 20 mM, pH 6.1. In one embodiment, the buffer is histidine acetate or sodium acetate in an amount of about 20 mM, pH 6.2. In one embodiment, the buffer is histidine acetate or sodium acetate in an amount of about 20 mM, pH 6.3. In one embodiment, the buffer is histidine acetate or sodium acetate in an amount of about 25 mM, pH 5.2. In one embodiment, the buffer is histidine acetate or sodium acetate in an amount of about 25 mM, pH 5.3. In one embodiment, the buffer is histidine acetate or sodium acetate in an amount of about 25 mM, pH 5.4. In one embodiment, the buffer is histidine acetate or sodium acetate in an amount of about 25 mM, pH 5.5. In one embodiment, the buffer is histidine acetate or sodium acetate in an amount of about 25 mM, pH 5.6. In one embodiment, the buffer is histidine acetate or sodium acetate in an amount of about 25 mM, pH 5.7. In one embodiment, the buffer is histidine acetate or sodium acetate in an amount of about 25 mM, pH 5.8. In one embodiment, the buffer is histidine acetate or sodium acetate in an amount of about 25 mM, pH 5.9. In one embodiment, the buffer is histidine acetate or sodium acetate in an amount of about 25 mM, pH 6.0. In one embodiment, the buffer is histidine acetate or sodium acetate in an amount of about 25 mM, pH 6.1. In one embodiment, the buffer is histidine acetate or sodium acetate in an amount of about 25 mM, pH 6.2. In one embodiment, the buffer is histidine acetate or sodium acetate in an amount of about 25 mM, pH 6.3.
The formulation further comprises sucrose in an amount of about 60 mM to about 240 mM. In some embodiments, the sucrose in the formulation is about 60 mM to about 230 mM, about 60 mM to about 220 mM, about 60 mM to about 210 mM, about 60 mM to about 200 mM, about 60 mM to about 190 mM, about 60 mM to about 180 mM, about 60 mM to about 170 mM, about 60 mM to about 160 mM, about 60 mM to about 150 mM, about 60 mM to about 140 mM, about 80 mM to about 240 mM, About 90 mM to about 240 mM, about 100 mM to about 240 mM, about 110 mM to about 240 mM, about 120 mM to about 240 mM, about 130 mM to about 240 mM, about 140 mM to about 240 mM, about 150 mM to about 240 mM, about 160 mM to about 240 mM, about 170 mM to about 240 mM, about 180 mM to about 240 mM, about 190 mM to about 240 mM, about 200 mM to about 240 mM, about 80 mM to About 160 mM, about 100 mM to about 140 mM, or about 110 mM to about 130 mM. In some embodiments, the sucrose in the formulation is about 60 mM, about 70 mM, about 80 mM, about 90 mM, about 100 mM, about 110 mM, about 120 mM, about 130 mM, about 140 mM, about 150 mM, about 160 mM, about 170 mM, about 180 mM, about 190 mM, about 200 mM, about 210 mM, about 220 mM, about 230 mM, or about 240 mM.
In some embodiments, the antibody concentration in the formulation is from about 40 mg / ml to about 125 mg / ml. In some embodiments, the antibody concentration in the formulation is about 40 mg / ml to about 120 mg / ml, about 40 mg / ml to about 110 mg / ml, about 40 mg / ml to about 100 mg / ml, about 40 mg / ml to about 90 mg / ml, about 40 mg / ml to about 80 mg / ml, about 40 mg / ml to about 70 mg / ml, about 50 mg / ml to about 120 mg / ml, about 60 mg / ml to about 120 mg / ml, about 70 mg / ml to about 120 mg / ml, about 80 mg / ml to about 120 mg / ml, about 90 mg / ml to about 120 mg / ml, or about 100 mg / ml to about 120 mg / ml. In some embodiments, the antibody concentration in the formulation is about 60 mg / ml. In some embodiments, the antibody concentration in the formulation is about 65 mg / ml. In some embodiments, the antibody concentration in the formulation is about 70 mg / ml. In some embodiments, the antibody concentration in the formulation is about 75 mg / ml. In some embodiments, the antibody concentration in the formulation is about 80 mg / ml. In some embodiments, the antibody concentration in the formulation is about 85 mg / ml. In some embodiments, the antibody concentration in the formulation is about 90 mg / ml. In some embodiments, the antibody concentration in the formulation is about 95 mg / ml. In some embodiments, the antibody concentration in the formulation is about 100 mg / ml. In some embodiments, the antibody concentration in the formulation is about 110 mg / ml. In some embodiments, the antibody concentration in the formulation is about 125 mg / ml.
In some embodiments, a surfactant is added to the antibody formulation. Exemplary surfactants include non-ionic surfactants such as polysorbates (eg, polysorbates 20, 80, etc.) or poloxamers (eg, poloxamer 188, etc.). The amount of surfactant added is such that it reduces aggregation of the formulated antibody and / or minimizes particle formation in the formulation and / or reduces adsorption. For example, the surfactant may be present in the formulation in an amount of about 0.001% to about 0.5% (w / v). In some embodiments, the surfactant (e.g., polysorbate 20) is about 0.005% to about 0.2%, about 0.005% to about 0.1%, about 0.005% to about 0.09%, about 0.005% to about 0.08%, About 0.005% to about 0.07%, about 0.005% to about 0.06%, about 0.005% to about 0.05%, about 0.005% to about 0.04%, about 0.008% to about 0.06%, about 0.01% to about 0.06%, about 0.02 % To about 0.06%, about 0.01% to about 0.05%, or about 0.02% to about 0.04%. In certain embodiments, a surfactant (eg, polysorbate 20) is present in the formulation in an amount of about 0.005% or about 0.005%. In certain embodiments, a surfactant (such as polysorbate 20) is present in the formulation in an amount of about 0.006% or about 0.006%. In certain embodiments, a surfactant (eg, polysorbate 20) is present in the formulation in an amount of about 0.007% or about 0.007%. In certain embodiments, a surfactant (eg, polysorbate 20) is present in the formulation in an amount of about 0.008% or about 0.008%. In certain embodiments, a surfactant (such as polysorbate 20) is present in the formulation in an amount of about 0.009% or about 0.009%. In certain embodiments, a surfactant (such as polysorbate 20) is present in the formulation in an amount of about 0.01% or about 0.01%. In certain embodiments, a surfactant (such as polysorbate 20) is present in the formulation in an amount of about 0.02% or about 0.02%. In certain embodiments, a surfactant (such as polysorbate 20) is present in the formulation in an amount of about 0.03% or about 0.03%. In certain embodiments, a surfactant (such as polysorbate 20) is present in the formulation in an amount of about 0.04% or about 0.04%. In certain embodiments, a surfactant (such as polysorbate 20) is present in the formulation in an amount of about 0.05% or about 0.05%. In certain embodiments, a surfactant (such as polysorbate 20) is present in the formulation in an amount of about 0.06% or about 0.06%. In certain embodiments, a surfactant (such as polysorbate 20) is present in the formulation in an amount of about 0.07% or about 0.07%. In certain embodiments, a surfactant (such as polysorbate 20) is present in the formulation in an amount of about 0.08% or about 0.08%. In certain embodiments, a surfactant (such as polysorbate 20) is present in the formulation in an amount of about 0.1% or about 0.1%. In certain embodiments, a surfactant (eg, polysorbate 20) is present in the formulation in an amount of about 0.2% or about 0.2%. In certain embodiments, a surfactant (such as polysorbate 20) is present in the formulation in an amount of about 0.3% or about 0.3%. In certain embodiments, a surfactant (such as polysorbate 20) is present in the formulation in an amount of about 0.4% or about 0.4%. In certain embodiments, a surfactant (such as polysorbate 20) is present in the formulation in an amount of about 0.5% or about 0.5%.
In one embodiment, the formulation contains the agents identified above (e.g., antibodies, buffers, sucrose, and / or surfactants) and is substantially free of one or more preservatives, such as benzyl alcohol, phenol, m-cresol, Chlorobutanol and benzethonium chloride. In another embodiment, a preservative may be included in the formulation, especially when the formulation is a multi-dose formulation. The concentration of the preservative may be in the range of about 0.1% to about 2%, preferably about 0.5% to about 1%. One or more other pharmaceutically acceptable carriers, excipients or stabilizers (such as those described in Remington's Pharmaceutical Sciences 16th Edition, Osol, A. Ed. (1980)) may be included in the formulation, with limitations Provided that it does not adversely affect the desired characteristics of the formulation. Acceptable carriers, excipients or stabilizers are non-toxic to the recipient at the dosages and concentrations used and include: other buffers; co-solvents; antioxidants, including ascorbic acid and methionine; chelating agents, such as EDTA Metal complexes (eg, Zn-protein complexes); biodegradable polymers, such as polyesters; and / or salt-forming counterions. Exemplary pharmaceutically acceptable carriers herein further include interstitial drug dispersants, such as soluble neutral active hyaluronidase glycoprotein (sHASEGP), such as human soluble PH-20 hyaluronidase glycoprotein, such as rHuPH20 (HYLENEX<sup>®</sup> , Baxter International, Inc.). Certain exemplary sHASEGPs and methods of use (including rHuPH20) are described in US Patent Publication Nos. 2005/0260186 and 2006/0104968. In one aspect, sHASEGP is combined with one or more additional glycosaminoglycans, such as chondroitin sulfate.
The formulations herein may also contain more than one protein necessary for the particular indication being treated, preferably a protein that has complementary activities that do not adversely affect other proteins. For example, if the antibody is anti-PDL1, it can be combined with another agent, such as a chemotherapeutic agent and an anti-neoplastic agent.
In some embodiments, the physical stability, chemical stability, or biological activity of the antibodies in the formulation is assessed or measured. Any method known in the art as described in the examples herein can be used to assess the stability and biological activity of antibodies in formulations. For example, the stability of antibodies in formulations can be measured by (but not limited to): size exclusion chromatography (SEC or SE-HPLC), electrofocusing such as imaging capillary (ICIEF), peptide localization, small Volume shading (HIAC) analysis and capillary electrophoresis (CE) technologies such as CE-dodecyl sulfate (CE-SDS) and CE-glycan analysis. In some embodiments, the antibody in the formulation is stable at -20 ° C for at least about 6 months, at least about 8 months, at least about 10 months, at least about 12 months, at least about 14 months, at least about 16 Months, at least about 18 months, at least about 20 months, at least about 21 months, at least about 22 months, at least about 23 months, at least about 24 months, at least about 3 years or at least about 4 years. In some embodiments, the antibody in the formulation is stable at 2 ° C to 8 ° C (e.g., 5 ° C) for at least about 6 months, at least about 8 months, at least about 10 months, at least about 12 months, at least about 14 months, at least about 16 months, at least about 18 months, at least about 20 months, at least about 21 months, at least about 22 months, at least about 23 months, or at least about 24 months. In some embodiments, the stability of the antibodies (ie, antibody monomers) in the formulation is measured by size exclusion chromatography after storage. In some embodiments, the stability of the antibodies (ie, antibody monomers) in the formulation is measured by electrofocusing with an imaging capillary or the like after storage. In some embodiments, after storage at -20 ° C for at least about 6 months, at least about 12 months, at least about 18 months, or at least about 24 months, the antibody monomers in the formulation are compared to all proteins (e.g., (Including antibodies and aggregates) is greater than about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, or about 95%. In some embodiments, after storage at 2 ° C to 8 ° C (e.g., 5 ° C) for at least about 6 months, at least about 12 months, at least about 18 months, or at least about 24 months, the antibody monomer in the formulation Compared to (for example, including antibodies and aggregates), the percentage is greater than about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 86%, about 87%, about 88%, About 89%, about 90%, about 91%, about 92%, about 93%, about 94%, or about 95%. In some embodiments, stirring at room temperature (e.g., about 15 ° C to 25 ° C) for at least about 2 hours, at least about 4 hours, at least about 6 hours, at least about 8 hours, at least about 10 hours, After at least about 12 hours, at least about 14 hours, at least about 16 hours, at least about 18 hours, at least about 20 hours, or at least about 24 hours, the antibody monomers in the formulation are compared to (e.g., including antibodies) And aggregates) greater than about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 86%, about 87%, about 88%, about 89%, and about 90% , About 91%, about 92%, about 93%, about 94%, or about 95%. In some embodiments, after being stored at -20 ° C for at least about 6 months, at least about 12 months, at least about 18 months, or at least about 24 months, all aggregates in the formulation (such as high molecular weight substances and low (Molecular weight substance) percentage is less than about 0.1%, about 0.2%, about 0.3%, about 0.4%, about 0.5%, about 0.6%, about 0.7%, about 0.8%, about 0.9%, about 1%, about 2%, Any of about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, or about 10%. In some embodiments, all aggregates in the formulation are stored after storage at 2 ° C to 8 ° C (e.g., 5 ° C) for at least about 6 months, at least about 12 months, at least about 18 months, or at least about 24 months. (E.g., high molecular weight substances and low molecular weight substances) with a percentage of less than about 0.1%, about 0.2%, about 0.3%, about 0.4%, about 0.5%, about 0.6%, about 0.7%, about 0.8%, about 0.9%, about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, or about 10%. In some embodiments, the stirring is at room temperature (e.g., about 15 ° C to 25 ° C) for at least about 2 months, at least about 4 months, at least about 6 months, at least about 8 months, at least about 10 months, After at least about 12 months, at least about 14 months, at least about 16 months, at least about 18 months, at least about 20 months, or at least about 24 months, all aggregates in the formulation (such as high molecular weight substances and low (Molecular weight substance) percentage is less than about 0.1%, about 0.2%, about 0.3%, about 0.4%, about 0.5%, about 0.6%, about 0.7%, about 0.8%, about 0.9%, about 1%, about 2%, Any of about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, or about 10%. In any of the embodiments herein, the stable formulation may be stored in a glass bottle, a metal alloy container, or an intravenous (IV) bag. In some embodiments, the metal alloy is a 316L stainless steel or a Herst alloy.
Formulations for in vivo administration should be sterile. This is easily achieved by filtering through a sterile filtration membrane before or after preparing the formulation.
III. Methods of treating and administering antibody formulations
According to known methods (such as intravenous administration (e.g., in a bolus or by continuous infusion over a period of time), by intramuscular, intraperitoneal, intracerebral spinal cord, The formulation is administered orally, topically or by inhalation) to a mammal, preferably a human, in need of treatment with the antibody. In one embodiment, the formulation is administered to a mammal by intravenous administration. For such purposes, the formulation may be injected, for example, using a syringe or via an IV catheter. In one embodiment, the formulation is administered to a mammal by subcutaneous administration.
The appropriate dose of the antibody (`` therapeutic effective amount '') will depend on, for example, the condition to be treated, the severity and progression of the condition, whether the antibody is administered for preventive or therapeutic purposes, previous therapies, the patient's clinical history And the response to the antibody, the type of antibody used, and the judgment of the attending physician. The antibody is appropriately administered to the patient at one time or after a series of treatments, and can be administered to the patient at any time from the date of diagnosis. Antibodies can be administered as a single treatment or in combination with other drugs or therapies suitable for the treatment of related conditions.
As a general recommendation, a therapeutically effective amount of the antibody administered to humans by one or more administrations will be in the range of about 0.01 to about 50 mg / kg of the patient's body weight. In some embodiments, the antibody used is, for example, administered at about 0.01 to about 45 mg / kg, about 0.01 to about 40 mg / kg, about 0.01 to about 35 mg / kg, about 0.01 to about 30 mg / kg, about 0.01 to about 25 mg / kg, about 0.01 to about 20 mg / kg, about 0.01 to about 15 mg / kg, about 0.01 to about 10 mg / kg, about 0.01 to about 5 mg / kg, or about 0.01 to about 1 mg / kg. In some embodiments, the antibody is administered at 15 mg / kg. However, other dosage regimens are also applicable. In one embodiment, the anti-PDL1 antibody described herein is about 100 mg, about 200 mg, about 300 mg, about 400 mg, about 500 mg, about 600 mg, about 700 mg, About 800 mg, about 900 mg, about 1000 mg, about 1100 mg, about 1200 mg, about 1300 mg, or about 1400 mg are administered to humans. This dose may be administered in a single dose or multiple doses (eg, 2 or 3 doses), such as infusion. The dose of antibody administered in a combination treatment may be reduced compared to a single treatment. The progress of this therapy is easily monitored by conventional techniques.
Formulations containing the anti-PDL1 antibodies described herein can be used in a variety of in vitro and in vivo diagnostic and therapeutic applications. For example, an antibody-containing formulation can be administered to an individual to treat a disease or disorder (e.g., a disease or disorder mediated by PD-1 and PD-L1 interactions)
In some embodiments, the disease or disorder is cancer. In some embodiments, the cancer is locally advanced cancer or metastatic cancer. In some embodiments, the cancer is selected from the group consisting of: solid tumor, hematological cancer, bladder cancer, brain cancer, breast cancer, colon cancer, colorectal cancer, gastric cancer, glioma, head cancer, leukemia, liver cancer, Lung cancer (e.g. non-small cell lung cancer), lymphoma, myeloma, neck cancer, ovarian cancer, melanoma, pancreatic cancer, kidney cancer, salivary cancer, gastric cancer, thymic epithelial cell cancer, thyroid cancer, and head and neck Squamous cell carcinoma. In some embodiments, the individual being treated has PD-L1-positive cancer cells (eg, as detected by IHC).
In some embodiments, the disease or condition is an infection. In some embodiments, the infection is a persistent infection. In some embodiments, the infection is a viral infection, a bacterial infection, a fungal infection, a worm infection, or a protozoal infection. In some embodiments, the viral infection is selected from the group consisting of: cytomegalovirus, Epstein-Barr virus, hepatitis B, hepatitis C virus, herpes virus, measles virus, influenza, Human immunodeficiency virus, human T-cell virus, lymphocytic choriomeningitis virus, respiratory syncytial virus and / or rhinovirus. In some embodiments, the bacterial infection is selected from the group consisting of: Helicobacter (Helicobacter spp. ), MycobacteriumMycobacterium spp. ), Porphyromonas (Porphyromonas spp. ), ChlamydiaChlamydia spp. ), Salmonella (Salmonella spp. ), ListeriaListeria spp. ), StreptococcusStreptococcus spp. ), Haemophilus (Haemophilus spp. ), Neisseria (Neisseria spp. ), Klebsiella (Klebsiella spp. ), Borrelia (Borrelia spp. ), Bacteroides (Bacterioides spp. ) And Treponema pallidumTreponema spp. ). In some embodiments, the protozoal infection is selected from the group consisting of: Leishmania (Leishmania spp. ), Plasmodium falciparum (Plasmodium falciparum ), SchistosomaSchistosoma spp. ), ToxoplasmaToxoplasma spp. ), TrypanosomaTrypanosoma spp. ) And AscarisTaenia spp. ). In some embodiments, the fungal infection is selected from the group consisting of: blastomycosis, coccidioidomycosis (coccidioiodmycosis ), Histoplasmosis (histoplamsosis ), Candidiasis (candidiasis ), Cryptococcosis (cryptococcosis Aspergillosisaspergillossi ), Mucormycosis (mucomycosis ) And pneumocystis disease (pneumocystosis ).
In some embodiments, the disease or disorder is an inflammatory disease. In some embodiments, the inflammatory disease is selected from the group consisting of: acute disseminated encephalomyelitis, Addison's disease, Alzheimer's disease, ankylosing spondylitis, Antiphospholipid syndrome, atherosclerosis, autoimmune hemolytic anemia, autoimmune hepatitis, arthritis, Behcet's disease, Berger's disease, bullous pemphigoid , Celiac disease, Chagas' disease, cholangitis, Crohn's disease, dermatomyositis, type 1 diabetes, filamentous nephritis, Goodpasture's syndrome, transplantation Substance-versus-host disease, Graves' disease, Guillain-Barré syndrome, Hashimoto's disease, urticaria, hyper-IgE syndrome, idiopathic thrombocytopenia Purpura, lupus erythematosus, lupus nephritis, multiple sclerosis, myasthenia gravis, organ transplant rejection, Parkinson's disease, pemphigus, malignant anemia, polymyositis, primary bile Sclerosis, psoriasis, Raynaud's syndrome, rheumatoid arthritis, scleroderma, Sjögren's syndrome, temporal arteritis, thyroiditis, ulcerative colitis, uveitis, vasculature Inflammation and Wegener's granulomatosis.
In some embodiments, an antibody-containing formulation can be administered to a subject to treat a disease or condition in combination with another therapeutic agent. For example, to treat cancer, the anti-PDL1 antibody formulations described herein can be administered in combination with another anti-cancer treatment, such as chemotherapy or a different antibody treatment.
IV. Products or sets
In another embodiment of the present invention, an article or kit comprising a container is provided, the container containing the aqueous pharmaceutical formulation of the present invention; and instructions for its use are provided as appropriate. Suitable containers include, for example, bottles, vials, bags and syringes. The container may be formed from a variety of materials, such as glass, plastic (such as polyvinyl chloride or polyolefin), or metal alloys (such as stainless steel or Herstoy). An exemplary container is a 300 cc metal alloy container (for example, for storage at -20 ° C). Another exemplary container may be a 10-50 cc glass bottle (eg, for storage at 2-8 ° C). For example, the container may be a 10 cc, 15 cc, 20 cc or 50 cc glass bottle. The container contains the preparation and the label on the container or the label associated with the container may indicate instructions for use. The article may further include other materials that are desirable from a commercial and user standpoint, including other buffers, diluents, filter paper, needles, syringes, and package inserts with instructions for use. In some embodiments, the article of manufacture further comprises one or more another agent (eg, a chemotherapeutic agent and an anti-neoplastic agent). Suitable containers for one or more reagents include, for example, bottles, vials, bags and syringes.
The description is deemed sufficient to enable one skilled in the art to practice the invention. Those skilled in the art will know from the foregoing description that various modifications of the invention other than those shown and described herein are within the scope of the accompanying patent applications. All publications, patents, and patent applications cited herein are hereby incorporated by reference in their entirety for all purposes.
Examples
The invention will be more fully understood with reference to the following examples. However, it should not be considered as limiting the scope of the invention. It should be understood that the examples and embodiments described herein are for illustrative purposes only, and those skilled in the art can make various modifications or changes to it, which are included in the spirit and scope of the present application and the scope of the accompanying patent application.
Examples 1 :anti PDL1 Development of antibody formulations
Anti-PDL1 antibody (α-PDL1) is a deglycosylated IgG1 antibody derived from CHO, which is intended to restore T cell function by inhibiting the PDL1 / PD1 interaction. Attacks at the beginning of development include potential Trp oxidation and glycosylation in the CDR region or near the CDR region, as well as some methionine oxidation. Pre-robustness studies indicate that pH is better than the previous target (pH 5.5). The target dose is a fixed dose, but it also covers weight-based doses. An analytical study was performed to analyze the stability of multiple formulations and one formulation was selected (60 mg / mL α-PDL1, 20 mM His AcO pH 5.8, 120 mM sucrose, 0.04% PS20). Initial formulation studies support up to three years of stability for drug substances (DS) and pharmaceutical products (DS).
Methods and materials
Manufacture α-PDL1 Formulation
Research and development of formulations for α-PDL1 materials undergoing ultrafiltration / diafiltration. The material was dialyzed into various formulation buffers using a 10,000 Dalton dialysis cartridge. After dialysis, adjust the protein concentration to the target concentration and add 10% PS20 stock solution to achieve the target PS20 concentration. The formulation was aseptically filled into a 2 cc Forma Vitrum glass bottle with a 1 mL fill volume and sealed with a 13 mm Daikyo 777-1 stopper. The samples were stored vertically at 5 ° C, 25 ° C, or 40 ° C.
Color, appearance and transparency (CAC)
At room temperature, use black and white backgrounds to visually determine the color, appearance, and transparency of samples under white fluorescent light, such as the European Pharmacopoeia (EP) method (Council of Europe.European Pharmacopoeia , 2008, 7th edition, EP 2.2.2 and EP 2.2.1). Fill a 3cc glass bottle with 1 mL of each test sample. A negative control (pure water) with the corresponding sample volume was used for comparison.
Protein concentration measurement
The protein concentration was determined by diluting the sample volume to approximately 0.5 mg / mL with 0.9% physiological saline and measuring by UV absorption on an Agilent 8453 spectrophotometer (Santa Clara, CA.). The sample is left blank for 0.9% physiological saline and the A is about 280 nm._max And also measure the absorbance at 320 nm. Calculate A_max With A₃₂₀ Difference between gains corrected A_max For using 1.5mL cm^-1 mg^-1 Absorptivity measures the final protein concentration.
Turbidity measurement
The average optical density of the sample at 350 nm was measured on a Agilent 8453 spectrophotometer in a quartz cuvette using a 1-cm path length. Use pure water as a blank.
Shading method for microscopic visible particles (HIAC Analysis )
Sample particle counting was performed by measuring light shielding with a Model 9703 HIAC-Royco (HACH, Loveland, CO.). PharmSpec v2.0 was used to list the average cumulative number of particles per milliliter of ≥ 2 mm, ≥ 5 mm, ≥ 10 mm, and ≥ 25 mm for each sample. A total of four readings of 1.6 mL of each sample were consumed for each test, the first reading was discarded, and the remaining 3 readings were averaged.
Size exclusion chromatography (SEC or SE-HPLC)
Size variant distribution was determined by size exclusion chromatography (SEC) using a TosoHaas Bioscience column G3000 SWXL (South San Francisco, CA.) on an Agilent 1200 HPLC (Santa Clara, CA., USA) at 30 ° C. All samples were injected undiluted into the column at 50 μg and dissolved over 60 minutes with UV absorption at 280 nm. Sample tests used two different SEC methods. Method 1 used 0.20 M potassium phosphate, 0.25 M potassium chloride, pH 6.2, while Method 2 used 0.20 M potassium phosphate, 0.25 M potassium chloride, pH 6.2, and 10 vol% isopropanol was used as the mobile phase. Results are reported as relative percentages of peak area of total area under the curve.
Imaging capillary isoelectric focusing (ICIEF)
The charge variant distribution was evaluated by iCIEF using an iCE280 analyzer (ProteinSimple) with a fluorocarbon-coated capillary filter (100 µm × 5 cm). Ampholyte solution consists of 0.35% methylcellulose (MC), 0.75% Pharmalyte 3-10 carrier ampholyte, 4.2% Pharmalyte 8-10.5 carrier ampholyte and 0.2% pI-labeled 7.40 and 0.15% pI-labeled 9.77 in pure water In the mixture. The anolyte was 80 mM phosphoric acid and the catholyte was 100 mM sodium hydroxide, both of which were contained in 0.10% methyl cellulose. The samples were diluted in pure water and CpB was added to each diluted sample at an enzyme-to-mass ratio of 1: 100, followed by incubation at 37 ° C for 20 minutes. The CpB-treated sample was mixed with an amphoteric electrolyte solution, and then focused by introducing a 1500 V potential for 1 minute, and then a 3000 V potential for 10 minutes. An image of a focused α-PDL1 charge variant was obtained by passing 280 nm UV light through a capillary tube and into the lens of a charge-coupled digital camera. This image is then analyzed to determine the distribution of multiple charge variants.
Peptide localization
Peptide localization was used to monitor tryptophan (W) and methionine (M) oxidation. In order to generate α-PDL1 peptide localization, after exposing the protein to dithiothreitol (DTT) and iodoacetic acid (IAA), the pancreas is used for the process of reducing disulfide bonds and changing the resulting free thiol to produce carboxymethyl derivatives Proteases digest proteins. The resulting peptides were separated by reverse-phase high-performance liquid chromatography (RP-HPLC) and monitored at 214 nm. The mass of the trypsin peptide was determined by LC-MS analysis of the separated and digested mixture using a ThermoFisher Scientific LTQ-Orbitrap mass spectrometer.
result
Choose a buffer system
During formulation development, two buffer systems were evaluated. One is 20 mM histidine acetate with 240 mM sucrose, pH 5.5, and the other is 200 mM succinate arginine, pH 5.5. Accelerated stability studies revealed that α-PDL1 has better stability in histidine acetate buffer than in succinate arginine buffer (Table 1). Therefore, histidine acetate was selected for further development of the formulation.
table 1. Α-PDL1 zero-order decomposition rate of the main peaks of ICIEF and SE-HPLC in histidine acetate and succinate arginine buffer at 30 ° C
Note: All formulations are stored at 30 ° C for up to 1 month. Analysis using ICIEF and SE-HPLC; * 150 mg / mL of 20 mM L-histidine acetate with α-PDL1, 240 mM sucrose, and 0.02% (w / v) polysorbate 20, pH 5.5; * * 150 mg / mL 200 mM succinate arginine, α-PDL1, 0.02% (w / v) polysorbate 20, pH 5.5.
Choose a stabilizer
Sucrose (120 mM) was selected based on its ability to protect proteins from freeze / thaw-induced aggregation and its use as a cryoprotectant during long-term frozen storage of drug substances (DS) and subsequent storage of drugs (DP) at 2 ° C to 8 ° C ) As a stabilizer for α-PDL1 liquid formulations.
During formulation development, 20 mM L-histidine acetate, pH 5.5, 0.02% (w / v) polysorbate 20 and 50 mg / mL α of sucrose in various concentrations ranging from 0 mM to 120 mM -PDL1 performs five freeze / thaw cycles. The product quality measured by SE-HPLC indicated that 60 mM sucrose was sufficient to prevent freeze / thaw-induced increase in α-PDL1 HMWS (Table 2). In addition, 120 mM sucrose was shown to maintain the stability of the drug substance when stored frozen at -20 ° C for at least 6 months (Table 3). Therefore, based on the results of freeze / thaw studies and long-term stability of the drug substance stored at -20 ° C, sucrose at a concentration of 120 mM was selected as the cryoprotectant for the α-PDL1 liquid formulation.
table 2. Effect of sucrose concentration on the stability of α-PDL1 SE-HPLC percent high molecular weight substances during freezing and thawing


Note: All formulations contain 50 mg / mL α-PDL1, 20 mM L-histidine acetate, 0.02% (w / v) polysorbate 20, pH 5.5. Analysis was performed using the following: SE-HPLC; F / T = freeze / thaw; HMWS = high molecular weight substance; SY = slightly yellow; CL = clear; PFVP = virtually no visible particles.

table 3. Long-term stability data of α-PDL1 API R & D batch

Note: All formulations contain 60 mg / mL of 20 mM L-histidine acetate with α-PDL1, 120 mM sucrose, 0.04% PS20, pH 5.8. This study used a 25cc 316L stainless steel can; NA = not applicable; CAC = color, appearance, and transparency; SY = slightly yellow, CL = clarified, PFVP = virtually free of visible particles; HMW = high molecular weight; LMW = low molecular weight ICIEF = imaging capillary isoelectric focusing; CE-SDS = sodium lauryl sulfate capillary electrophoresis; NT = not tested; TBD = to be determined.

Pre-Tuning Robustness Study: Selecting protein concentration, pH Polysorbate 20 concentration
A partial factorial experimental design (DOE) design was used to further examine the effect of α-PDL1 formulation parameters on protein stability. A total of 12 different α-PDL1 formulations were tested (10 experiments and 2 center points). The three factors that changed in the study were a pH range of 5.0-6.0 with 0.5 unit intervals, a protein concentration range of 40-120 mg / mL, and a polysorbate 20 concentration range of 0.005% -0.06% (w / v) (Table 4). All formulations were buffered with 20 mM histidine acetate with 120 mM sucrose, except for the last two formulations indicated in Table 4. The 25 mM histidine acetate formulation was evaluated as it was considered the worst case scenario in terms of risk of oxidation. Evaluate 20 mM sodium acetate buffer as a backup buffer system and compare with histamine acetate buffer. The formulations were stored at 25 ° C for 2 months and at 40 ° C for 1 month. Statistical analysis of the interactions between formulation parameters was performed using the JMP software (JMP, 9th edition, SAS Institute Inc., Cary, NC) on the stability data studied above.
table 4. Α-PDL1 APIs and drug formulations evaluated in DOE studies

Note: yes^a Center point^b Worst case scenario: low protein concentration, high PS20 concentration, high histidine acid concentration;^c 20 mM sodium acetate (Na-Ace) buffer was tested.
Compared to pH 5.0 and 5.5, as measured by ICIEF at 40 ° C and 25 ° C, the main peak loss rate of the formulation at pH 6.0 is slightly lower (Figures 1A-1B and 2A-2B, respectively). ICIEF observed that the concentration had no significant effect on the loss of the main peak. Analysis of Formulation F1 shows that in ICIEF, the increase in acidic variants mainly results in the loss of the main peak, while the peak loss caused by the basic charge variants is not significant. Under the same storage conditions, as measured by SE-HPLC at 40 ° C and 25 ° C, the formulation at pH 6.0 also has a slower monomer peak loss rate (Figure 3A-Figure 3B and Figure 4A-Figure 4B, respectively). ). Analysis of Formulation F1 shows that in SEC, at high temperatures (ie, 40 ° C and 25 ° C), the formation of HMWS and LMWS causes monomer loss. Both SEC and ICIEF pH rate profiles reveal that pH 5.5-6.0 is the optimal pH range for α-PDL1. In order to achieve the best protein stability above pH 5.5 and to allow the range of ± 0.3 pH units in formulated APIs and pharmaceuticals, the target of pH 5.8 was selected.
The above formulation studies also revealed that 120-mg / mL α-PDL1 formulations in the 5.0-6.0 range, as determined by SE-HPLC, compared to 40 mg / mL formulations at the same pH due to higher HMWS formation The compound has a slightly higher but not significant monomer peak loss rate (Figures 3A-3B and 4A-4B). Based on this information and to support formulations with improved product stability and ease of patient administration, α-PDL1 was selected at a concentration of 60 mg / mL.
As indicated by the statistical analysis above, it was observed that polysorbate 20 (PS20) at a concentration range of 0.005% -0.06% (w / v) had no effect on protein stability (Figures 1-4).
It is known that hydrogen peroxide impurities contained in the polysorbate 20 raw material can cause oxidation of tryptophan (W) and methionine (M). L-Histidine can also increase the above-mentioned oxidation risk. Samples containing the selected worst case scenario formulations with higher concentrations of polysorbate 20 and L-histidine were analyzed by peptide localization. The analysis results show that even the combination of higher histidine concentration (25 mM histidine acetate buffer) and higher PS20 (0.06% PS20) does not show significant risk of oxidation (Table 5) and histidine buffer is suitable for Blend α-PDL1.
table 5. Percent Trp and M in selected formulations by peptide localization²⁵³ Oxidation

In order to assess the possible decomposition of PS20 in the formulation during storage, formulations F1 to F10 (Table 4) were stored at 40 ° C for 1 month. Store for 2 months at 25 ° C, 2 months at 5 ° C or 6 months at 5 ° C. No PS20 decomposition was observed for the evaluated formulations at any elevated temperature (ie, 40 ° C and 25 ° C) and at a storage temperature of 5 ° C. Change the fill volume of the selected formulation (ie F1, F2, F3 and F6) to 7 ml (high fill) or 4 ml (low fill), and then store at 5 ° C for 6 months. The decomposition rate has a significant effect (Figure 5).
The formation of microscopically visible particles (SbVP) in different formulations stored at 5 ° C for 6 months was evaluated by HIAC analysis as a measure of stability (Table 6). No measurable change in SbVP was observed in the tested formulations.


table 6. HIAC data of SbVP formation after 6 months storage at 5 ° C

Note: Two 1 mL filled vials were combined for small volume HIAC analysis.
Freeze-thaw experiments were used to further study the stability of the formulations. Formulations F1 to F10 (Table 4) were subjected to five freeze-thaw cycles during storage at -20 ° C or stored at a high storage temperature of 5 ° C for 0 to 6 months and the α-PDL1 monomer was subsequently analyzed by SEC and ICIEF Percentages (Figures 6A and 6B) and the percentage of major peaks in the formulation (Figures 6C and 6D). No significant changes were observed in the percentage of monomers and the percentage of main peaks after freeze-thaw cycles and storage at the specified time points.
The raw materials in the F2 formulation were evaluated by performing five freeze-thaw cycles during storage in a stainless steel tank at -20 ° C for up to 6 months, followed by stability measurements by CAC, SEC and ICIEF (Table 7) Drug stability (Table 4). No change was observed after 6 months of storage at -20 ° C.
table 7. Drug substance stability in stainless steel small tanks stored at -20 ° C
Note: F / T = freeze / thaw; SY = slightly yellow; CL = clear.
By performing three freeze-thaw cycles, and then storing in stainless steel cans or Herst alloy cans at -20 ° C, 5 ° C, or 25 ° C for up to 3 months, the stability was then evaluated by SEC to assess Stability of the drug substance in the formulation of 100 mg / mL α-PDL1, 20 mM histidine acetate, 120 mM sucrose, 0.04% PS20, pH 5.6 (Figures 7A and 7B). No difference was observed in storage in stainless steel cans and Herst alloy cans at pH 5.6. After three freeze-thaw cycles at -20 ° C, the drug substance is stable for up to 3 months. Although there are minor differences in stainless steel cans and Herstoy cans, both are suitable for bulk drug storage.
Store at 16 ° C in a 20cc vial at -5 ° C, 25 ° C, or 40 ° C for up to 3 months, and then measure the stability by SEC and ICIEF to assess that it contains 50 mg / mL α-PDL1, 20 Pharmaceutical stability in formulations of mM histidine acetate, 120 mM sucrose, 0.04% PS20, pH 5.6 (Figures 8A and 8B). After three months of storage at 5 ° C, no change was observed. At 40 ° C, the monthly pH 5.6 decomposition rate was 0.66% and 22% by SEC and ICIEF analysis, respectively.
The evaluation of the buffer in the F12 formulation was based on the decomposition rate of the main peak measured by SE-HPLC and ICIEF (Table 8). Sodium acetate buffer provides protein stability similar to histamine acetate buffer. Two test formulations were 50 mg / mL 20-mM L-histidine acetate with α-PDL1, 120 mM sucrose, and 0.04% (w / v) polysorbate 20, pH 5.5 and 0 mg / mL with α-PDL1 20 mM sodium acetate, 120 mM sucrose and 0.04% (w / v) polysorbate 20, pH 5.5.
table 8. Α-PDL1 zero-order decomposition rate of the main peaks of ICIEF and SE-HPLC in histidine acetate and sodium acetate buffer at 40 ° C

Note: All formulations are stored at 40 ° C for up to 1 month.
Overall, DoE design stability studies revealed that at 40 ° C, ICIEF did not observe a significant effect of concentration on main peak loss, while lower pH had slightly faster main peak rate loss (Figures 1A-B). SE-HPLC also did not observe significant interactions at 40 ° C, however, higher concentration formulations showed faster monomer loss (Figures 3A-B). It was also found that lower pH has faster monomer rate loss. Similar results were observed at 25 ° C (Figs. 2A-2B and 4A-4B). Statistical analysis revealed no meaningful interactions (connections) between any of the test formulation parameters.
Stirring and Thermal Stress Study
The stability of the drug when agitating stress in a glass bottle in the presence of an increased concentration of PS20 was investigated. Formulations containing 57 mM histidine acetate, 120 mM sucrose, and 57 mg / mL in pH 5.5 were evaluated in 1 mL fills in 2 cc glass bottles with various concentrations of PS20 in the range of 0.005% to 0.06%. The glass bottle was then stirred at 70 rpm for 3 days at room temperature before measuring the stability (Figure 9A) and turbidity (Figure 9B) by SEC. The stability of the formulations with PS20 content between 0.005 and 0.06% does not change during stirring. However, formulations lacking PS20 showed increased monomer loss due to increased HMWS. In this experiment, 0.005% of PS20 was sufficient to protect the protein from the agitation stress in the glass bottle.
The stability of the drug formulation (Table 4) was studied at various temperatures and times, and then subjected to stirring stress in glass bottles. Each formulation F1-F10 was evaluated in a 1 mL fill in a 2cc glass bottle. The glass bottle was stirred at 70 rpm for 1 day at room temperature, and then the stability was measured by SEC (Fig. 10). In this experiment, stirring has no effect on the stability of the drug stored for a long time at 40 ° C, 25 ° C, or 5 ° C.
In order to support the IV bag transport that usually occurs in a hospital environment, α- formulated in 20 mM histidine acetate, 240 mM sucrose, pH 5.5 with 0.005% -0.02% (w / v) polysorbate 20 PDL1 was subjected to an IV bag stirring study. By injecting 400-600 mg of α-PDL1 solution and using an orbital shaker at 100 rpm and stirring at 5 ° C for up to 6 hours, the most commonly used 250 mL of polyvinyl chloride containing isotonic sodium chloride solution (0.9% NaCl) (PVC) or Polyolefin (PO) IV bags for evaluation. The results support weight-based dosing and indicate that a minimum of 0.015% (w / v) polysorbate 20 is required in the protein solution to prevent the formation of visible particles (related to protein precipitation) during transport (Table 9). In addition, in order to reduce the risk of decomposition of polysorbate 20 during storage, the concentration of polysorbate 20 was increased from 0.02% (w / v) to 0.04% (w / v).


table 9. Study on IV Bag Stirring Using Different Amounts of α-PDL1 Drugs Containing PS20

Note: All formulations 50 mg / mL 20-mM L-histidine acetate with α-PDL1, 240 mM sucrose, pH 5.5. Analysis was performed using SE-HPLC. NT = Not tested; CAC = Color, appearance, and clarity; CO = Colorless; CL = Clear; PFVP = Actually free of visible particles.
α-PDL1 Evaluation of stability of formulations
For the master cell bank and working cell bank produced in a formulation containing 20 mM histidine acetate, 120 mM sucrose and 0.04% PS20 in a pH range of 5.2 to 6.3 The material was subjected to additional pH screening (Table 10). Analysis by SE-HPLC and ICIEF showed that pH 5.7-6.3 is quite chemically and physically stable and the allowable range of pH 5.5-6.3 in the formulation is appropriate (Figure 11A and Figure 11B). Higher pH decreases the monomer and main peak decomposition rates, and the rate becomes flat between about pH 5.7 and 6.3.
table 10. PH screening of formulations

The effects of formulation excipients on the oxidation of tryptophan (W) and methionine (M) in α-PDL1 formulations were studied. Peptide localization showed no significant increase in oxidation. Formulations containing 20 mM histidine acetate, 120 mM sucrose, 0.04% PS20, and a solution pH of 5.8 show that when the formulation is stored at high temperature for one month, there is no obvious tryptophan and methionine oxidation in the drug or drug substance Increase (Table 11).
table 11. Trp, M in selected formulations determined by peptide localization²⁵³ And M⁴²⁹ Oxidation percentage

Note: All α-PDL1 formulations contain 20 mM L-histidine acetate, 120 mM sucrose, 0.04% PS20, pH 5.8.
Based on the results of research and statistical analysis of these formulations, a liquid formulation consisting of 60 mg / mL 20-mM histidine acetate containing α-PDL1, 120 mM sucrose, 0.04% polysorbate 20, and a target pH of 5.8 was selected. For clinical research.
Clinical trial doses will be administered at a uniform dose of 1200 mg α-PDL1 per patient. A vial configuration with a nominal 20 mL fill (1200 mg α-PDL1) in a 20 cc glass bottle was chosen to meet the target product profile.
A freeze / thaw study was performed using the intended formulation containing 60 mg / mL of 20 mM L-histidine acetate with α-PDL1, 120 mM sucrose, and 0.02% (w / v) polysorbate 20, pH 5.8. Analysis results after five freeze / thaw cycles confirmed that 120 mM sucrose protected α-PDL1 from freeze / thaw induced aggregation (Table 12). The similar long-term stability of the liquid formulation is expected to indicate that it is stable for more than 6 months at 2-8 ° C (Table 13). This formulation is being continuously monitored for 36 months. Table 14 shows the target formulations and testing ranges of the α-PDL1 API and API.

table 12. Representative freeze / thaw stability data for α-PDL1 API R & D batch

Note: Batch PP400L-02142013 contains 60 mg / mL of 20 mM L-histidine acetate with α-PDL1, 120 mM sucrose, and 0.04% (w / v) polysorbate 20, pH 5.8. CL = clarified; SY = slightly yellow; PFVP = virtually no visible particles; NA = not applicable, ICIEF = imaging capillary isoelectric focusing; CE-SDS = sodium lauryl sulfate capillary electrophoresis; HMW = high molecular weight; LMW = Low molecular weight.

table 13. Stability data of α-PDL1 drug development batch

Batch PP400L-02142013-DP contains 60 mg / mL of 20 mM L-histidine acetate with α-PDL1, 120 mM sucrose, and 0.04% (w / v) polysorbate 20, pH 5.8. NA = Not applicable; CAC = Color, appearance and sharpness; SY = Slightly yellow, CL = Clear, PFVP = Actually without visible particles; HMW = High molecular weight; LMW = Low molecular weight; ICIEF = Isoelectric focusing of imaging capillary CE-SDS = sodium lauryl sulfate capillary electrophoresis, NT = not tested.

table 14. α-PDL1 drug substance and drug target formulation and test research scope
Since α-PDL1 drug (60 mg / mL) will be diluted by isotonic sodium chloride solution (0.9% NaCl) and administered by infusion, the compatibility of the active ingredients is tested under the following simulated preparation and administration conditions And stability: 1) Dilute α-PDL1 drug in an infusion bag containing 0.9% NaCl in the range of 2.4-9.6 mg / ml (nominal concentration after dilution) to cover the dose range in clinical research; 2) short-term exposure In an infusion bag containing an isotonic sodium chloride solution (the product contact surface material of the bag is made of PVC or polyolefin); 3) using an IV infusion line (the product contact surface is PVC or polyolefin); and 4) in an inline filter Use 0.2 μm (filter membrane is PES).
The samples were tested by storage at 2 ° C-8 ° C for 24 hours or exposure to scattered light at 30 ° C for 24 hours. Test samples using appropriate stability indicators, including: purity by SE-HPLC and ICIEF, protein concentration (by UV), microscopically visible particles by opacity test, color, transparency / opaque light, and pH ( Table 15).

table 15. Α-PDL1 stability in 0.9% NaCl infusion bag with and without 0.2 μm in-line filter after 24 hours dilution and storage at 5 ° C or 30 ° C
table 15 ( Continued ) : Α-PDL1 stability in 0.9% NaCl infusion bag with and without 0.2 μm in-line filter after 24 hours dilution and storage at 5 ° C or 30 ° C
table 15 ( Continued ) : Α-PDL1 stability in 0.9% NaCl infusion bag with and without 0.2 μm in-line filter after 24 hours dilution and storage at 5 ° C or 30 ° C
table 15 ( Continued ) : Α-PDL1 stability in 0.9% NaCl infusion bag with and without 0.2 μm in-line filter after 24 hours dilution and storage at 5 ° C or 30 ° C
table 16. Stability of α-PDL1 diluted in 0.9% NaCl infusion bag at 5 ° C for up to 6 hours
CO = colorless, CL = clarified, PFVP = virtually no visible particles, A₃₅₀ = Absorbance at 350 nm

Product testing in the simulated dosing studies described above is physically and chemically stable under test conditions. Infusion bags, infusion sets, filters, and / or IV administration aids composed of different product-contact materials are added after successful qualification.
In addition to static stability, an IV bag stirring study was performed using α-PDL1 formulated in 20 mM histidine acetate, 120 mM sucrose, pH 5.8 with 0.02% PS20, and 0.02% PS20 was potentially used in pharmaceuticals during storage The lowest observable PS20 content. Stirring was performed at 2-8 ° C using an orbital shaker at a speed of 100 rpm. The data show that the drug has 0.02% PS20, and α-PDL1 is diluted in an IV bag and stabilized after stirring at 5 ° C (Table 16).
Antibody sequences used in the examples
α-PDL1 Light chain variable region

α-PDL1 Heavy chain variable region

α-PDL1 Complete light chain

α-PDL1 Complete heavy chain

FIG. 1 is a series of curves showing the statistical analysis of the stability data of α-PDL1 formulation measured at 40 ° C. using JMP software by ICIEF. A) The average major peak rate loss from a partial factorial experimental design (DOE). B) Main peak analysis from partial factor DOE. The main peak contains an α-PDL1 charged substance, which has the same pH as the molecular pI (isoelectric point).

FIG. 2 is a series of curves showing statistical analysis of stability data of α-PDL1 formulation measured at 25 ° C. using JMP software by ICIEF. A) The average major peak rate loss from a partial factorial experimental design (DOE). B) Main peak analysis from partial factor DOE. The main peak contains an α-PDL1 charged substance, which has the same pH as the molecular pI (isoelectric point).

FIG. 3 is a series of curves showing statistical analysis of stability data of α-PDL1 formulation at 40 ° C. measured by SE-HPLC using JMP software. A) The average major peak rate loss from a partial factorial experimental design (DOE). B) Main peak analysis from partial factor DOE. The main peak contains α-PDL1 monomer.

FIG. 4 is a series of curves showing statistical analysis of stability data of α-PDL1 formulation at 25 ° C. measured by SE-HPLC using JMP software. A) The average major peak rate loss from a partial factorial experimental design (DOE). B) Main peak analysis from partial factor DOE. The main peak contains α-PDL1 monomer.

FIG. 5 is a graph showing the lack of significant PS20 decomposition of various α-PDL1 formulations stored at various temperatures and times. The remaining PS20 percentage (%) curve in the formulations F1 to F10 as detected by the evaporative light scattering detector (ELSD). a is time zero (T0); b is 40 ° C, 1M; c is 25 ° C, 2M; d is 5 ° C, 2M; e is 5 ° C, 6M; f is 5 ° C, 6M, 20cc glass bottle (GV), High filling; and g is 5 ° C, 6M, 20cc glass bottle (GV), low filling.

Figure 6 is a series of curves showing the stability of α-PDL1 formulations stored in glass bottles (GV) for up to 6 months at -20 ° C or 5 ° C. A) A curve of the percentage (%) of monomers in the formulation after five freeze-thaw cycles during a specified time period stored at -20 ° C. B) Curve of the percentage (%) of monomers in the formulation stored at 5 ° C for the specified time. C) A curve of the percentage (%) of the main peak obtained from the formulation after five freeze-thaw cycles during the specified time storage at -20 ° C. D) Curve obtained from the percentage of the main peak (%) of the formulation stored at 5 ° C for the specified time.

FIG. 7 is a series of curves showing the stability of the α-PDL1 formulation after three freeze-thaw cycles and storage in a stainless steel or Herst alloy canister. A) Curve of the percentage (%) of monomers in the formulation after 3 months of storage at the specified temperature. B) Curve of the main peak percentage (%) in the formulation after 3 months of storage at the specified temperature.

Figure 8 is a series of curves showing the stability of the α-PDL1 formulation stored in a 20cc bottle. A) Curve of the percentage (%) of monomers in the formulation after 3 months of storage at the specified temperature. B) Curve of the main peak percentage (%) in the formulation after 3 months of storage at the specified temperature.

FIG. 9 is a series of curves showing the stability of α-PDL1 formulations containing PS20 at various concentrations when stirred in a glass bottle. A) A curve of the percentage (%) of monomers in the formulation after stirring at room temperature for a specified time. B) Turbidity curve as measured by absorbance measurement at 350 nm after stirring at room temperature for a specified time.

FIG. 10 is a graph showing the stability of an α-PDL1 formulation stored in a glass bottle for a period of time at a specified temperature and then stirred. The percentage change in monomer in the formulation was measured by SEC.

FIG. 11 is a series of curves showing a comparison of the weekly rate of loss of α-PDL1 with increasing pH. A) Weekly percentage loss of monomer (%) in the formulation after storage at 40 ° C. B) Curve of percent loss (%) of the main peak per week in the formulation after storage at 40 ° C.

Claims (41)

A stable aqueous pharmaceutical formulation comprising an anti-PDL1 monoclonal antibody at a concentration of about 40 mg / ml to about 125 mg / ml, and a histidine acetate or sodium acetate at a concentration of about 15 mM to about 25 mM Polysorbate at a concentration of about 60 mM to about 240 mM, at a concentration of about 0.005% (w / v) to about 0.06% (w / v), and at a pH of about 5.0 to about 6.3. The formulation of claim 1, wherein the monoclonal antibody in the formulation is about 40 mg / ml to about 80 mg / ml. The formulation of claim 1, wherein the monoclonal antibody in the formulation is about 54 mg / ml to about 66 mg / ml. The formulation of claim 1, wherein the monoclonal antibody in the formulation is about 60 mg / ml. The formulation of claim 1, wherein the monoclonal antibody in the formulation is about 60 mg / ml to about 125 mg / ml. The formulation of claim 1, wherein the monoclonal antibody in the formulation is about 125 mg / ml. The formulation of any one of claims 1 to 6, wherein the concentration of the histidine acetate or sodium acetate is about 17 mM to about 22 mM. The formulation of any one of claims 1 to 6, wherein the concentration of the histidine acetate or sodium acetate is about 20 mM. The formulation of any one of claims 1 to 8, wherein the sucrose in the formulation is about 60 mM to about 180 mM. The formulation of any one of claims 1 to 8, wherein the sucrose in the formulation is about 120 mM. The formulation of any one of claims 1 to 10, wherein the pH of the formulation is about 5.5 to about 6.1. The formulation of any one of claims 1 to 10, wherein the pH of the formulation is about 5.5 or about 5.8. The formulation according to any one of claims 1 to 12, wherein the polysorbate in the formulation is polysorbate 20. The formulation of any one of claims 1 to 13, wherein the polysorbate in the formulation is about 0.02% to about 0.04%. The formulation of any one of claims 1 to 5 and 7 to 14, wherein the monoclonal antibody in the formulation is about 60 mg / ml, the sucrose in the formulation is about 120 mM, and the pH is about 5.8. The formulation of any of 6 to 8 and 11 to 14, wherein the monoclonal antibody in the formulation is about 125 mg / ml, sucrose in the formulation is about 240 mM, and the pH is about 5.5. The formulation of any one of claims 1 to 16, wherein the monoclonal antibody has not been previously lyophilized. The formulation of any one of claims 1 to 17, wherein the monoclonal antibody is a full-length antibody. The formulation according to any one of claims 1 to 18, wherein the monoclonal antibody is an IgG1, IgG2, IgG3 or IgG4 antibody. The formulation according to any one of claims 1 to 19, wherein the monoclonal antibody is a humanized antibody. The formulation of any one of claims 1 to 20, wherein the monoclonal antibody is an antibody fragment comprising an antigen-binding region. The formulation of claim 21, wherein the antibody fragment is a Fab or F (ab ') ₂ fragment. The formulation of any one of claims 1 to 22, wherein the monoclonal antibody comprises (a) a light chain variable region comprising: (1) HVR-L1, which comprises an amino acid sequence RASQDVSTAVA (SEQ ID NO: 1); (2) HVR-L2, which comprises an amino acid sequence SASFLYS (SEQ ID NO: 2); (3) HVR-L3, which comprises an amino acid sequence QQYLYHPAT (SEQ ID NO: 3); and (b) a heavy chain variable region comprising: (1) HVR-H1, which comprises an amino acid sequence GFTFSDSWIH (SEQ ID NO: 4); (2) HVR-H2, which comprises an amino acid sequence AWISPYGGSTYYADSVKG (SEQ ID NO: 5); (3) HVR-H3, which comprises an amino acid sequence RHWPGGFDY (SEQ ID NO: 6). The formulation according to any one of claims 1 to 23, wherein the monoclonal antibody comprises a light chain variable region comprising an amino acid sequence of SEQ ID NO: 7 and a heavy chain comprising an amino acid sequence of SEQ ID NO: 8 Variable region. The formulation according to any one of claims 1 to 23, wherein the monoclonal antibody comprises a light chain variable region comprising an amino acid sequence of SEQ ID NO: 7 and a heavy chain comprising an amino acid sequence of SEQ ID NO: 32 Variable region. The formulation according to claim 24 or 25, wherein the monoclonal antibody comprises a light chain comprising an amino acid sequence of SEQ ID NO: 9 and a heavy chain comprising an amino acid sequence of SEQ ID NO: 10. The formulation of any one of claims 1 to 26, wherein the monoclonal antibody is stored in a glass bottle or a metal alloy container. The formulation of claim 27, wherein the metal alloy is 316L stainless steel or hastelloy. The formulation of any one of claims 1 to 28, wherein the formulation is stable at 2-8 ° C for at least 6 months, at least 12 months, at least 18 months, or at least 24 months. The formulation of claim 29, wherein the antibody in the formulation retains at least about 80% of its biological activity after storage. The formulation according to claim 30, wherein the biological activity is measured by an antibody bound to PD-L1. The formulation as claimed in any one of claims 1 to 31, which is sterile. The formulation of any one of claims 1 to 32, which is suitable for administration to an individual. The formulation of any one of claims 1 to 33 for intravenous (IV) administration. The formulation according to claim 1, wherein the monoclonal antibody is in an amount of about 60 mg / mL, the histidine acetate is at a concentration of about 20 mM, the sucrose is at a concentration of about 120 mM, and the polysorbate It is polysorbate 20 at a concentration of 0.04% (w / v), and the pH of the formulation is about 5.8. The formulation according to claim 1, wherein the monoclonal antibody is in an amount of about 125 mg / mL, the histidine acetate is at a concentration of about 20 mM, the sucrose is at a concentration of about 240 mM, and the polysorbate It is polysorbate 20 at a concentration of 0.02%, and the pH of the formulation is about 5.5. An article comprising a container containing a stable aqueous pharmaceutical formulation according to any one of claims 1 to 36. The article of claim 37, wherein the container is a glass bottle or a metal alloy container. The article of claim 38, wherein the metal alloy is 316L stainless steel or Herst alloy. A method of treating a disease or condition in an individual, comprising administering to the individual an effective amount of a formulation according to any one of claims 1 to 36, wherein the disease or condition is selected from the group consisting of infections, cancers and inflammatory diseases Group. The formulation according to any one of claims 1 to 36, wherein the monoclonal antibody comprises a N297A or D265A / N297A substitution in the constant region, and the number of the residue is as EU index in Kabat.